

# Investigating the Role of Maternal Age in the Occurrence of Non-Chromosomal Congenital Anomalies

Ph.D. Thesis

**Boglárka Pethő M.D.**

Translational Medicine Program

Health Sciences Division

SEMMELWEIS UNIVERSITY



Supervisor:

Nándor Ács M.D., Ph.D., D.Sc.

Official reviewers:

Demetra-Gabriela Socolov M.D., Ph.D., D.Sc.

Nikoletta Nagy M.D., Ph.D., D.Sc.

Head of the Complex

Examination Committee:

Ferenc Bánhidly M.D., Ph.D.

Members of the Complex

Examination Committee:

Ádám László M.D., Ph.D.

Zsolt Melczér M.D., Ph.D.

Budapest

2024

***“Research is to see what everybody else has seen, and to think what nobody else has thought”***

Albert Szent-Györgyi

## TABLE OF CONTENT

|  |           |
|--|-----------|
| <b>1 LIST OF ABBREVIATIONS .....</b>   | <b>4</b>  |
| <b>2 STUDENT PROFILE .....</b>   | <b>6</b>  |
| <b>2.1 Vision and mission statement, specific goals .....</b>  | <b>6</b>  |
| <b>2.2 Scientometrics .....</b>  | <b>6</b>  |
| <b>2.3 Future plans .....</b>  | <b>6</b>  |
| <b>3 SUMMARY OF THE THESIS.....</b>  | <b>7</b>  |
| <b>4 GRAPHICAL ABSTRACT .....</b>  | <b>8</b>  |
| <b>5 INTRODUCTION.....</b>   | <b>9</b>  |
| <b>5.1 Overview of the topic.....</b>  | <b>9</b>  |
| <b>5.1.1 What is the topic? .....</b>  | <b>9</b>  |
| <b>5.1.2 What is the problem to solve?.....</b>  | <b>9</b>  |
| <b>5.1.3 What is the importance of the topic? .....</b>  | <b>9</b>  |
| <b>5.1.4 What would be the impact of our research results? .....</b>   | <b>9</b>  |
| <b>5.2 Maternal age – a critical factor in pregnancy outcome.....</b>  | <b>10</b> |
| <b>5.3 Congenital anomalies – the leading cause of neonatal mortality and morbidity .....</b>  | <b>11</b> |
| <b>5.4 Potential association between NCAs and maternal age .....</b>   | <b>12</b> |
| <b>6 OBJECTIVES.....</b>   | <b>14</b> |
| <b>6.1 Study I. – Investigating the Impact of Maternal Age on the Development of Non-Chromosomal Congenital Anomalies in the Hungarian Population between 1980 and 2009.....</b> | <b>14</b> |
| <b>6.2 Study II. – Investigating the Impact of Maternal Age on the Development of Non-Chromosomal Congenital Anomalies Worldwide .....</b>                                       | <b>14</b> |
| <b>7 METHODS .....</b>   | <b>15</b> |
| <b>7.1 Study I.....</b>  | <b>15</b> |
| <b>7.1.1 Study design .....</b>  | <b>15</b> |
| <b>7.1.2 Setting .....</b>   | <b>15</b> |

|       |  |    |
|-------|--|----|
| 7.1.3 | Ethics and patient consent .....                                       | 16 |
| 7.1.4 | Participants .....   | 16 |
| 7.1.5 | Variables and data sources.....  | 17 |
| 7.1.6 | Bias and evidence synthesis .....                                      | 17 |
| 7.1.7 | Statistical methods.....   | 18 |
| 7.2   | Study II. ....   | 19 |
| 7.2.1 | Literature search and eligibility criteria .....                       | 19 |
| 7.2.2 | Study selection and data extraction .....                              | 20 |
| 7.2.3 | Quality assessment.....  | 21 |
| 7.2.4 | Data synthesis and analysis.....                                       | 21 |
| 8     | RESULTS.....   | 23 |
| 8.1   | Study I: Population-based registry analysis.....                       | 23 |
| 8.1.1 | Participants .....   | 23 |
| 8.1.2 | Characteristics of the study population.....                           | 23 |
| 8.1.3 | Risk of NCAs by maternal age category.....                             | 25 |
| 8.1.4 | Level of evidence .....  | 30 |
| 8.2   | Study II: Meta-analysis .....  | 31 |
| 8.2.1 | Study selection.....   | 31 |
| 8.2.2 | Study characteristics .....  | 32 |
| 8.2.3 | Risk of bias assessment.....   | 32 |
| 8.2.4 | Heterogeneity and publication bias.....                                | 32 |
| 8.2.5 | Risk of NCAs by maternal age category.....                             | 46 |
| 9     | DISCUSSION .....   | 59 |
| 9.1   | Summary of findings, international comparisons (including all studies) | 59 |
| 9.2   | Strengths (including all studies) .....                                | 67 |
| 9.3   | Limitations (including all studies).....                               | 68 |



|             |   |           |
|-------------|---|-----------|
| <b>10</b>   | <b>CONCLUSIONS .....</b>                            | <b>70</b> |
| <b>11</b>   | <b>IMPLEMENTATIONS FOR PRACTICE.....</b>            | <b>71</b> |
| <b>12</b>   | <b>IMPLEMENTATION FOR RESEARCH .....</b>            | <b>72</b> |
| <b>13</b>   | <b>IMPLEMENTATION FOR POLICYMAKERS.....</b>         | <b>73</b> |
| <b>14</b>   | <b>FUTURE PERSPECTIVES .....</b>                    | <b>74</b> |
| <b>15</b>   | <b>REFERENCES.....</b>                              | <b>75</b> |
| <b>16</b>   | <b>BIBLIOGRAPHY .....</b>                           | <b>94</b> |
| <b>16.1</b> | <b>Publications related to the thesis .....</b>     | <b>94</b> |
| <b>16.2</b> | <b>Publications not related to the thesis .....</b> | <b>95</b> |
| <b>17</b>   | <b>ACKNOWLEDGEMENTS.....</b>                        | <b>96</b> |

## 1 LIST OF ABBREVIATIONS

|                 |   |
|-----------------|---|
| <b>AMA</b>      | advanced maternal age   |
| <b>CA</b>       | chromosomal anomaly   |
| <b>CHD</b>      | congenital heart defect   |
| <b>CI</b>       | confidence interval   |
| <b>EUROCAT</b>  | European Concerted Action on Congenital Anomalies and Twins (a network of population-based congenital anomaly registries across Europe) |
| <b>GDM</b>      | gestational diabetes mellitus   |
| <b>GRADE</b>    | Grading of Recommendations Assessment, Development and Evaluation (a tool for grading the quality of evidence)                          |
| <b>HCCSCA</b>   | Hungarian Case-Control Surveillance of Congenital Abnormalities   |
| <b>HCAR</b>     | Hungarian Congenital Abnormality Registry   |
| <b>ICD</b>      | International Classification of Diseases  |
| <b>IVF</b>      | <i>in vitro</i> fertilization   |
| <b>KSH</b>      | <i>Központi Statisztikai Hivatal</i> (Hungarian Central Statistical Office)   |
| <b>MEDLINE</b>  | Medical Literature Analysis and Retrieval System Online (the bibliographic database of the National Library of Medicine)                |
| <b>NCA</b>      | non-chromosomal anomaly   |
| <b>NTD</b>      | neural tube defects   |
| <b>OR</b>       | odds ratio  |
| <b>PECO</b>     | population, exposure, comparator, outcome (a framework for formulating scientific questions)  |
| <b>PRISMA</b>   | Preferred Reporting Items for Systematic Reviews and Meta-Analyses  |
| <b>PROSPERO</b> | International prospective register of systematic reviews  |
| <b>QUIPS</b>    | Quality in Prognostic Studies (a tool to assess the study quality and risk of bias)   |
| <b>ROBVIS</b>   | a risk of bias visualization tool for systematic reviews  |
| <b>RR</b>       | risk ratio  |
| <b>SD</b>       | standard deviation  |

|               |  |
|---------------|--|
| <b>STROBE</b> | strengthening the reporting of observational studies in epidemiology (a checklist of items that should be included in observational research articles) |
| <b>WHO</b>    | World Health Organization  |

## 2 STUDENT PROFILE

### 2.1 Vision and mission statement, specific goals

My vision is a world where women receive state-of-the-art prenatal care, ensuring the best possible outcomes for the next generation. My mission is to promote the adoption of innovative screening and monitoring techniques in prenatal care. My specific goal is to elevate screening methods for non-chromosomal birth defects to the highest possible standard, enhancing early detection and intervention worldwide.



### 2.2 Scientometrics

|   |                  |
|---|------------------|
| <b>Number of all publications:</b>                                  | 5                |
| Cumulative IF:  | 21.391           |
| Av IF/publication:  | 4.278            |
| Ranking (SCImago):  | D1:2, Q1:2, Q3:1 |
| <b>Number of publications related to the subject of the thesis:</b> | 2                |
| Cumulative IF:  | 13.4             |
| Av IF/publication:  | 6.7              |
| Ranking (Sci Mago):   | D1:2, Q1:, Q2: - |
| <b>Number of citations on Google Scholar:</b>                       | 31               |
| <b>Number of citations on MTMT (independent):</b>                   | 11               |
| <b>H-index:</b>   | 3                |

The detailed bibliography of the student can be found on pages 94-95.

### 2.3 Future plans

I plan to expand my research in prenatal care by utilizing my extensive knowledge in this area. A thorough understanding of healthcare necessitates combining practical experience with academic knowledge. I am committed to actively engaging in prenatal patient care to improve my skills and expand my perspective. Through daily contact with pregnant women, my aim is to gain a deep knowledge of their distinct demands, challenges, and worries.


With the cohesion of my research and clinical experiences in the field of prenatal medicine, my goal is to build a professional path that raises prenatal care to the highest possible level, thereby improving the well-being of mothers and their babies.

### **3 SUMMARY OF THE THESIS**

There is a well known association between maternal age at birth and non-chromosomal congenital anomalies (NCAs), but the exact details are still under active research. Our aim was to identify maternal age groups with elevated risk of NCAs and to analyze the age-dependent risk variation of different anomalies. To improve our comprehension and practical use, we conducted a thorough investigation utilizing a database that encompasses the entire population of Hungary over almost three decades, as well as a meta-analysis of existing population-based studies worldwide. We found strong evidence that the risk of occurrence of NCAs – excluding cases with concomitant chromosomal anomalies (CAs) – is higher for mothers over 40: RR = 1.25 (CI: 1.08–1.46) in the meta-analysis and 1.35 (CI: 1.23–1.49) in the population based study. The elevated risk in case of very young mothers was also evidenced in the population based study, however, the risk increase for the same age group in the meta-analysis did not turn out to be significant. The year-by-year data available in the population based data enabled a more precise delineation of the lowest risk maternal age range: mothers between 23 and 32 years age had the lowest chance for NCAs. When investigating specific NCA categories, concordance between the two studies was strongest for the circulatory system and cleft lip and palate, with both showing elevated risk in the 40+ age group.

The findings underscore the importance of revising current prenatal screening protocols to ensure they also account for maternal age. The results suggest that it may be beneficial to use maternal age as a screening criterion for both fetal echocardiography and neurosonography. In addition, public health policy should incorporate educational campaigns targeting high-risk age groups to emphasize the significance of prenatal care and screening. Customized counseling taking into account risks specific to different age groups can improve the effectiveness of prenatal care and assist pregnant women in making well-informed decisions.

4 GRAPHICAL ABSTRACT



## **5 INTRODUCTION**

### **5.1 Overview of the topic**

#### **5.1.1 What is the topic?**

The focus of my research is to investigate the impact of maternal age on the occurrence of non-chromosomal congenital anomalies (NCAs) in order to identify specific age-related risk categories and improve prenatal screening protocols.

#### **5.1.2 What is the problem to solve?**

The issue lies in the limited evidence regarding the exact relationship between maternal age and the occurrence of NCAs. This lack of clarity makes it difficult to develop accurate prenatal screening protocols and public health strategies.

#### **5.1.3 What is the importance of the topic?**

The importance of this topic cannot be overstated, as congenital anomalies are frequent with 3-5% worldwide(1, 2) and play a significant role in infant mortality (6% of infant death worldwide)(3) and morbidity rates (approximately 20%)(4, 5) as well as result in substantial healthcare expenses(6). By understanding the influence of maternal age on NCAs, we can improve prenatal screening protocols and public health strategies, consequently reducing the occurrence and impact of these anomalies on families and the healthcare system.

#### **5.1.4 What would be the impact of our research results?**

The outcomes of our research will have significant impact by enhancing prenatal screening protocols and public health strategies. Healthcare providers can enhance the effectiveness of prenatal care by identifying maternal age groups that are at a higher risk for NCAs. Public health campaigns can be customized to provide education and assistance to age groups that are at a higher risk, ultimately decreasing the occurrence and effect of NCAs. Furthermore, our findings will provide direction for future investigations and policy choices focused on improving maternal and child health outcomes.

## **5.2 Maternal age – a critical factor in pregnancy outcome**

Over the previous few decades, women's typical delivery age has increased in developed countries.(7) Postponing childbearing is a complex phenomenon caused by social and cultural changes.(8, 9) A growing number of couples are conceiving their first child while the mother is between the ages of 30 and 35.(10) According to the literature, advanced maternal age (AMA) begins at age 35 ( $\geq 35$  years old) but this is by far not a universal definition, and a distinct age limit could be established for each adverse perinatal outcome. The proportion of births to mothers over the age of 35 has doubled since 1990, accounting for approximately 20% of births in 2021; birth rates among mothers in their forties have also steadily increased during this time.(11) In addition to social trends, innovations in assisted reproduction techniques are increasingly allowing women to have children after the age of 35 or even 40.(12)

Many studies have linked postponement of childbearing to a variety of pregnancy and fetal complications (13-15) as well as recommendations for managing these high-risk pregnancies.(16) AMA has been linked to an increased risk of gestational diabetes mellitus(17-19), hypertensive disorders of pregnancy(20, 21), preterm delivery(22, 23), fetal growth restriction(24, 25), stillbirth(26, 27), and cesarean delivery(28, 29), among other complications. The results of the large epidemiological studies were also confirmed by studies with animal models, which make it possible to explore the mechanisms behind poor pregnancy outcomes and to develop therapeutic methods.(30) AMA, even in older pregnant women without additional health conditions like gestational hypertension or diabetes, is still associated with poorer obstetric and perinatal outcomes. This suggests that advanced maternal age alone is a significant and independent risk factor.(31) In addition to high-risk pregnancies and perinatal outcomes, AMA plays an important role in congenital anomalies. This association is strong and well known in relation to chromosomal anomalies, however, in case of NCAs, it is less coherently reported in the literature.

Very young maternal age ( $< 20$  year old) is also a major risk factor for adverse pregnancy outcomes (higher rates of eclampsia, low birth weight and preterm delivery to mention the most important).(32, 33) The global adolescent birth rate has decreased by more than 30 percent between 2000 and 2022, going from 65 to 42 births per 1,000 adolescent girls aged 15-19.(34) This trend is the result of education, better access to contraception and



social changes.(35) Very young maternal age does not seem to be an independent risk factor for most outcomes. Rather, the increased risk appears to be a consequence of the circumstances associated with becoming pregnant without planning as an adolescent.(36) Substance abuse, higher rates of sexually transmitted infections, poorer nutritional conditions and low socioeconomic status may explain poorer pregnancy outcomes.(37-39)

### **5.3 Congenital anomalies – the leading cause of neonatal mortality and morbidity**

Congenital anomalies are structural or functional abnormalities that develop during intrauterine life and can be detected intrauterinely, at birth, or, occasionally, during infancy.(40) Congenital anomalies affect three to five percent of all births worldwide (1, 2), which is a main cause of infant mortality(41) and morbidity, responsible for the loss of 25.3–38.8 million disability-adjusted life years globally.(42) According to the EUROCAT survey, the average relative frequency of birth defects in Europe was 23.9 per thousand births in 2010.(43) The 2010 Global Burden of Disease study estimates that congenital anomalies account for 6% of infant deaths worldwide(3), while other studies show that approximately 20% of neonatal and infant mortality is associated with congenital anomalies.(4, 44)

The overall occurrence of significant birth defects has remained consistent over time. However, both increasing (e.g. atrioventricular septal defect, tetralogy of Fallot, omphalocele) and decreasing (e.g. anencephaly, common truncus, transposition of the great arteries, and cleft lip with and without cleft palate) trends were observed for certain conditions.(5)

Congenital anomalies impose a significant burden on society as a whole, particularly on affected families and the health and social care systems. Furthermore, congenital anomaly-related hospitalizations are extraordinarily costly, accounting for 4.1% of all hospitalizations and 7.7% of entire hospital expenses (among patients under 65 years), and with an estimated annual expense of \$22.2 billion in the United States in 2019.(6) These facts emphasize the global significance of congenital anomalies in research, prevention and screening. It is essential to prioritize appropriate intervention as a matter of public health. Several known maternal lifestyle risk factors and chronic illnesses are clearly associated with the occurrence of congenital anomalies. For example, a meta-

analysis found that maternal tobacco use during pregnancy increases the risk of congenital anomalies (OR = 1.18; CI: 1.03–1.34).(45) The risk-increasing effect of maternal diabetes is also considered in genetic screening. A comprehensive study found that pre-gestational diabetes has a significant effect (RR = 2.66; CI: 2.04–3.47).(46)

#### **5.4 Potential association between NCAs and maternal age**

Among congenital anomalies, chromosomal anomalies (CAs) are clearly associated with advanced maternal age (47-50), a long-standing fact that has resulted in the current professional screening protocols.(51, 52) However, there is no consensus with regard to the degree of association between NCAs and maternal age.

While the role of maternal age in the development of NCAs is generally accepted, the literature is inconsistent regarding the risk of NCAs in specific age groups. This is a major issue not only because of the trend towards delayed childbearing but also because of the risks of adolescent pregnancies. Some studies show a risk-increasing effect only for the very young(53) (generally defined as under 20 years old) or only for the advanced-aged(generally defined 35 years old or older) population(54), while others for both age categories.(55, 56)

When examining the effect of maternal age on NCAs, a comprehensive analysis is justified not only by the inconsistent data. Studies are very heterogeneous in terms of age categories and the classification of NCAs: On the one hand, there is no universally accepted reference age category, on the other hand, anomalies are classified in various ways that may or may not correspond to International Classification of Diseases (ICD) categories.

The underlying maternal age related factors contributing to the increased risk of NCAs are known, even though the precise biological links remain undetermined. The susceptibility of the very young age group can be largely attributed to the teratogenic effects resulting from the lifestyle and living conditions of mothers who became pregnant at a very young age, as well as their limited adoption of primary prevention measures. In detail, these factors may encompass smoking, drug and alcohol abuse (the combined prevalence of substance is 41.0%), low socioeconomic status, low level of education, and a lack of sufficient folic acid supplementation which is common in case of intentional childbearing.(57) Insufficient consumption of folic acid is unequivocally linked to an elevated susceptibility to neural tube defects.(58) To what extent AMA is responsible

directly and indirectly (i.e. via age-related chronic diseases) for the increased risk of NCAs is not yet established. The necessary basic research – e.g. that would clarify the role of age-related decline of oocyte quality and deteriorated repair processes in increased risk of NCAs – is still missing.

## **6 OBJECTIVES**

### **6.1 Study I. – Investigating the Impact of Maternal Age on the Development of Non-Chromosomal Congenital Anomalies in the Hungarian Population between 1980 and 2009**

The aim of this study was to use our distinct database to determine the specific 10-year period of maternal age in Hungary that has the lowest risk for NCAs. Additionally, we also wanted to compare other maternal ages to this specific period in order to offer an original perspective on the relationship between maternal age and NCAs. The reason for this approach was to enhance our comprehension of age-related vulnerabilities and provide insights for modifying prenatal screening protocols according to the maternal age.

### **6.2 Study II. – Investigating the Impact of Maternal Age on the Development of Non-Chromosomal Congenital Anomalies Worldwide**

The objective of this study was to perform a comprehensive meta-analysis investigating the occurrence of NCAs based on maternal age. Despite thorough investigation on this subject, the full scope and characteristics of the association between maternal age and NCAs are still uncertain. The existing literature lacks a unanimous agreement on the specific particulars of this relationship. The objective of this study was to elucidate these factors and offer valuable perspectives for formulating age-specific guidelines for prenatal screening and public health strategies.

## **7 METHODS**

### **7.1 Study I.**

#### **7.1.1 Study design**

We conducted a population-based study in Hungary over a span of nearly 30 years to examine the occurrence of NCAs in relation to the age of the mothers. This study collected cases from the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA), and the total number of live births during the study period from the Hungarian Central Statistical Office (KSH). Instead of comparing arbitrary age categories, we used the restricted cubic spline model to identify high- and low-risk maternal age groups.<sup>(59)</sup> We present our population-based study in accordance with the guidelines outlined in the STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guideline.<sup>(60)</sup>

#### **7.1.2 Setting**

Our study examines the HCCSCA, which was established in 1980 and ended in 2009.<sup>(61)</sup> The data collection process underwent modifications in 1997, specifically impacting the collection of matched controls that were not utilized in the present study. Consequently, this led to slight adjustments in the structure of the HCCSCA. The data collected from 1980 to 2009 through the HCCSCA was consolidated into a single, validated database.<sup>(62)</sup> In 2002, the legal basis of data privacy was called into question and data collection was halted until 2005 following the concerns raised by a mother.


Physicians in Hungary have been required to report patients as cases with congenital anomalies to the Hungarian Congenital Abnormality Registry (HCAR) since 1962. This reporting obligation applies from birth until the end of the first postnatal year. The HCAR, established in 1962, was the inaugural international registry of congenital anomalies with a national focus.<sup>(63)</sup> Starting from 1984, the prenatal diagnostic centers were required to inform the HCAR about any prenatally diagnosed fetuses with or without elective termination of pregnancy, if they were found to have malformations. The HCCSCA has registered cases from the HCAR since 1980.

### 7.1.3 Ethics and patient consent

The data analysis was conducted with the approval of the Scientific and Research Ethics Committee of the Medical Research Council, Hungary (BMEÜ/920-3/2022/EKU). Our study did not report any registry data that could be identified. There is no legal requirement for obtaining informed consent in order to register a baby with a congenital anomaly.

### 7.1.4 Participants

Cases with CAs in the HCAR were enrolled to the HCCSCA if they met all the following selection criteria: (1) reported to the HCAR within 3 months after birth or elective termination of pregnancy, (2) none of the three mild congenital anomalies (hip dislocation, congenital inguinal hernia, and large haemangioma) were present alone, and (3) did not have congenital anomaly-syndromes caused by gene mutations or chromosomal anomalies with preconceptional origin. In our analysis, we excluded cases with incomplete data or the co-presence of chromosomal anomalies (**Figure 1**). The main task of the HCCSCA has been the detection of teratogenic/fetotoxic agents and other environmental effects during pregnancy resulting in the development of birth defects. The case group contains live births, stillbirths, and elective terminations of pregnancies following prenatal malformation diagnosis. For the number of controls, the total number of live births by maternal age in Hungary during the study period was obtained from the KSH.



**Figure 1.** *Study plan*(64)

### **7.1.5 Variables and data sources**

The data collection process recorded the following information for each patient: NCA(s), gender, maternal age, paternal age, birth date, birth weight, gestational age, place of mother's residence, birth order, mother's and father's level of education, employment status and type of employment, mother's marital status, outcome of previous pregnancies, maternal diseases during pregnancy (specified by month), medication during pregnancy (specified by month), and the mother's smoking habits and alcohol consumption patterns.(62)

The maternal age was documented at the moment of childbirth or termination of pregnancy as a result of fetal anomaly. Data regarding maternal diseases, lifestyle factors, and medication usage during pregnancy were gathered through various methods. Initially, mothers submitted their comprehensive medical records pertaining to their current pregnancy, which were then meticulously documented by professionals (prospective, medically recorded data). Subsequently, a questionnaire was sent via mail to the mothers, which included inquiries regarding maternal illnesses, drug treatments during pregnancy, and pregnancy supplements. The information collected was retrospective and based on self-reports from the mothers. Finally, nurses from different regions visited all the mothers. They assisted mothers in gathering and presenting their medical records and completing the supplementary data collection questionnaire.

### **7.1.6 Bias and evidence synthesis**

The maternal ages were documented using birth certificates, guaranteeing a high degree of precision in the data. The distinct characteristics of data collection and verification additionally bolster the dependability of the data. Nevertheless, the categorization of results was not uniform throughout the extensive duration of the study. When converting various ICD categories, the groupings used may not always align perfectly.

We employed the GRADEpro tool to evaluate the degree of evidence underlying our findings.(65) The GRADE is a standardized methodology that allows for clear and consistent evaluation of evidence quality, and thus enables the judgement of the reliability of study results.

### 7.1.7 Statistical methods

Primary data extraction and organization were carried out in Microsoft Excel. Statistical analysis was carried out in R (version 4.1.3).(66)

The aim of our analysis was to determine high risk maternal age for each NCA category. We used a two-way approach.

First, we identified the best ten-year period of maternal age corresponding to the anomaly's lowest relative frequency. Risk was calculated as: number of cases among live births + stillbirths + elective terminations of pregnancies following prenatal diagnosis of malformation / total number of live births in the population. Risk ratios (RR) for each year were determined by taking the best ten-year period as a "reference risk". (Despite the case-control approach, RR could be used because data collection included the whole population.) Cases with maternal age less than 13 (1 case) and greater than 45 years (9 cases) were excluded because the very low number of cases in these maternal age ranges would have made the regression unreliable. The confidence interval (CI) of relative frequency was estimated according to Agresti and Coull.(67)

Second, we fitted a non-linear, non-parametric logistic regression model on the original data (namely, a restricted cubic splines model using 5 knots at the .05 .275 .5 .725 and .95 quantiles, as recommended in literature; explanatory variable: maternal age; response variable: presence or absence of NCAs) using the "rms" R package (version 6.2.0).(68) The resulting relative frequency estimates of the regression were transformed to the RR scale in order to enable graphical representation in the figure showing the year-by-year risk estimates calculated above.

A grouping of NCA categories based on high risk maternal age was done by considering the confidence bands in addition to assessing the shape of the curves: a curve may appear U shaped at first glimpse but the risk increase is not necessarily statistically substantiated in both directions, i.e. the CI-band may contain the  $RR = 1$  line corresponding to zero effect.

All CIs were calculated at a confidence level  $(1-\alpha)$  of 95%.



## **7.2 Study II.**

We documented our systematic review and meta-analysis based on the guidance of the PRISMA 2020 guideline (69), and we adhered to the Cochrane Handbook for Systematic Reviews of Interventions.(70) The protocol of the study was prospectively registered on PROSPERO (International Prospective Register of Systematic Reviews) (71) (registration number CRD42021283593), and we adhered to it, with some deviations: Title modification for the purpose of enhancing clarity and conciseness; Subgroup analyses were performed without prior specification; The searches involved examining reference lists of eligible articles for screening purposes. Only population-based studies that provided precise NCA counts were included in order to facilitate risk assessment. For the sake of simplicity in understanding, Risk Ratios were utilized instead of Odds Ratios. Publication bias was assessed only visually. However, these modifications primarily pertain to technical aspects and do not change the underlying conceptual framework of the study.

### **7.2.1 Literature search and eligibility criteria**

#### *Information sources*

The search was systematically carried out in three extensive medical databases: MEDLINE (via PubMed), the Cochrane Library (CENTRAL), and Embase on October 19, 2021.

#### *Search strategy*

We conducted a systematic search using the following search term: ("maternal age" OR "maternal ages" OR "mother age" OR "mother ages") AND (((congenital OR birth) AND (anomaly OR anomalies OR disorder OR disorders OR malformation OR malformations OR defect OR defects)) OR congenital abnormalities. The search was conducted without any language restrictions or filters. In addition, we examined the bibliography of the eligible articles.

#### *Eligibility criteria*

The research question was formulated utilizing the PECO framework. We included population-based studies reporting on pregnant women (P). We did not have pre-defined exclusion criteria (e.g., age range, country, comorbidities) for our population. Eligible studies compared different maternal age groups (E and C) regarding NCAs. We examined every pre-defined age group reported by the eligible studies. Our primary outcome (O)

was the rate of all NCAs combined, while the secondary outcomes were the various specific structural defects. We did not have pre-defined diagnostic criteria for the NCAs. Studies not reporting the total number of patients and the number of NCAs by age group were not eligible. The following exclusion criteria were pre-defined: CAs as target outcomes; case-control or cohort studies; case series; and case reports.

### **7.2.2 Study selection and data extraction**

#### *Study selection*

After removing duplicates, the selection was performed independently by three review authors, first by title, then by abstract, and finally based on full text according to the aforementioned criteria. Endnote v20 (Clarivate Analytics, Philadelphia, PA, USA) reference manager software was used for the selection. We calculated Cohen's kappa coefficient after each selection process to measure interrater reliability.(72) Disagreements were resolved through consensus. In cases where consensus could not be reached, a final decision was made with the participation of a fourth independent review author. The study selection process is shown using the PRISMA 2020 flowchart (**Figure 5**).

#### *Data extraction*

The author and two additional researchers independently gathered data from the eligible articles. In instances of disagreement, the decision was made by reaching a consensus. If a consensus could not be reached, a final decision was made by including a fourth researcher. The following data were extracted with a standardized collection method to an MS Excel sheet (Office 365, Microsoft, Redmond, WA, USA): first author, the year of publication, study population, study period, study site (region), study design, demographic data of the patients, total number of patients in the age groups, number of NCAs in the age groups, and further information necessary for assessing the risk of bias in the studies.

To investigate which maternal age increases the probability of particular NCAs, we utilized the age categories from the included studies or defined new ones by combining two or more age groups. The age group of 20- to 30-year-old mothers was used as a reference group. In defining the age groups, the ideal 10-year period was based on other studies, including our own work.(64) We aimed to look at very young mothers (under 20 years), advanced maternal age (35 years or older, as commonly defined); and mothers

over 40. In addition, we created additional groupings for the 30–35 and 35–40 maternal ages so that the potential association between maternal age and risk change of a given NCA may be more accurately determined. A study was included in the data analysis, if data was available for the reference age category and at least one additional age category for at least one NCA. To ensure consistency, we classified the endpoints according to ICD-10.

### **7.2.3 Quality assessment**

The author and an additional researcher performed the risk of bias assessment independently with the help of the Quality in Prognostic Studies (QUIPS) tool.(73) Disagreements were resolved by a third researcher. A web-based Risk of Bias VISualization (ROBVIS) tool for systematic reviews was used to visualization of the results.(74)

### **7.2.4 Data synthesis and analysis**

As a general rule, we carried out a mathematical synthesis if there were at least three matching articles regarding the age groups and NCAs. In a very few cases, when for non of the age groups were at least 3 studies available for the given anomaly, we carried out the meta-analysis of even only two studies to get at least a limited information.

All statistical analyses were made with R (66) using the 5.5.0 version of meta (75), and the 0.0.9000 version of the dmetar (76) packages.

We anticipated considerable between-study heterogeneity in the study population; therefore, a random-effects model was used to pool effect sizes. RRs with 95% CI was calculated as a random effects estimate with the metabin function of the meta R package. The Mantel-Haenszel method(77-79) was used to pool RRs. Since the exact Mantel-Haenszel method was used, we did not apply continuity correction to handle zero cell counts.(80)

For outcomes with at least five studies, a Hartung-Knapp adjustment was used.(81, 82) We applied the Paule-Mandel method (83) to estimate the between-study variance (tau squared).

Additionally, between-study heterogeneity was investigated by Cochrane's Q test. Significant heterogeneity was considered at  $p < 0.1$ . Higgins & Thompson's  $I^2$  statistics and 95% CI (82) were reported to illustrate the total variation across studies due to between-study heterogeneity.

Following the recommendations of IntHout et al.(84), where applicable, we also reported the prediction intervals (i.e., the expected range of effects of future studies) of the pooled estimates.

A Cochrane Q test was used between subgroups to assess the age group differences. The null hypothesis was rejected at a 5% significance level. We used forest plots to summarize the results graphically.

Publication bias (a.k.a. small study effect) was assessed visually using funnel plots (forest function of the meta R package), where asymmetry suggests potential bias. Formal assessment was not carried out if less than 10 studies were available, due to the increased risk of unreliable or misleading conclusions.

## 8 RESULTS

### 8.1 Study I: Population-based registry analysis

#### 8.1.1 Participants

Over the study period, a total of 31,128 cases of NCAs were identified in Hungary, alongside 2,808,345 live births recorded during the same timeframe. **Table 1** presents the age distribution of the study population, showing that 7.66% of all births fell into the very young (under 20 years) and 6.62% into the advanced (35 years or more) maternal age categories. Additionally, mothers over 40 accounted for 1.11% of births. This means that 14.28% of births were in the maternal age groups expected to pose an increased risk. Mean maternal age was practically the same among cases (26.0 years; SD = 5.4) and in the total population (26.1 years; SD = 5.1).

**Table 1.** *Age distribution of cases and total population by age(64)*

| Maternal age | Number of live births in Hungary 1980 - 2009 | Number of cases of NCA in Hungary 1980 – 2009 |
|--------------|--|---|
| 13 – 19      | 214 718                                      | 3 060   |
| 20 – 24      | 940 062                                      | 10 474  |
| 25 – 29      | 981 027                                      | 10 073  |
| 30 – 34      | 486 657                                      | 5 182   |
| 35 – 39      | 154 753                                      | 1 893   |
| 40 – 45      | 31 128                                       | 446   |

#### 8.1.2 Characteristics of the study population

Thanks to the population-wide data collection, we had individual information about the cases. In the table below, we summarized some of this information. (**Table 2**) The most notable is the sex of the fetuses, which is around 65% male.

**Table 2.** *Baseline characteristics table(64)*


|                                 | maternal age: all<br>(13–45 years)<br>[count: 31,118] |            |     |
|---------------------------------|---|------------|-----|
|                                 | count   | mean       | SD  |
| <b>birth mass (g)</b>           | 30,908  | 3,018      | 707 |
| <b>gestation period (weeks)</b> | 30,995  | 38.5       | 3.2 |
| <b>paternal age (years)</b>     | 1,851   | 32.1       | 6.4 |
|                                 | count   | proportion |     |
| <b>gender</b>                   |   |            |     |
| male                            | 20,046  | 65.64%     |     |
| female                          | 10,492  | 34.36%     |     |
| NA                              | 580   |            |     |
| <b>birth order</b>              |   |            |     |
| primiparous                     | 16,309  | 55.76%     |     |
| multiparous                     | 12,939  | 44.24%     |     |
| NA                              | 1,870   |            |     |
| <b>maternal smoking</b>         |   |            |     |
| smoker                          | 2,776   | 35.51%     |     |
| nonsmoker                       | 5,041   | 64.49%     |     |
| NA                              | 23,301  |            |     |
| <b>maternal education</b>       |   |            |     |
| managerial                      | 1,377   | 15.26%     |     |
| professional                    | 2,450   | 27.14%     |     |
| skilled worker                  | 2,376   | 26.32%     |     |
| semiskilled                     | 2,327   | 25.78%     |     |
| unskilled                       | 496   | 5.50%      |     |
| NA                              | 22,092  |            |     |

### **8.1.3 Risk of NCAs by maternal age category**

The relative frequency of NCAs in the study period was 1.1% (excluding cases with only mild anomalies and cases with concomitant chromosomal anomalies, as described in the methodology earlier).

All NCAs (ICD-10 Q00-Q89):

In the first step, all NCAs were analyzed together (**Figure 2**). We found a risk-increasing effect for both the advanced and the very young maternal age. The lowest risk ten-year period turned out to fall between 23 and 32 years (light gray shading); both lower (RR = 1.2; CI: 1.17–1.23) and higher (RR = 1.15; CI: 1.11–1.19) maternal age pose an almost identically increased risk of anomalies. The year-by-year RRs (circle markers) imply an increasing trend in both directions. The fitted regression line (black, with a dark gray confidence band) stresses that both very young and advanced maternal age increase risk even more. Even though the confidence range becomes wider in the very young and old maternal age groups due to the low number of cases, the trend is still clear.



**Figure 2.** *Analysis of all NCAs by maternal age(64)* The figure shows the estimated risk ratios of NCAs as a function of maternal age with the best ten-year-period as "reference risk" (circle markers). The best ten-year-period is highlighted with light gray. The black curve shows the result of the restricted cubic splines regression, the dark gray area is its confidence range.



In the next step, NCAs were analyzed one-by-one by ICD categories (**Figure 3** and **Table 6**).

Congenital malformations of the nervous system (ICD-10: Q00-Q07)

The lowest risk ten-year-period in this category was detected between 26-35 years of maternal age. This is also the only NCA category where only the young maternal age is significantly associated with increased risk. Looking at the entire low-age group (< 26 years), the risk increase is 25%. For the very young age group (< 20), there is an even higher risk: RR = 1.71 (CI: 1.48–1.97).

Congenital malformations of eye, ear, face and neck (ICD-10: Q10-Q18)

The best-ten-year period for this type of anomaly was between 30–39 years. The advanced maternal age above this period shows a risk-increasing effect while young age (< 30 years) does not. Looking at the figure, the results appear to be somewhat inconsistent, because the risk increase already becomes significant above 35 years, which is still in the best-ten-year period. The risk increase is especially high above 40 years: RR = 2.09 (CI: 1.25–3.49).

Congenital malformations of the circulatory system (ICD-10: Q20-Q28)

The lowest risk ten-year-period falls between 23–32 years. Outside this age range, there is an increase in risk at both very young (< 23 years; RR = 1.07; CI: 1.01–1.13) and advanced maternal ages (> 32 years; RR = 1.33; CI: 1.24–1.42), but it is more pronounced in vase of the advanced age group. From a clinical point of view, it is noteworthy that within the advanced maternal age group, the risk was particularly elevated in mothers over 40 years: RR = 1.72 (CI: 1.45–2.05).

Congenital malformations of the respiratory system (ICD-10: Q30-Q34)

According to our analysis, respiratory system anomalies could not be proven to be associated with maternal age. Though a lowest risk ten-year-period was determined here as well, this is unlikely to reflect reality due to the scarcity of cases and the associated increased role of random data variation.

#### Cleft lip and cleft palate (ICD-10: Q35-Q37)

The lowest risk ten-year-period was found to be between 25–34 years of maternal age for this group of NCAs. There is an increase in risk both below (RR = 1.07; CI: 1.01–1.13) and above (RR = 1.33; CI: 1.24–1.42) this maternal age range, but it is more pronounced at advanced ages. In this case, too, mothers aged 40 and above faced the highest risk: RR = 1.58 (CI: 1.16–2.16).

#### Congenital malformations of the digestive system (ICD-10: Q38-Q45)

The lowest risk was for maternal age between 24 and 33 years, with both lower (RR = 1.23; CI: 1.14–1.31) and older (RR = 1.15; CI: 1.02–1.29) maternal age as a significant risk-increasing factor. The most pronounced increase in risk was observed for mothers under the age of 20: RR = 1.46 (CI: 1.31; 1.64).

#### Congenital malformations of genital organs (ICD-10: Q50-Q56)


The lowest risk ten-year-period was found between 25–34 years. Both the younger (RR = 1.15; CI: 1.08–1.22) and the more advanced (RR = 1.16; CI: 1.04–1.29) maternal age increases the risk – to a similar extent – The risk is expected to increase by around 30% for mothers both under 20 and over 40 years.

#### Congenital malformations of the urinary system (ICD-10: Q60-Q64)

The lowest risk ten-year-period was detected between 15–24 years. Higher maternal age increases the risk (RR = 1.34; CI: 1.19–1.50), with an even higher risk above 40: RR = 2.27 (CI: 1.53–3.38). Though the below 20 age category overlaps with the lowest risk age range, a risk increase could still be detected: RR = 1.29 (CI: 1.04–1.60).

#### Congenital malformations and deformations of the musculoskeletal system (ICD-10: Q65-Q79)

The optimal age range is between 27–36 years. Both the younger (RR = 1.17; CI: 1.12–1.23) and the older (RR = 1.29; CI: 1.14–1.44) maternal age increases the risk. The probability of these anomalies increases most in people under 20 years of age: RR = 1.57 (CI: 1.46–1.70).



**Figure 3.** Summary results for the NCA categories(64)

### 8.1.4 Level of evidence

The level of evidence was only assessed in case of the overall outcome “all NCAs combined”. Here, we found a “moderate” level (i.e. level 3 on a 4-level scale with levels “very low”, “low”, “moderate”, and “high”) of evidence certainty for both the very young (< 23 years) and the advanced (> 32 years) age groups. The main reason for this is the observational study design and the lack of inclusion of confounders in the analysis.


**Table 3.** *Grading of the primary outcomes(64)*

| Certainty assessment  |                       |              |               |              |             |                        | № of patients(1) |               | Effect                 |  | Certainty     | Importance |
|---|-----------------------|--------------|---------------|--------------|-------------|------------------------|------------------|---------------|------------------------|--|---------------|------------|
| № of studies  | Study design          | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations   | maternal ages    | maternal ages | Relative (95% CI)      | Absolute (95% CI)                                      |               |            |
| all non-chromosomal congenital anomalies together - very young maternal age |                       |              |               |              |             |                        |                  |               |                        |  |               |            |
| 1   | observational studies | not serious  | not serious   | not serious  | not serious | dose response gradient |                  |               | RR 1.20 (1.17 to 1.23) | 1 fewer per 100 (from 1 fewer to 1 fewer) <sup>a</sup> | ⊕⊕⊕○ Moderate | CRITICAL   |
| all non-chromosomal congenital anomalies together - advanced maternal age   |                       |              |               |              |             |                        |                  |               |                        |  |               |            |
| 1   | observational studies | not serious  | not serious   | not serious  | not serious | dose response gradient |                  |               | RR 1.15 (1.11 to 1.19) | -  | ⊕⊕⊕○ Moderate | CRITICAL   |

## 8.2 Study II: Meta-analysis

### 8.2.1 Study selection

After duplicate removal, 15,547 studies were identified by our search in the three screened databases, from which 72 full-text articles were included in our synthesis following the selection process shown in **Figure 4** below.




**Figure 4.** PRISMA 2020 flowchart representing the study selection process(85)

### 8.2.2 Study characteristics

The baseline characteristics of the included studies are detailed in **Table 4**. Our meta-analysis includes population-based studies from all over the world: 37 studies come from the Americas, 17 from Europe, 14 from Asia, 3 from Australia, and 1 from Africa; the precise geographic location is indicated in the baseline table. In terms of the data collection period, the included studies encompass an overall timeframe between 1940 and 2018. All studies are population-based, with 36 studies carried out at the national level, 34 at the subnational level, and two at the multinational level, mostly based on the corresponding registries.

### 8.2.3 Risk of bias assessment

The results of the risk of bias assessment are presented in **Figure 5**. The overall risk of bias (possible levels are low, medium and high) is 88% low, 12% moderate, and 0% high. The two component bias aspects with the highest risk were the bias due to confounding (38% low, 62% moderate, 0% high) and bias due to participation (51% low, 49% moderate, 0% high). The main source of risk of bias in both cases is the limited reporting of population characteristics.



**Figure 5.** Risk of bias assessment using the ROBVIS tool(85)

### 8.2.4 Heterogeneity and publication bias

Most of our analyses showed a significant and high level (i.e.,  $P > 75\%$ ) of heterogeneity. This is attributable to the diversity of geographical regions, population sizes, date and duration of the study periods represented by the included studies.

Upon visual inspection of the funnel plots no significant plot asymmetry was found that would suggest publication bias.

**Table 4.** *Baseline charecteriscics of the included articles(85)*

| <b>Author (year)</b> | <b>Ref</b> | <b>Country</b>   | <b>Study period</b> | <b>Total</b> | <b>Cases</b> | <b>Age category</b>                  | <b>Congenital anomalies</b>  |
|----------------------|------------|------------------|---------------------|--------------|--------------|--------------------------------------|--|
| Agopian 2009         | (86)       | Texas (USA)      | 1999 - 2004         | 2208758      | 325          | <20, 20-24, 25-29, 30-34, 35-39, ≥40 | Omhalocele   |
| Baer 2014            | (87)       | California (USA) | 2005 - 2010         | 3070957      | 1279         | <19, 20-24, 25-29, 30-34, ≥35        | Gastroschisis  |
| Beckman 1976         | (88)       | Sweden           | 1950 - 1973         | 61061        | 280          | <24, 25-29, 30-34, ≥35               | Cleft palate, Cleft lip with or without cleft palate, Polydayctyly, Syndactyly, Clubfoot |
| Bergman 2015         | (89)       | Europe           | 2001 - 2010         | 5871855      | 10929        | <20, 20-24, 25-29, 30-34, 35-39, ≥40 | Hypospadiasis  |
| Baird 1994           | (90)       | Canada           | 1966 - 1981         | 576815       | 702          | <20, 20-24, 25-29, 30-34, 35-39, ≥40 | Isolated Cleft palate, Cleft lip and cleft palate  |
| Bodnár 1970          | (91)       | Hungary          | 1958 - 1967         | 115215       | 2100         | <19, 20-24, 25-29, 30-39, ≥40        | all NCAs, Nervous system, Circulatory system, Urogenital anomalies, Musculoskeletal      |

|               |       |                            |             |         |          |   |                            |
|---------------|-------|----------------------------|-------------|---------|----------|---|----------------------------|
|               |       |                            |             |         |          |   | system, Digestive system   |
| Borman 1986   | (92)  | New Zealand                | 1978        | 52143   | 104      | <20, 20-24, 25-29, ≥30                      | Anencephalus, Spina bifida |
| Borque 2021   | (93)  | Canada                     | 2012 - 2018 | 1001080 | 231      | <20, 20-24, 25-29, 30-34, 35-39, ≥40        | Gastroschisis              |
| Bugge 2017    | (94)  | Greenland (Denmark)        | 1989 - 2015 | 26666   | 33       | <20, 20-24, 25-29, 30-34, 35-39, 40-44, ≥45 | Gastroschisis, Omphalocele |
| Byron 1998    | (95)  | Australia                  | 1980 - 1990 | 358679  | 59; 104  | <20, 20-24, 25-29, 30-34, 35-39, ≥40        | Gastroschisis, Omphalocele |
| Canfield 2009 | (96)  | Texas (USA)                | 1999 - 2003 | 1827317 | 514; 643 | <20, 20-24, 25-29, 30-34, 35-39, ≥40        | Anencephalus, Spina bifida |
| Canon 2012    | (97)  | Arkansas (USA)             | 1998 - 2007 | 196050  | 1455     | <20, 20-24, 25-29, 30-34, ≥35               | Hypospadias                |
| Croen 1995    | (98)  | California (USA)           | 1983 - 1988 | 1028255 | 29848    | <20, 20-24, 25-29, 30-34, 35-39, ≥40        | all NCAs                   |
| DeRoo 2003    | (99)  | Washington (USA)           | 1987 - 1990 | 298138  | 608      | <20, 20-24, 25-29, 30-34, 35-39, ≥40        | Cleft lip and cleft palate |
| Dott 2003     | (100) | Metropolitan Atlanta (USA) | 1968 - 1999 | 1029143 | 249      | <20, 20-24, 25-34, ≥35                      | Diaphragmatic hernia       |



|                |       |                          |             |          |      |   |   |
|----------------|-------|--------------------------|-------------|----------|------|---|---|
| Dudin 1997     | (101) | Palestina                | 1986 - 1993 | 26934    | 148  | 15-19, 20-24, 25-29, 30-39, $\geq 40$             | Neural tube defects                       |
| Fedrick 1976   | (102) | Scotland (UK)            | 1961 - 1972 | 1162939  | 3246 | <20, 20-24, 25-29, 30-34, 35-39, 40-44, $\geq 45$ | Anencephlaus                              |
| Feldman 1982   | (103) | New York, Brooklyn (USA) | 1968 - 1976 | 173670   | 179  | <20, 20-24, 25-29, 30-34, $\geq 35$               | Neural tube defects                       |
| Forrester 2004 | (104) | Hawaii (USA)             | 1986 - 2000 | 281866   | 544  | <19, 20-24, 25-29, 30-34, 35-39, $\geq 40$        | Cleft lip and cleft palate                |
| Forrester 1999 | (105) | Hawaii (USA)             | 1986 - 1997 | 229584   | 150  | 19 $\geq$ , 20-24, 25-29, 30-34, 35-39, $\geq 40$ | Omphalocele, Gastroschisis                |
| Forrester 2000 | (106) | Hawaii (USA)             | 1986 - 1997 | 246231   | 245  | 19 $\geq$ , 20-24, 25-29, 30-34, 35-39, $\geq 40$ | Anencephaly, Spina bifida, Encephalocele  |
| Friedman 2016  | (107) | USA                      | 2005 - 2013 | 24836777 | 5985 | <20, 20-24, 25-29, 30-34, $\geq 35$               | Gastroschisis                             |
| Gupta 1967     | (108) | Nigeria                  | 1964        | 4220     | 15   | 15-19 20-24, 25-29, 30-34, 35-39, 40-44           | CHD                                       |
| Hansen 2021    | (109) | Australia                | 1990 - 2016 | 765419   | 8173 | <20, 20-24, 25-29, 30-34, 35-39, $\geq 40$        | CHD                                       |
| Hay 1972       | (110) | USA                      | 1961 - 1966 | 8475600  | 1063 | <20, 20-24, 25-29, 30-34, 35-39, $\geq 40$        | Anencephlay, Spina bifida, Hydrocephalus, |

|              |       |                     |             |        |      |                                      |   |
|--------------|-------|---------------------|-------------|--------|------|--------------------------------------|---|
|              |       |                     |             |        |      |                                      | Congenital heart defects, Cleft lip without cleft palate, Cleft lip and palate, Cleft palate without cleft lip, Tracheoesophageal fistula and other esophageal defects, Omhalocele, Imperforate anus and other anorectal defects, Hypospadiasi, Position foot defects, Polydactyly, Syndactyly, Reduction deformities |
| Hollier 2000 | (111) | Dallas (Texas, USA) | 1988 - 1994 | 102728 | 3466 | <20, 20-24, 25-29, 30-34, 35-39, ≥40 | all NCAs  |

|                        |       |                      |             |          |       |  |   |
|------------------------|-------|----------------------|-------------|----------|-------|--|---|
| Jaikrishan 2012        | (112) | India                | 1995 - 2011 | 141540   | 1370  | 15-19, 20-29, $\geq 30$                    | Clubfoot, CHD, Cleft palate/lip, NTD, Hypospadias |
| Janerich 1972          | (113) | New York State (USA) | 1945 - 1970 | 4555614  | 4450  | 15-19; 20-24; 25-29; 30-34; 35-39; 40-44   | Spina bifida                                      |
| Janerich 1972          | (114) | New York State (USA) | 1945 - 1967 | 4074079  | 3090  | 15-19; 20-24; 25-29; 30-34; 35-39; 40-44   | Anencephaly                                       |
| Jaruratanasirikul 2016 | (115) | Southern Thailand    | 2009 - 2013 | 186393   | 269   | <20; 20-<25; 25-<30; 30-<35; $\geq 35$     | Oral clefts                                       |
| Jones 2016             | (116) | USA                  | 1995 - 2012 | 21040437 | 8866  | <20; 20-24; 25-29; 30-34; 35<              | Gastroschisis                                     |
| Kazaura 2004           | (117) | Norway               | 1967 - 1998 | 1869388  | 699   | <20; 20-24; 25-29; 30-34; 35-39; $\geq 40$ | Gastroschisis, Omphalocele                        |
| Kirby 2013             | (118) | USA                  | 1995 - 2005 | 13233235 | 4713  | <20; 20-24; 25-29; 30-34; 35<              | Gastroschisis                                     |
| Liu 2013               | (119) | Canada               | 2002 - 2010 | 2283223  | 26488 | <19; 20-24; 25-29; 30-34; 35-39; 40<       | CHD   |
| Liu 2019               | (120) | Canada               | 2004 - 2015 | 3327762  | 1517  | <19; 20-24; 25-29; 30-34; 35-39; 40<       | Spina bifida, Anencephaly/encephalocele           |

|                      |       |   |             |         |      |                                      |  |
|----------------------|-------|---|-------------|---------|------|--------------------------------------|--|
| Li 2019              | (121) | Zhejiang Province (China, People's Republic of) | 2010 - 2016 | 1748023 | 2790 | <20; 20-25; 30-35; ≥ 35              | Kidney and urinari tract defects   |
| Loc-Uyen 2015        | (122) | Texas (USA)                                     | 1999 - 2011 | 4970525 | 2549 | <19; 20-24; 25-29; 30<               | Gastroschisis  |
| Luo 2019             | (123) | Shenzhen (China, People's Republic of)          | 2003 - 2017 | 591024  | 777  | <25; 25-;30-; 35<                    | Cleft lip and palate   |
| Martinez-Frias 1984  | (124) | Spain   | 1976        | 264502  | 52   | <19; 20-24; 25-29; 30-34; 35-39; 40< | Gastroschisis, Omphalocele   |
| Materna-Kiryluk 2009 | (125) | Poland  | 1998 - 2002 | 716089  | 8683 | <19; 20-24; 25-29; 30-34; 35-39; 40< | all NCAs (Excluded muskuloskeletal defects),Diaphragmatic hernia,Gastroschisis, Omphalocele, Neural tube defects, Microcephalus, Hydrocephalus, Congenital heart |

|               |       |                        |             |          |      |                                    |   |
|---------------|-------|------------------------|-------------|----------|------|------------------------------------|---|
|               |       |                        |             |          |      |                                    | defects,<br>Hypospadias, Renal<br>agenesis or<br>hypoplasia, Cystic<br>kidney disease,<br>Hydronephrosis, cleft<br>palate, cleft lip with or<br>without cleft palate,<br>Oesophageal atresia,<br>Small intestinal/large<br>intestinal atresia or<br>stenosis, Anal atresia<br>or stenosis |
| McGivern 2015 | (126) | Europe                 | 1980 - 2009 | 11478586 | 3373 | <20; 20-24; 25-29; 30-34; 35<      | Diaphragmatic hernia  |
| Miller 2011   | (127) | Atlanta (Georgia, USA) | 1968 - 2005 | 1301340  | 5289 | <35; 35<                           | CHD   |
| Mucat 2019    | (128) | Malta                  | 2000 - 2014 | 55943    | 2225 | 20-24; 25-29; 30-34;<br>35-39; 40< | all NCAs, Nervous<br>system, Eye,ear, face,<br>neck, Circulatory  |

|               |       |                           |             |        |      |  |  |
|---------------|-------|---------------------------|-------------|--------|------|--|--|
|               |       |                           |             |        |      |  | system, Respiratory<br>system, Digestive<br>system, Genital<br>organs, Urinary<br>system,<br>Muskoloskeletal<br>system |
| Nazer 2007    | (129) | Chile                     | 1996 - 2005 | 21083  | 1767 | <15; 15-19; 20-24; 25-29; 30-34; 35-39; 40-44; 45< | all NCAs   |
| Nazer 2013    | (130) | Chile                     | 2002 - 2011 | 15636  | 1174 | <15; 15-19; 20-24; 25-29; 30-34; 35-39; 40-44; 45< | all NCAs   |
| Parkes 2020   | (131) | England,<br>Scotland (UK) | 2003 - 2010 | 219486 | 5154 | <19; 20-29; 30-39; 40<                             | all NCAs   |
| Pasnicki 2013 | (132) | Poland                    | 1988 - 2007 | 192438 | 2769 | <18; 20-24; 25-29; 30-34; 35-39; 40<               | all NCAs, Nervous<br>system, Circulatory<br>system, Cleft lip and<br>cleft palate, Digestive<br>system, Genital        |

|              |       |   |             |         |       |   |  |
|--------------|-------|---|-------------|---------|-------|---|--|
|              |       |   |             |         |       |   | organs, Urinary<br>system,<br>Muskoloskeletal<br>system, Other |
| Persson 2019 | (133) | Sweden  | 1992 - 2012 | 2050491 | 28628 | >24; 25-29; 30-34; 35<                          | CHD  |
| Petrova 2009 | (134) | Norway and<br>Arkhangelskaja<br>Oblast (Russia) | 1995 - 2004 | 434567  | 615   | <19; 20-24; 25-29; 30-<br>34; 35<               | Neural tube defects:<br>Anencephalus, Spina<br>bifida          |
| Pradat 1992  | (135) | Sweden  | 1981 - 1986 | 573422  | 1605  | <20; 20-24; 25-29; 30-<br>34; 35-39; 40-44; >44 | CHD  |
| Purkey 2019  | (136) | California (USA)                                | 2008 - 2012 | 2054516 | 6325  | <19; 20-24; 25-29; 30-<br>34; 35<               | CHD  |
| Rankin 1999  | (137) | Northern<br>England (UK)                        | 1986 - 1996 | 426694  | 296   | 11-19; 20-24; 25-29;<br>30-34; 35-39; >40       | Gastroschisis,<br>Omphalocele,<br>Omphalocele                  |
| Rankin 2000  | (138) | Northern<br>England (UK)                        | 1984 - 1996 | 507405  | 934   | 11-19; 20-24; 25-29;<br>30-34; 35-39; >40       | Neural tube defects  |
| Rider 2013   | (139) | Utah (USA)                                      | 1999 - 2008 | 480125  | 8510  | <24; 25-29; 30-34; 35-<br>39; 40-60             | all NCAs   |

|              |       |                                      |             |                     |        |  |  |
|--------------|-------|--------------------------------------|-------------|---------------------|--------|--|--|
| Roeper 1987  | (140) | California (USA)                     | 1968 - 1977 | 3297071             | 166    | <19; 20-24; 25-29; 30-34; 35-39; 40<               | Gastroschisis, Omphalocele   |
| Salihu 2003  | (141) | New York State (USA)                 | 1992 - 1999 | 2153955;<br>2149340 | 595    | <19; 20-24; 25-29; 30-34; 35-39; 40<               | Omphalocele, Gastroschisis   |
| Salim 2019   | (142) | Brazil                               | 1996 - 2014 | 4270114             | 5062   | <19; 20-29; 30-34; 35-39; 40<                      | Circulatory system   |
| Sarkar 2013  | (143) | India                                | 2011 - 2012 | 12896               | 286    | <20; 20-30; 30<                                    | all NCAs   |
| Sever 1982   | (144) | Los Angeles County (California, USA) | 1966 - 1972 | 2945555             | 962    | <14; 15-19; 20-24; 25-29; 30-34; 35-39; 40-44; 45< | Anencephalus, Spina bifida, Encephalocele, Neural tube defects, SUM  |
| Shields 1981 | (145) | Denmark                              | 1940 - 1971 | 2406654             | 548    | <19; 20-24; 25-29; 30-34; 35-39; 40-44; 45<        | Cleft palate   |
| Short 2019   | (146) | USA                                  | 2006 - 2015 | 17686317            | 3489   | <19; 20-24; 25-29; 30<                             | Gastroschisis  |
| StLouis 2017 | (147) | USA                                  | 1999 - 2007 | 13105878            | 138999 | <19; 20-24; 25-29; 30-34; 35<                      | all NCAs, Anencephalus, Spina bifida, Encephalocele, Anotia/microtia, Common truncus CHD, Transposition of |



|  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|
|  |  |  |  |  |  |  | <p>the great arteries ,Tetralogy of Fallot,Atrioventricular septal defect without Down syndrome, Hypoplastic left heart syndrome, Coarctation of the aorta, Aortic valve stenosis, Cleft palate without cleft lip, Cleft lip with and without cleft palate, Esophageal atresia/tracheoesophageal fistula, Pyloric stenosis, Rectal and large intestinal atresia/stenosis, Hypospadiasb, Upper limb deficiency,</p> |
|--|--|--|--|--|--|--|--|

|               |       |  |             |         |       |                                      |  |
|---------------|-------|--|-------------|---------|-------|--------------------------------------|--|
|               |       |  |             |         |       |                                      | Lower limb deficiency, Any limb deficiency, Diaphragmatic hernia, Gastroschisis, Omphalocele |
| Tan 1996      | (148) | England, Wales (UK)                          | 1987 - 1993 | 4873547 | 1043  | <20; 20-24; 25-29; 30-34; 35-39; >40 | Gastroschisis, Omphalocele   |
| Tan 2005      | (149) | Singapore                                    | 1994 - 2000 | 328077  | 7870  | <20; 20-24; 25-29; 30-34; 35-39; >40 | all NCAs   |
| Tan 2008      | (150) | Singapore                                    | 1993 - 2002 | 460532  | 121   | <20; 20-24; 25-29; 30-34; 35-39; >40 | Gastroschisis, Omphalocele   |
| Williams 2005 | (151) | Atlanta (USA)                                | 1968 - 2000 | 877604  | 211   | <20; 20-24; 24<                      | Gastroschisis  |
| Xie 2016      | (152) | Hunan Province (China, People's Republic of) | 2005 - 2014 | 925413  | 17753 | <20; 20-24; 25-29; 30-34; 35<        | all NCAs   |
| Xie 2018      | (153) | China (People's Republic of)                 | 2012 - 2016 | 673060  | 6289  | <20, 20-24, 25-29, 30-34, ≥35        | Congenital heart defects   |
| Xu 2011       | (154) | China (People's Republic of)                 | 1996 - 2007 | 6308594 | 1601  | <19; 20-24; 25-29; 30-34; 35<        | Gastroschisis  |

|            |       |   |             |         |      |   |                      |
|------------|-------|---|-------------|---------|------|---|----------------------|
| Zhang 2012 | (155) | China (People's Republic of)                      | 2012        | 62526   | 976  | <25; 25-30; 35<                           | all NCAs             |
| Yang 2006  | (156) | California (USA)                                  | 1989 - 1997 | 2506188 | 550  | <20; 20-24; 25-29;<br>30-34; 35-39; 40-55 | Diaphragmatic hernia |
| Zhou 2020  | (157) | Southern Jiangsu<br>(China, People's Republic of) | 2014 - 2018 | 238712  | 1707 | <19; 20-24; 25-29; 30-34; 35<             | all NCAs             |

### 8.2.5 Risk of NCAs by maternal age category

The role of maternal age in the occurrence of NCAs: **Table 5** summarizes our results. By default forest plots and summary statistics were prepared including all eligible studies regardless of concomittant CAs.

#### All NCAs (Figure 6, Figure 7)

Regarding our primary outcome, i.e. analyzing all NCAs combined, we found that age > 35 (RR = 1.31, CI: 1.07–1.61) and especially age > 40 (RR = 1.44; CI: 1.25–1.66) increase the risk of NCAs. For this outcome we conducted two subgroup analyses to investigate the question more deeply. First, we examined the age risk of all NCAs excluding cases with co-occurrent chromosomal anomalies, we found significant results for the > 40 age category (RR = 1.25; CI: 1.08–1.46). Next, we carried out the analysis for studies where the presence of chromosomal anomalies was allowed: the risk of NCAs was found to increase with maternal age > 35 (RR = 1.26; CI: 1.12–1.42) and > 40 (RR = 1.63; CI: 1.26–2.09).

#### Congenital malformations of the nervous system (Q00–Q07)

Despite the analysis of up to 10 studies for each age group, we found no significant association between maternal age and congenital nervous system malformations (see **Supplementary Figure 3** of the article).

#### Congenital malformations of the circulatory system (Q20–Q28) (Figure 8)

We found a risk-increasing effect of maternal age > 40 (RR = 1.94; CI: 1.28–2.93). Among the diseases of the circulatory system, we also specifically analyzed the group of congenital heart defects (CHD) (**Figure 9**), where we also found risk-increasing effect for advanced maternal age: for the > 35 group: RR = 1.50; CI: 1.11–2.04; and for the > 40 group: RR = 1.75; CI: 1.32–2.32 was found. For the very young maternal age (< 20) group a preventive effect was observed (RR = 0.87; CI: 0.78–0.97).

#### Cleft lip and cleft palate (Q35–Q37) (Figure 10)

Maternal age > 40 elevated the risk of cleft lip and cleft palate (RR = 1.57; CI: 1.11–2.20). Regarding cleft palate separately (see **Supplementary Figure 10** of the article), we found an even higher risk with advanced maternal age, which appears as early as the 35th year (for age > 35: RR = 1.78; CI: 1.16–2.73; and for age > 40: RR = 1.77; CI: 1.48–2.11).

#### Congenital malformations of the digestive system (Q38–Q45) (Figure 11)

We found a risk-increasing effect for maternal age > 40 (RR = 2.16; CI: 1.34–3.49).

#### Congenital malformations of the urinary system (Q60–Q64)

We could not detect an association between maternal age and congenital malformations of the urinary system after analyzing three eligible population-based studies with homogeneous age categories (see **Supplementary Figure 13** of the article).

#### Congenital malformations and deformations of the musculoskeletal system (Q65–Q79)

We did not find an association with maternal age. However, this can also be explained by the low number of studies and their heterogeneity, and also by the complex nature of the group (see **Supplementary Figure 14** of the article).

#### Other malformation categories


Regarding the congenital malformations of the eye, ear, face, and neck (Q10–Q18), congenital malformations of the respiratory system (Q30–Q34), and congenital malformations of genital organs (Q50–Q56), we did not find enough studies with homogenous age groups and NCAs to carry out a mathematical synthesis.

On the other hand, we found a clear association between maternal age and some individual malformations. The risk of omphalocele was higher in both very young (age < 20, RR = 1.44; CI: 1.08–1.92) and advanced maternal age (age > 40, RR = 2.57; CI: 1.77–3.73) group. Based on 22 eligible articles (age < 20, RR = 3.08; CI: 2.74–3.47), gastroschisis shows a strong association with very young maternal age (**Figure 12**).

Additionally, we also re-sorted our study level outcomes by year of publication to detect any apparent trend in case of outcomes where sufficient number of articles were available to have any chance to reliably assess any effect (see **Supplementary Figures 38-47** of the article) and we could not find any convincing trend upon visual inspection. As an alternate approach, we also analyzed the subset of studies published from 2005 onward (see **Supplementary Figures 48-57** of the article): no clear and convincing trend could be identified, only weak trends in a few cases (summarized in **Supplementary Table 6**).


**Table 5.** Summary of our results based on ICD-10 categories (85)

| <b>Congenital anomaly</b>          | <b>ICD-10 Category</b> | <b>Age &lt; 20</b> | <b>N</b> | <b>Age 30-35</b>  | <b>N</b> | <b>Age 35-40</b>   | <b>N</b> | <b>Age &gt; 35</b> | <b>N</b> | <b>Age &gt; 40</b> | <b>N</b> |
|------------------------------------|------------------------|--------------------|----------|-------------------|----------|--------------------|----------|--------------------|----------|--------------------|----------|
| All NCAs<br>(with or without CAs)  | Q00-Q89                | 1.08 (0.89; 1.32)  | 14       | 1.23 (0.85; 1.78) | 13       | 1.47 (0.87; 2.49)  | 9        | 1.31 (1.06; 1.61)  | 13       | 1.44 (1.25; 1.66)  | 11       |
| All NCAs<br>(without CAs)          | Q00-Q89                | 1.21 (0.59; 2.49)  | 5        | 1.54 (0.55; 4.32) | 6        | 1.73 (0.45; 6.70)  | 5        | 1.37 (0.76; 2.45)  | 6        | 1.25 (1.08; 1.46)  | 6        |
| All NCAs<br>(with CAs)             | Q00-Q89                | 1.15 (0.87; 1.52)  | 10       | 1.02 (0.99; 1.06) | 7        | 1.20 (0.99; 1.44)  | 4        | 1.26 (1.12; 1.42)  | 7        | 1.63 (1.26; 2.09)  | 6        |
| <b>Nervous system</b>              | Q00-Q07                | 1.16 (0.74; 1.81)  | 10       | 1.64 (0.70; 3.81) | 8        | 2.56 (0.64; 10.32) | 5        | 1.53 (0.80; 2.94)  | 8        | 1.56 (0.67; 3.62)  | 7        |
| Encephalocele                      | Q01                    | 1.76 (0.44; 7.12)  | 3        | 1.51 (0.33; 6.83) | 3        | no data            |          | 1.43 (0.57; 3.60)  | 3        | no data            |          |
| Congenital hydrocephalus           | Q03                    | 1.19 (1.02; 1.38)  | 2        | no data           |          | no data            |          | no data            |          | no data            |          |
| Spina bifida                       | Q05                    | 1.30 (0.93; 1.82)  | 9        | 1.15 (0.65; 2.06) | 8        | 1.79 (0.61; 5.31)  | 5        | 1.39 (0.75; 2.59)  | 8        | 1.96 (0.72; 5.31)  | 5        |
| Anencephaly                        | Q00.0                  | 1.40 (0.98; 1.99)  | 9        | 1.15 (0.72; 1.84) | 8        | 1.20 (0.53; 2.72)  | 6        | 1.02 (0.60; 1.72)  | 8        | 1.30 (0.71; 2.38)  | 6        |
| <b>Circulatory System</b>          | Q20-Q28                | 0.87 (0.68; 1.11)  | 3        | 1.09 (1.00; 1.20) | 3        | 1.18 (0.94; 1.49)  | 3        | 1.33 (0.97; 1.82)  | 3        | 1.94 (1.28; 2.93)  | 4        |
| Congenital Heart Defects           | Q20-Q26                | 0.87 (0.78; 0.97)  | 10       | 1.45 (0.83; 2.52) | 10       | 1.91 (0.65; 5.62)  | 6        | 1.50 (1.11; 2.04)  | 10       | 1.75 (1.32; 2.32)  | 6        |
| <b>Cleft lip and palate</b>        | Q35-Q37                | 0.93 (0.76; 1.14)  | 6        | 1.58 (0.77; 3.22) | 6        | 1.85 (0.59; 5.75)  | 4        | 1.47 (0.95; 2.28)  | 6        | 1.57 (1.11; 2.20)  | 4        |
| Cleft palate                       | Q35                    | 0.99 (0.56; 1.73)  | 6        | 1.42 (0.66; 3.06) | 8        | 2.08 (0.54; 7.99)  | 5        | 1.78 (1.16; 2.73)  | 8        | 1.77 (1.48; 2.11)  | 5        |
| <b>Digestive System</b>            | Q38-Q45                | 0.98 (0.71; 1.37)  | 2        | no data           |          | no data            |          | no data            |          | 2.16 (1.34; 3.49)  | 2        |
| <b>Urinary System</b>              | Q60-Q64                | no data            |          | 0.97 (0.75; 1.26) | 3        | no data            |          | 0.86 (0.57; 1.29)  | 3        | no data            |          |
| Hypospadias                        | Q54                    | 0.99 (0.91; 1.07)  | 5        | 1.06 (0.96; 1.17) | 4        | no data            |          | 1.11 (0.88; 1.39)  | 4        | no data            |          |
| <b>Musculoskeletal System</b>      | Q65-Q79                | 0.88 (0.72; 1.08)  | 2        | no data           |          | 0.93 (0.71; 1.22)  | 2        | 0.94 (0.65; 1.37)  | 2        | 0.90 (0.55; 1.46)  | 3        |
| Congenital Diaphragmatic<br>Hernia | Q79.0                  | 0.96 (0.88; 1.06)  | 5        | 1.74 (0.52; 5.80) | 4        | no data            |          | 1.52 (0.79; 2.91)  | 5        | no data            |          |
| Omphalocele                        | Q79.2                  | 1.44 (1.08; 1.92)  | 14       | 1.13 (0.85; 1.50) | 14       | 1.35 (0.98; 1.87)  | 13       | 1.47 (1.20; 1.79)  | 14       | 2.57 (1.77; 3.73)  | 13       |
| Gastroschisis                      | Q79.3                  | 3.08 (2.74; 3.47)  | 22       | 0.32 (0.23; 0.44) | 17       | 0.27 (0.16; 0.47)  | 12       | 0.22 (0.15; 0.32)  | 17       | 0.41 (0.23; 0.74)  | 11       |




**Figure 6.** Forest plot representing the RR with 95% CI of all non-chromosomal anomalies (ICD-10: Q00-Q89) in different age groups compared to the 20-30 age group(85)







**Figure 7.** Forest plot representing the RR with 95% CI of all NCAs combined (excluding studies where co-incidence of CAs was allowed) ICD-10 Q00-Q89 in different age groups compared to the 20-30 age group (85)




**Figure 8.** Forest plot representing the RR with 95% CI of congenital anomalies of the circulatory system (ICD-10: Q20-Q28) in different age groups compared to the 20-30 age group. (85)



**Figure 9** Forest plot representing the RR with 95% CI of congenital heart defects (ICD-10: Q20-Q26) in different age groups compared to the 20-30 age group(85)



**Figure 10.** Forest plot representing the RR with 95% CI of cleft lip and cleft palate (ICD-10: Q35-Q37) in different age groups compared to the 20-30 age group.(85)



**Figure 11.** Forest plot representing the RR with 95% CI of congenital anomalies of the digestive system (ICD-10: Q38-Q45) in different age groups compared to the 20-30 age group.(85)





Figure 12. (continued below)





**Figure 12.** Forest plot representing the RR with 95% CI of gastroschisis (ICD-10: Q79.3) in different age groups compared to the 20-30 age group.(85)

**Table 6.** Comparing the findings of both of our studies

| Congenital anomaly              | ICD-10 Category | meta-analysis<br>reference age range: 20-35 |                   |                          | population-based analysis<br>reference age range: individual for each |                          |                          |
|---------------------------------|-----------------|---|-------------------|--------------------------|---|--------------------------|--------------------------|
|                                 |                 | age < 20                                    | age > 35          | age > 40                 | age < 20  | age > 35                 | age > 40                 |
| All NCAs (with or without CAs)  | Q00-Q89         | 1.08 (0.89; 1.32)                           | 1.31 (1.06; 1.61) | <b>1.44 (1.25; 1.66)</b> | no data   | no data                  | no data                  |
| All NCAs (without CAs)          | Q00-Q89         | 1.21 (0.59; 2.49)                           | 1.37 (0.76; 2.45) | 1.25 (1.08; 1.46)        | <b>1.37 (1.32; 1.43)</b>  | 1.21 (1.16; 1.26)        | 1.35 (1.23; 1.49)        |
| All NCAs (with CAs)             | Q00-Q89         | 1.15 (0.87; 1.52)                           | 1.26 (1.12; 1.42) | <b>1.63 (1.26; 2.09)</b> | no data   | no data                  | no data                  |
| <b>Nervous system</b>           | Q00-Q07         | 1.16 (0.74; 1.81)                           | 1.53 (0.80; 2.94) | 1.56 (0.67; 3.62)        | <b>1.71 (1.48; 1.97)</b>  | 1.05 (0.87; 1.26)        | 1.25 (0.84; 1.86)        |
| Encephalocele                   | Q01             | 1.76 (0.44; 7.12)                           | 1.43 (0.57; 3.60) | no data                  | no data   | no data                  | no data                  |
| Congenital hydrocephalus        | Q03             | 1.19 (1.02; 1.38)                           | no data           | no data                  | no data   | no data                  | no data                  |
| Spina bifida                    | Q05             | 1.30 (0.93; 1.82)                           | 1.39 (0.75; 2.59) | 1.96 (0.72; 5.31)        | no data   | no data                  | no data                  |
| Anencephaly                     | Q00.0           | 1.40 (0.98; 1.99)                           | 1.02 (0.60; 1.72) | 1.30 (0.71; 2.38)        | no data   | no data                  | no data                  |
| <b>Eye, ear, face, and neck</b> | Q10-Q18         | no data                                     | no data           | no data                  | 1.25 (0.94; 1.66)   | 1.24 (0.92; 1.69)        | <b>2.09 (1.25; 3.49)</b> |
| <b>Circulatory system</b>       | Q20-Q28         | 0.87 (0.68; 1.11)                           | 1.33 (0.97; 1.82) | <b>1.94 (1.28; 2.93)</b> | 1.16 (1.07; 1.26)   | <b>1.40 (1.29; 1.52)</b> | <b>1.72 (1.45; 2.05)</b> |
| Congenital heart defects        | Q20-Q26         | 0.87 (0.78; 0.97)                           | 1.50 (1.11; 2.04) | <b>1.75 (1.32; 2.32)</b> | no data   | no data                  | no data                  |
| <b>Respiratory system</b>       | Q30-Q34         | no data                                     | no data           | no data                  | 1.82 (0.83; 4.03)   | 1.00 (0.40; 2.51)        | 1.32 (0.29; 6.13)        |
| <b>Cleft lip and palate</b>     | Q35-Q37         | 0.93 (0.76; 1.14)                           | 1.47 (0.95; 2.28) | 1.57 (1.11; 2.20)        | 1.21 (1.05; 1.40)   | <b>1.45 (1.26; 1.67)</b> | 1.58 (1.16; 2.16)        |
| Cleft palate                    | Q35             | 0.99 (0.56; 1.73)                           | 1.78 (1.16; 2.73) | <b>1.77 (1.48; 2.11)</b> | no data   | no data                  | no data                  |
| <b>Digestive system</b>         | Q38-Q45         | 0.98 (0.71; 1.37)                           | no data           | <b>2.16 (1.34; 3.49)</b> | <b>1.46 (1.31; 1.64)</b>  | 1.16 (1.02; 1.32)        | 1.15 (0.85; 1.57)        |
| <b>Genital organs</b>           | Q50-Q56         | no data                                     | no data           | no data                  | 1.36 (1.24; 1.50)   | 1.15 (1.03; 1.29)        | 1.30 (1.02; 1.66)        |
| <b>Urinary system</b>           | Q60-Q64         | no data                                     | 0.86 (0.57; 1.29) | no data                  | 1.29 (1.04; 1.60)   | <b>1.90 (1.56; 2.32)</b> | <b>2.27 (1.53; 3.38)</b> |
| Hypospadias                     | Q54             | <b>0.99 (0.91; 1.07)</b>                    | 1.11 (0.88; 1.39) | no data                  | no data   | no data                  | no data                  |
| <b>Musculoskeletal System</b>   | Q65-Q79         | 0.88 (0.72; 1.08)                           | 0.94 (0.65; 1.37) | 0.90 (0.55; 1.46)        | <b>1.57 (1.46; 1.70)</b>  | 1.12 (1.02; 1.23)        | 1.07 (0.86; 1.34)        |
| Congenital Diaphragmatic Hernia | Q79.0           | <b>0.96 (0.88; 1.06)</b>                    | 1.52 (0.79; 2.91) | no data                  | no data   | no data                  | no data                  |
| Omphalocele                     | Q79.2           | 1.44 (1.08; 1.92)                           | 1.47 (1.20; 1.79) | <b>2.57 (1.77; 3.73)</b> | no data   | no data                  | no data                  |
| Gastroschisis                   | Q79.3           | <b>3.08 (2.74; 3.47)</b>                    | 0.22 (0.15; 0.32) | <b>0.41 (0.23; 0.74)</b> | no data   | no data                  | no data                  |
| <b>Other</b>                    | Q80-Q89         | no data                                     | no data           | no data                  | <b>1.45 (1.25; 1.68)</b>  | 1.35 (1.15; 1.59)        | 1.70 (1.23; 2.36)        |



## 9 DISCUSSION

### 9.1 Summary of findings, international comparisons (including all studies)

The main findings of our studies support our hypothesis. The relative frequency of all NCAs combined is strongly related to maternal age. The importance of our findings lies not only in their clinical relevance, but in their quality. The population based study encompasses a long time period for a whole country with almost 3 million births, maternal age data is available by year, all level 2 malformation categories of ICD-10 were assessed, aims for a high level of transparency, and a complex statistical analysis approach was used – this is particularly apparent if we compare it with other similar studies (e.g. those included in the meta-analysis). The meta-analysis provides a higher level of evidence for a worldwide audience than our registry analysis. It is the first of its kind (i.e. analyzing all NCAs combined and also separately by categories), and we made our best to avoid typical design flaws (c.f. Ahn et al 2022, (158)): we only pooled population-based studies with matching age groups and NCA categories.

#### All NCAs combined (ICD-10: Q00-Q89)

Our meta-analysis revealed risk increase above 35 and a more relevant increase above 40. It thus confirmed the risk-increasing effect of advanced maternal age. In contrast, our population-based study found that both very young and advanced maternal age increases the risk, when all NCAs are considered collectively.

Though the meta-analysis also shows an increase in risk in very young mothers, but here statistical significance does not support a clinical association. The main reason for this is the high heterogeneity (temporal and geographical differences), which suggests that the risk-increasing effect of young maternal age may be prevalent in certain regions (6/14 of the included articles also found a risk-increasing effect of extremely young maternal age). Despite the topic being extensively researched, the age distributions of different NCAs show inconsistencies in the literature. The risk increasing effect of advanced maternal age is consistent with previous research(54, 159, 160), highlighting the importance of considering advanced maternal age as a risk factor in prenatal care and genetic counseling. The 2022 meta-analysis on the subject (158) addressed advanced maternal age as a risk factor. The increased risk observed in older mothers can be attributed to a

variety of factors, including increased rate of IVF (in vitro fertilization) (161-164), increased prevalence of comorbidities particularly pregestational diabetes mellitus (165-167), and a higher likelihood of long-term exposure to environmental factors.(168, 169) In contrast to our findings, certain studies have questioned the risk-increasing effect of advanced maternal age.(53, 170) This may be explained by the fact that the increase in maternal age in Europe is especially associated with women of higher social status, which may have led to a decrease in the risk of NCA in this age group compared to previous trends.(53, 171)

Several studies indicate that advanced maternal age is linked to a decreased risk of NCAs. To explain this, researchers hypothesize that the embryonic development is more strongly influenced by the “all-or-nothing” phenomenon than the aging of the egg – this results in a higher chance surviving fetuses are anatomically normal.(172)

In line with our population-based study, Reefhuis et al.(55) demonstrated that women under 20 years and women over 35 years are at increased risk of having a fetus with an NCA. Croen et al.(173) also observed this association in their data analysis from the California Birth Defects Monitoring Program, except for the Afro-American population. Analyzing data from the EUROCAT database, Loane et al. argue (53) that greater attention should be given to the screening of adolescent mothers, as they are more prone to having multiple risk factors. Possible factors contributing to this increased risk among younger mothers encompass insufficient prenatal care, a greater prevalence of socioeconomic disadvantages, and an elevated vulnerability to nutritional deficiencies during pregnancy.(57)

The effect of advanced maternal age on the risk of chromosomal anomalies is well known. In addition to chromosomal anomalies, the prevalence of NCAs is also higher, so as a significant confounder, we excluded the co-occurrence of chromosomal anomalies from our population-based study and in the case of meta-analysis, we also performed an analysis that tests the hypothesis without the co-occurrence of chromosomal anomalies. In this case, we found a 25% increase in risk for mothers over 40. This further supports the idea that a mother's age can be an independent risk factor, since having chromosomal anomalies at the same time is one of the most significant variables that can influence the occurrence.

### Congenital malformations of the nervous system (ICD-10: Q00-Q07)

In the case of neural tube defects (NTD), there is already a well-known and high level of evidence that folic acid supplementation is effective in preventing these disorders.(174) In addition to this well known preventive option, there are further possibilities for secondary prevention of this group of anomalies through neurosonography or fetal MR scans. Hence, it is crucial in clinical practice to identify risk factors in order to improve the criteria for diagnostic approaches.

Our population-based analysis reveals a significant and large increase in risk in very young mothers, but the meta-analysis shows no significant effect on the risk. The latter could be explained by the high level of heterogeneity caused by population differences. As a result, we cannot draw broad conclusions, but we do see an increase in risk locally both in advanced and very young age categories. The studies included in the meta-analysis demonstrate either no significant effect or a significant risk increase.

The literature is not consistent on the age effect in this case either. Most studies have found a 'U-shaped' relationship between maternal age and the relative frequency of NTDs.(103, 175) Other researchers suggest that a higher risk of NTD is probably associated with increased maternal age.(176) The heterogeneous results could be attributed to an inappropriate NTD definition, as grouping was not applied uniformly across studies. Some anomalies were explicitly associated with young maternal age (e.g. anencephaly)(102, 177), while other isolated anomalies were more common in older mothers(e.g. spina bifida, encephalocele).(177)

*Encephalocele (ICD-10: Q01):* No significant effect was found for any age category in our meta-analysis. Wen et al. discovered that younger maternal ages are specifically associated with encephaloceles. This association was not explained by maternal education level or the timing of prenatal care initiation in their study.(178) A 2024 meta-analysis found that the age of the mother was a factor in the occurrence of encephaloceles. Two publications showed a link between encephaloceles and very young maternal age, while another publication documented a connection with advanced maternal age.(179)

*Congenital hydrocephalus (ICD-10: Q03):* In our meta-analysis, we were only able to examine the effect of very young maternal age, and even in this category, only 2 studies could be mathematically synthesised. As a result, an increase in risk is observed

in the very young age group, which, despite combining the findings of only two papers, is a mathematically significant result. Reefhuis and Honein also discovered that teenage mothers had a significantly higher risk of having hydrocephalus offsprings than mothers aged 25–29 years (OR = 1.56; CI: 1.23–1.96). The increased risk could be attributed to confounding lifestyle factors like insufficient prenatal care and exposure to harmful substances.(55) A 2023 case-control analysis also confirms this link.(180) Another study also identified a risk increasing effect of maternal age, but for very young and advanced age (U-shaped distribution).(181) In contrast, in another study maternal age was not associated with any subtype of hydrocephalus.(182) In this case, a variety of causal factors may explain the inconsistency of the literature.

*Spina bifida (ICD-10: Q05)*: Most of the studies included in the meta-analysis found an increase in risk among mothers in the examined age groups. However, due to the large confidence intervals, the pooled values cannot statistically prove or disprove the risk-increasing effect. Consistent with our findings, the literature reviews on this subject do not acknowledge the potential for maternal age to increase the risk of spina bifida.(183, 184)

*Anencephaly (ICD-10: Q00.0)*: Most of the articles included in the meta-analysis do not show a significant effect and the pooled value does not show evidence for the presence or absence of a risk factor. The literature does not mention maternal age as a relevant risk factor for anencephaly either.(185, 186)

#### Congenital malformations of eye, ear, face and neck (ICD-10: Q10-Q18)

There was insufficient data for mathematical synthesis in the meta-analysis. Our population-based study showed a clinically and statistically significant increase in risk over the age of 40 years. Congenital anomalies of the face and neck are one of the most difficult to diagnose prenatally (187), and there is no clear reference in the literature to the risk factor we have studied. A 2024 study in the same setting as ours (i.e. using ICD-10 categories) found no association with maternal age.(188) Given the paucity of data on this topic, further studies are needed to assess the link.

### Congenital Malformations of the Circulatory System (ICD-10: Q20-Q28)

There is a clinically and statistically significant increase in risk above the age of 40 years in both the meta-analysis and the population-based study. In the case of the meta-analysis, despite the large heterogeneity, this is strong evidence. The effect of very young maternal age is not detected in the meta-analysis, and although it is significant in the population-based analysis, the effect is minimal.

The risk-increasing effect of advanced maternal age can be found in the literature(189), but most research specifically focuses on cardiac malformations within other anomalies of the circulatory system.

*Congenital Heart Defects(CHD) (ICD-10:Q20-Q26):* Due to the differences in ICD classifications and for conceptual reasons, this group was not included in the population-based study (only ICD main groups were analysed). In the meta-analysis, there is a statistically and clinically significant increase in risk in advanced maternal age (both 35 and over 40). There is a slight protective effect in the very young maternal age category, but this is barely clinically relevant.

The study of this subgroup of anomalies is particularly important, both in terms of their frequency and severity, as well as due to the potential for specific screening methods. Currently, fetal echocardiography is not recommended based on the mother's age.(190, 191)

Similar to our results, several studies – including a 2024 meta-analysis on the subject – report an increase in risk in advanced maternal age.(55, 188, 192, 193) Mamasoula et al. identify both very young and advanced maternal age as a risk factor and specifically highlight the association of very severe CHDs in the very young group.(194) Our study and the scientific literature are consistent on the risk-adjusting effect of advanced maternal age, but further publications are not consistent for very young mothers. This finding necessitates additional investigation to validate and explore the influence of behavioral or genetic factors.

### Congenital malformations of the respiratory system (ICD-10: Q30-Q34)

The meta-analysis lacked sufficient data for mathematical synthesis. The population-based analysis yielded estimates with a wide confidence interval due to the limited sample size, so the presence or absence of risk could not be determined in this study either. Most

of the studies in the literature failed to confirm or refute the existence of a link with maternal age.(170)

Varela et al. described an association between lower social status and congenital respiratory disorders(195) , which may increase the need to examine the very young age of the mother.

#### Cleft lip and cleft palate (ICD-10: Q35-Q37)

In this anomaly group, there is a significant increase in risk above 40 according to both our population-based analysis and the meta-analysis. In our population-based study, we found an increased risk in both the under-20 and the over-35 age groups, but the meta-analysis could not confirm this. There is no consensus in the literature on the association with maternal age either: neither its existence nor its exact nature is agreed upon. A study carried out in California showed that women older than 39 years had twice the risk of having a child with left lip and cleft palate when compared to mothers between 25 and 29 years.(196) In contrast, a 2002 meta-analysis found no association with maternal age (197), which is also confirmed by a 2010 study.(198)

*Cleft palate (Q35):* When analysed independently, there is a clinically and statistically significant increase in risk for cleft lip above 35, not just above 40, but smaller confidence intervals above 40 provide stronger evidence. According to a 2012 meta-analysis mothers aged 35 to 39 years had a 20% higher risk of having a child with a cleft palate, and mothers aged 40 or more had a 28% higher risk.(199)

#### Congenital malformations of the digestive system (ICD-10:Q38-Q45):

Our results are very contradictory, because the meta-analysis shows that there is a significant increase in risk above 40, while the population-based study shows an increase in risk already

above 35 and below 20. A severe limitation is that only two articles were included in the meta-analysis. The available evidence concerning maternal age is contradictory. Loane et al. found that young maternal age is a risk factor(53), while a meta-analysis in 2022 could not confirm the effect of maternal age in either the very young or the advanced maternal age group.(158)

#### Congenital malformations of genital organs (ICD-10: Q50-Q56)

In the meta-analysis, there were insufficient data to examine the maternal age groups in question. In our population-based study, we observed an increase in risk of around 15% in both the very young and advanced age categories. There is limited data available in the literature that has examined these differences as a group. The risk-increasing effect of advanced maternal age is confirmed by Reefhuis et al for male genital defects, moreover, they also found that very young maternal age is a risk-increasing effect in case of female genital defects.(55) A meta-analysis has demonstrated a risk-increasing effect of advanced maternal age when genital organ defects were merged with urinary anomalies. In this setting, the risk increase for mothers over 35 was 46%.(158)

*Hypospadias (ICD-10:Q54)*: Based on the meta-analysis, we can conclude that there is no effect in the younger population while the evidence to determine the presence or absence of risk in the elderly population is insufficient. The literature supports the risk-increasing effect of advanced maternal age. According to Fisch et al. and Porter et al., advanced maternal age is associated with a marked increase in risk.(200, 201)

#### Congenital malformations of the urinary system (ICD-10: Q60-Q64)

The 3 studies included in this meta-analysis did not show a significant effect of advanced maternal age (study count for the rest of the age groups was insufficient). However, in our population-based study, we found a risk-increasing effect for both the very young and the advanced maternal age, with a 2-fold increase in risk above 40. Another population-based study in Washington state confirmed the risk-increasing effect of advanced maternal age, but they found only a 20% increase in risk.(202)

#### Congenital malformations and deformations of the musculoskeletal system (ICD-10: Q65-Q79)

Based on our population-based study, both very young and advanced maternal age have a risk-increasing effect. Based on a meta-analysis, however, we were unable to confirm the presence or absence of risk. Considering the diseases in this group, very limited data are available in the literature.

*Congenital diaphragm hernia (ICD-10: Q79.0)*: The meta-analysis could not prove either a risk or a protective effect in any of the examined age groups. A population-

based study written in 2019 did not find an association between maternal age and congenital diaphragma hernia either.(203) In contrast, a registry analysis in 2022 found that both very young and advanced maternal age pose increased risk.(204)

*Omphalocele (ICD-10: Q79.2)*: The meta-analysis suggests that both very young and advanced maternal age increase the risk, with this risk-increasing effect being particularly pronounced over 40. Marshall et al. came to the same conclusion (205) and an earlier review article described this link as well.(206)

*Gastroschisis (ICD-10: Q79.3)*: In our meta-analysis, we found a 3-fold increase in risk in the young and a protective effect in the older age groups. The relevant scientific literature confirms the finding for the young age group. A review in 2000 found a clear and strong risk-increasing effect of young maternal age.(207) A 2020 meta-analysis of 29 studies looking into the possible factors underlying the risk-influencing effect of young maternal age discovered that maternal smoking (RR = 1.56; CI 1.40–1.74), illicit drug use (RR = 2.14; CI 1.48–3.07), and alcohol consumption (RR = 1.40; CI 1.13–1.70) were all associated with an increased risk of gastroschisis.(208) A 2024 study discovered that the prevalence of gastroschisis increased by 61% between 1980 and 2017 in the surveillance programmes studied. The increase was observed across all age groups, with mothers under the age of 20 having the highest incidence.(209)



## **9.2 Strengths (including all studies)**

The strengths of our research greatly enhance the dependability and application of our findings. A meta-analysis combined with a population-based study offers a thorough and strong investigation into the influence of maternal age on NCAs.

The population-based study provided several distinct advantages to our research. The extensive number of cases and controls yielded a sizeable dataset, which is crucial for rigorous statistical analysis. We employed a distinctive database and rigorous data collection techniques to guarantee the precise recording of information. The meticulous gathering of this data minimized potential biases and improved the dependability of our results. In addition, the innovative statistical methodology we utilized enabled us to depict reality with greater precision, so circumventing the constraints linked to arbitrary grouping by age.

Throughout our meta-analysis, we followed our pre-registered protocol rigorously, guaranteeing transparency and consistency in our methods. Through the implementation of a meticulous approach, we guaranteed the incorporation of a wide range of population-based publications from different geographical areas across the globe. This method enabled us to acquire a thorough and inclusive viewpoint on NCAs. Through the analysis of data from a substantial number of cases, we have improved the applicability of our conclusions, ensuring that our findings are pertinent to a wide range of people. The inclusion of studies with an international scope enhances the generalizability and application of our conclusions, offering insights that are useful on a worldwide scale.

### **9.3 Limitations (including all studies)**

Although our research offers valuable insights into the association between maternal age and NCAs, it is crucial to recognize the inherent limitations in our study designs.

The population-based study revealed comparable constraints. Throughout the extended duration of the study, minor modifications in the screening techniques and rates of detection may have had an impact on our findings. Furthermore, the definitions of certain individual anomalies exhibited variations over time or were completely absent in certain cases, resulting in inconsistencies. Although the documents were organized based on ICD-10 categories, there were instances where it was challenging to precisely identify anomalies, which had a negative effect on the accuracy of our data. An other limitation of this study was the lack of a multivariate model, which was due to the insufficient information available on the general population compared to the detailed data on pathological cases.

A notable constraint in the meta-analysis stems from the fact that all the studies included in it have a retrospective design. The retrospective nature of this study hinders our ability to determine causality and restricts the evaluation of certain confounding variables. Publication bias is a common concern in meta-analyses, referring to the tendency of studies with non-significant results to be less likely to be published. Though we could not detect significant publication bias in our analysis, it is important to note that failing to prove the presence of bias does not prove its absence. Another source of concern may be the presence of high level of heterogeneity. However, this should only partly be considered a limitation, because heterogeneity is often a natural characteristic of the studied variable resulting from the effect of various confounders. The potential sources of heterogeneity in our study may be the following: high variability of sample sizes (smaller studies have a higher chance of random variation); the prolonged duration of the period from which studies were collected (resulting in variation of screening methods, lifestyle factors specific for age categories, the ICD categorization), geographical variations (potential variation in the detection quality screening methods, and probably even in the probability of malformations e.g. due to nutritional or socio-economic causes), categorization (not all studies used explicit ICD categories, and different editions of ICD

were in use for different studies), the definition of “total number of births” (are stillbirths as well as elective abortions – carried out either due to or not due to fetal anomalies – included).

Recognizing these constraints emphasizes the necessity for careful appreciation of our discoveries and emphasizes the significance of future investigations to tackle these concerns. In order to obtain more conclusive findings and deepen our understanding of the effects of maternal age on NCAs, it is crucial to conduct prospective studies that employ consistent definitions, improved data collection methods, and incorporate multivariate analyses.

## 10 CONCLUSIONS

- 1.) Both very young (< 20 years) and advanced maternal ages (> 35 years) are associated with an increased risk of non-chromosomal congenital anomalies (NCAs) in Hungarian population. The evidence pertaining to the advanced age category is more robust and valid worldwide.
- 2.) In the Hungarian population, mothers between the ages of 23 and 32 have the lowest risk of NCAs.
- 3.) Very young maternal age increases the risk of nervous system anomalies in the Hungarian population.
- 4.) Eye, ear, face, and neck anomalies are associated to advanced maternal age in the Hungarian population.
- 5.) Anomalies in the circulatory system exhibit a higher risk in advanced maternal age. This relationship remains valid even in the absence of concurrent chromosomal anomalies.
- 6.) Congenital heart defects demonstrate higher risk at advanced (40+) maternal age and there is a suspected mild prophylactic effect in very young mothers.
- 7.) In the case of cleft lip and palate, both very young and advanced maternal age pose an increased risk in the Hungarian population, with this association being evident worldwide above the age of 40.
- 8.) Very young and advanced maternal age increase the risk of digestive system anomalies in the Hungarian population, while this risk is also evident worldwide above the age of 40.
- 9.) Genital organ anomalies exhibit a heightened risk in both very young and advanced maternal age groups in the Hungarian population.
- 10.) For urinary system anomalies, both very young and advanced maternal age increase the risk in the Hungarian population. This effect is greater in advanced maternal age group.
- 11.) Anomalies of the musculoskeletal system are more likely to occur in both advanced and very young mothers in the Hungarian population, but the risk is higher in younger mothers.
- 12.) Gastroschisis is associated with a threefold risk in very young mothers.

## **11 IMPLEMENTATIONS FOR PRACTICE**

Early translation of research findings into clinical practice is crucial.(210, 211) It is worth considering to treat maternal age as an independent risk factor when developing prenatal screening protocols – and not only because of co-morbidities or because of the higher risk of chromosomal anomalies. Considering this factor is crucial for optimizing prenatal care and enhancing the identification of NCAs among various age groups of mothers.

Indications for fetal echocardiography and neurosonography do not currently include maternal age-based screening.(190, 191, 212, 213) Based on our results, when developing recommendations for fetal echocardiography and neurosonography, it is advisable to include advanced maternal age as an indication for fetal echocardiography and very young maternal age as an indication for fetal neurosonography. Screening protocols that take maternal age into account can improve the child's prospects by enabling timely identification for proactive medical planning, enabling parents to make informed decisions about their pregnancy. This approach recognizes the differences that women struggle with at different stages of life and contributes to personalized, effective care.

## **12 IMPLEMENTATION FOR RESEARCH**

### *Methodology issues*

In the analysis of the articles used for the meta-analysis, difficulties were encountered with the uniform maternal age categorisation (at least the broadly consistent use in the literature of the advanced maternal age categories /above 35/ and very young /under 20/), the lack of a standard reference age (we mark this as 20-30 based on our two analyses) and the lack of consistency with ICD categories. For future studies on this topic - in addition to eliminating the above problems - we recommend providing complete raw data (i.e. total and diseased birth count for each maternal age) for a more precise and complete synthesis of the data.

### *Study design*

It is advisable to prioritize the analysis of the impact of maternal age by using prospective data collection in a multivariate model. Since the potential confounders are largely known (e.g. financial status, healthcare access, lifestyle choices, genetics), future research should further analyze them. This may affect the intrinsic risk increasing effect of maternal age on NCAs. Currently, detailed data are usually available in a case-matched control model for both cases and controls, but this is not suitable for estimating true prevalence, and for population studies we do not have more detailed information on the control population. A comprehensive pregnancy registry can generate a reliable dataset for multivariate analysis and generalisable results.

### *New aspects*

We hope, our findings will facilitate further research of the biological background. It is essential to establish the biological model behind the statistical-clinical association we have found. Due to the nature of the topic, collaboration with co-disciplines (geneticists, pediatricians, epidemiologists) can provide additional insights and valuable new aspects and enhance the quality and complexity of research.

### 13 IMPLEMENTATION FOR POLICYMAKERS

We have little influence on the social and societal trends that lead to delayed childbearing, so it is primarily the task of decision-makers, but also of us as practitioners, to respond to these trends with the appropriate sensitivity and effectiveness. Although the risk-increasing effects of advanced maternal age are generally more discussed in the developed world, the increased risks associated with pregnancy in very young mothers are also important to prioritise.

Regarding NCAs, at-risk mother age groups should be given top priority at several layers of prevention. To implement *primary prevention* strategies effectively, policymakers should consider the development of accessible educational programs targeting both the general population and healthcare professionals. Women should be educated about both the risk for pregnancy at particular ages and the available diagnostic methods. As *second prevention*, prioritizing comprehensive surveillance helps to implement effective monitoring systems and encourages early detection and intervention practices in healthcare facilities. Integrating emerging evidence into policy decisions helps improve early detection, intervention strategies, and outcomes for affected fetuses. Based on our studies, one of the most game-changer changes could be the provision of maternal and human resources for maternal age-based screening protocols for fetal echocardiography and neurosonography. As for *tertiary prevention*, mobilising adequate attention and resources is also essential, as the substantially unchanged high prevalence of NCAs in developed countries indicates that the provision of treatment protocols, rehabilitation programmes and psychosocial support can improve the quality of life of those affected.

## **14 FUTURE PERSPECTIVES**

Building on our previous findings, we intend to continue our research on this topic in our research group, with the goal of contributing to a higher level of perinatal screening.

We should relaunch the Hungarian database, because the uniqueness of the data collection methodology and the wide range of information collected can greatly contribute to the understanding of the topic.

We plan to reproduce the meta-analysis regularly, following the current concept, as this is an intensively researched area and a significant number of new publications are expected to be published each year. It is our expectation that our publications will lead to the development of a more uniform maternal reference age and a more standardized definition of NCAs. These changes could increase the proportion of publications that can be included and synthesised, while reducing the limitations due to the expected lower heterogeneity. We also plan to conduct a meta-analysis of publications using a multivariate model.



## 15 REFERENCES

1. Nutrition, physical activity, and obesity: Data, trends and maps.: Centers for Disease Control and Prevention; 2023 [Available from: <https://www.cdc.gov/nccdphp/dnpao/data-trends-maps/index.html>].
2. Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, et al. National population-based estimates for major birth defects, 2010-2014. *Birth Defects Res.* 2019;111(18):1420-35.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380(9859):2095-128.
4. Roncancio CP, Misnaza SP, Pena IC, Prieto FE, Cannon MJ, Valencia D. Trends and characteristics of fetal and neonatal mortality due to congenital anomalies, Colombia 1999-2008. *J Matern Fetal Neonatal Med.* 2018;31(13):1748-55.
5. Stallings EB, Isenburg JL, Rutkowski RE, Kirby RS, Nembhard WN, Sandidge T, et al. National population-based estimates for major birth defects, 2016-2020. *Birth Defects Res.* 2024;116(1):e2301.
6. Swanson J, Ailes EC, Cragan JD, Grosse SD, Tanner JP, Kirby RS, et al. Inpatient Hospitalization Costs Associated with Birth Defects Among Persons Aged <65 Years - United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2023;72(27):739-45.
7. Economic UNDo, Division SAP. World fertility patterns 2015–data booklet (ST/ESA/SER. A/370). United Nations New York; 2015.
8. Waldenstrom U. Postponing parenthood to advanced age. *Ups J Med Sci.* 2016;121(4):235-43.
9. Safdari-Dehcheshmeh F, Noroozi M, Taleghani F, Memar S. Factors Influencing the Delay in Childbearing: A Narrative Review. *Iran J Nurs Midwifery Res.* 2023;28(1):10-9.
10. Stone L. Declining fertility in America. American Enterprise Institute. 2018.
11. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2021. *Natl Vital Stat Rep.* 2023;72(1):1-53.
12. Yurchuk T, Petrushko M, Fuller B. State of the art in assisted reproductive technologies for patients with advanced maternal age. *Zygote.* 2023;31(2):149-56.

13. Frick AP. Advanced maternal age and adverse pregnancy outcomes. *Best Pract Res Clin Obstet Gynaecol.* 2021;70:92-100.
14. Frederiksen LE, Ernst A, Brix N, Braskhoj Lauridsen LL, Roos L, Ramlau-Hansen CH, et al. Risk of Adverse Pregnancy Outcomes at Advanced Maternal Age. *Obstet Gynecol.* 2018;131(3):457-63.
15. Cao J, Xu W, Liu Y, Zhang B, Zhang Y, Yu T, et al. Trends in maternal age and the relationship between advanced age and adverse pregnancy outcomes: a population-based register study in Wuhan, China, 2010-2017. *Public Health.* 2022;206:8-14.
16. Glick I, Kadish E, Rottenstreich M. Management of Pregnancy in Women of Advanced Maternal Age: Improving Outcomes for Mother and Baby. *Int J Womens Health.* 2021;13:751-9.
17. Koenigbauer JT, Fangmann L, Rostin P, Balke S, Weid P, Henrich W, et al. Advanced maternal age (AMA) and 75 g oGTT glucose levels are predictors for insulin therapy in women with gestational diabetes (GDM). *J Perinat Med.* 2023;51(9):1154-62.
18. Jiang C, Wen H, Hu T, Liu Y, Dai X, Chen Y. Perinatal characteristics and pregnancy outcomes of advanced maternal age women with gestational diabetes mellitus: A retrospective cohort study. *Health Sci Rep.* 2024;7(2):e1903.
19. Ustianowski L, Udzik J, Szostak J, Goracy A, Ustianowska K, Pawlik A. Genetic and Epigenetic Factors in Gestational Diabetes Mellitus Pathology. *Int J Mol Sci.* 2023;24(23).
20. Li H, Nawsherwan, Khan A, Haq IU, Mei SY. Do Hypertensive Disorders of Pregnancy and Abnormal Placentation Mediate the Association between Advanced Maternal Age and Adverse Perinatal Outcomes? *Iran J Public Health.* 2022;51(5):1057-66.
21. Liu X, Ruan Y, Liu Y, Zhang W. [Relationship between maternal age and hypertensive disorders in pregnancy]. *Zhonghua Yi Xue Za Zhi.* 2015;95(1):19-22.
22. Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, et al. Born too soon: the global epidemiology of 15 million preterm births. *Reprod Health.* 2013;10 Suppl 1(Suppl 1):S2.
23. Waldenstrom U, Cnattingius S, Vixner L, Norman M. Advanced maternal age increases the risk of very preterm birth, irrespective of parity: a population-based register study. *BJOG.* 2017;124(8):1235-44.

24. Hirata Y, Katsukura Y, Henmi Y, Ozawa R, Shimazaki S, Kurosawa A, et al. Advanced maternal age induces fetal growth restriction through decreased placental inflammatory cytokine expression and immune cell accumulation in mice. *J Reprod Dev.* 2021;67(4):257-64.
25. Lubrano C, Taricco E, Coco C, Di Domenico F, Mando C, Cetin I. Perinatal and Neonatal Outcomes in Fetal Growth Restriction and Small for Gestational Age. *J Clin Med.* 2022;11(10).
26. Abate M, Arefaynie M, Muche A, Molla A, Wodajo S, Temesgen K, et al. The effect of maternal age on still birth in Africa: A systematic review and meta-analysis. *Health Sci Rep.* 2024;7(5):e2105.
27. Kortekaas JC, Kazemier BM, Keulen JKJ, Bruinsma A, Mol BW, Vandenbussche F, et al. Risk of adverse pregnancy outcomes of late- and postterm pregnancies in advanced maternal age: A national cohort study. *Acta Obstet Gynecol Scand.* 2020;99(8):1022-30.
28. Attali E, Doleeb Z, Hiersch L, Amikam U, Gamzu R, Yogev Y, et al. The risk of intrapartum cesarean delivery in advanced maternal age. *J Matern Fetal Neonatal Med.* 2022;35(25):8019-26.
29. Veenstra J, Cohen Z, Korteweg FJ, van der Ham DP, Kuppens SM, Kroese JA, et al. Unplanned cesarean sections in advanced maternal age: A predictive model. *Acta Obstet Gynecol Scand.* 2024;103(5):927-37.
30. Dalton-O'Reilly J, Heazell AEP, Desforges M, Greenwood S, Dilworth M. Murine models of advanced maternal age: a systematic review and meta-analysis. *Reproduction.* 2023;166(4):M1-M12.
31. Pinheiro RL, Areia AL, Mota Pinto A, Donato H. Advanced Maternal Age: Adverse Outcomes of Pregnancy, A Meta-Analysis. *Acta Med Port.* 2019;32(3):219-26.
32. Duran MN, Pek E, Demir SS, Karacaer KO, Demir B. Maternal and foetal risks associated with teenage pregnancy - a comparative retrospective study in Turkey. *J Obstet Gynaecol.* 2024;44(1):2364787.
33. Diabelkova J, Rimarova K, Dorko E, Urdzik P, Houzvickova A, Argalasova L. Adolescent Pregnancy Outcomes and Risk Factors. *Int J Environ Res Public Health.* 2023;20(5).

34. UNICEF. Adolescent health 21.07.2024. [Available from: <https://data.unicef.org/topic/child-health/adolescent-health/>].
35. Wado YD, Sully EA, Mumah JN. Pregnancy and early motherhood among adolescents in five East African countries: a multi-level analysis of risk and protective factors. *BMC Pregnancy Childbirth*. 2019;19(1):59.
36. Imamura M, Tucker J, Hannaford P, da Silva MO, Astin M, Wyness L, et al. Factors associated with teenage pregnancy in the European Union countries: a systematic review. *Eur J Public Health*. 2007;17(6):630-6.
37. Mann L, Bateson D, Black KI. Teenage pregnancy. *Aust J Gen Pract*. 2020;49(6):310-6.
38. Hacker M, Firk C, Konrad K, Paschke K, Neulen J, Herpertz-Dahlmann B, et al. Pregnancy complications, substance abuse, and prenatal care predict birthweight in adolescent mothers. *Arch Public Health*. 2021;79(1):137.
39. Fleming N, O'Driscoll T, Becker G, Spitzer RF, Canpago C. Adolescent Pregnancy Guidelines. *J Obstet Gynaecol Can*. 2015;37(8):740-56.
40. Birth defects not linked to maternal age. *Nurs Stand*. 1991;5(25):14.
41. Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. *Birth Defects Res A Clin Mol Teratol*. 2006;76(11):747-56.
42. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2197-223.
43. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. *Adv Exp Med Biol*. 2010;686:349-64.
44. Almli LM, Ely DM, Ailes EC, Abouk R, Grosse SD, Isenburg JL, et al. Infant Mortality Attributable to Birth Defects - United States, 2003-2017. *MMWR Morb Mortal Wkly Rep*. 2020;69(2):25-9.
45. Salmasi G, Grady R, Jones J, McDonald SD, Knowledge Synthesis G. Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. *Acta Obstet Gynecol Scand*. 2010;89(4):423-41.

46. Balsells M, Garcia-Patterson A, Gich I, Corcoy R. Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2012;28(3):252-7.
47. Polani PE, Alberman E, Berry AC, Blunt S, Singer JD. Chromosome abnormalities and maternal age. *Lancet*. 1976;1(7984):516-7.
48. Ferguson-Smith MA. Maternal age and Down syndrome. *Lancet*. 1978;2(8082):213.
49. Cuckle H. Maternal age-standardisation of prevalence of Down's syndrome. *Lancet*. 1999;354(9178):529-30.
50. Ma JY, Li S, Chen LN, Schatten H, Ou XH, Sun QY. Why is oocyte aneuploidy increased with maternal aging? *J Genet Genomics*. 2020;47(11):659-71.
51. American College of O, Gynecologists' Committee on Practice B-O, Committee on G, Society for Maternal-Fetal M. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol*. 2020;136(4):e48-e69.
52. Fiorentino DG, Hughes F. Fetal Screening for Chromosomal Abnormalities. *Neoreviews*. 2021;22(12):e805-e18.
53. Loane M, Dolk H, Morris JK, Group EW. Maternal age-specific risk of non-chromosomal anomalies. *BJOG*. 2009;116(8):1111-9.
54. Hollier LM, Leveno KJ, Kelly MA, DD MC, Cunningham FG. Maternal age and malformations in singleton births. *Obstet Gynecol*. 2000;96(5 Pt 1):701-6.
55. Reefhuis J, Honein MA. Maternal age and non-chromosomal birth defects, Atlanta--1968-2000: teenager or thirty-something, who is at risk? *Birth Defects Res A Clin Mol Teratol*. 2004;70(9):572-9.
56. Zhou Y, Yang D, Mao X, Zhou H, Wang L. Epidemiology of birth defects in a national hospital-based birth defect surveillance spot in Southern Jiangsu, China, 2014-2018. *Front Med (Lausanne)*. 2023;10:1138946.
57. Miranda VIA, da Silva Dal Pizzol T, Silveira MPT, Mengue SS, da Silveira MF, Lutz BH, et al. The use of folic acid, iron salts and other vitamins by pregnant women in the 2015 Pelotas birth cohort: is there socioeconomic inequality? *BMC Public Health*. 2019;19(1):889.
58. van Gool JD, Hirche H, Lax H, De Schaepdrijver L. Folic acid and primary prevention of neural tube defects: A review. *Reprod Toxicol*. 2018;80:73-84.

59. Lusa L, Ahlin C. Restricted cubic splines for modelling periodic data. *PLoS One*. 2020;15(10):e0241364.
60. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg*. 2014;12(12):1495-9.
61. Czeizel AE, Rockenbauer M, Siffel C, Varga E. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980-1996. *Teratology*. 2001;63(5):176-85.
62. Ács N, Mátrai Á, Kaposi A. First data from the new, unified database of the Hungarian case-control surveillance of congenital abnormalities. *Journal of Maternal-Fetal and Neonatal Medicine*. 2021;34(17):2887-92.
63. Czeizel AE, Metneki J, Beres J. 50 years of the Hungarian Congenital Abnormality Registry. *Congenit Anom (Kyoto)*. 2014;54(1):22-9.
64. Petho B, Matrai A, Agocs G, Veres DS, Harnos A, Vancsa S, et al. Maternal age is highly associated with non-chromosomal congenital anomalies: Analysis of a population-based case-control database. *BJOG*. 2023.
65. GRADEpro [Available from: <https://www.gradepro.org/>].
66. R Foundation for Statistical Computing V, Austria. R Core Team (2021) R: A language and environment for statistical computing. .
67. Agresti A aBAC. Approximate Is Better Than "Exact" for Interval Estimation of Binomial Proportions. *The American Statistician* 52 (2): 119. 1998.
68. Harrell J FE. *Rms: Regression Modeling Strategies* 2021.
69. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)*. 2021;74(9):790-9.
70. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev*. 2019;10(10.1002):1461858.
71. PROSPERO [Available from: <https://www.crd.york.ac.uk/prospero/>].

72. McHugh ML. Interrater reliability: the kappa statistic. *Biochemia medica*. 2012;22(3):276-82.
73. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *bmj*. 2019;366.
74. McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. *Research synthesis methods*. 2021;12(1):55-61.
75. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health*. 2019;22(4):153-60.
76. Ebert MHaPCaTFaDD. dmetar: Companion R Package For The Guide 'Doing Meta-Analysis in R' 2019 [Available from: <http://dmetar.protectlab.org/>].
77. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst*. 1959;22(4):719-48.
78. Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. *Am J Epidemiol*. 1986;124(5):719-23.
79. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. *Stat Methods Med Res*. 2001;10(6):375-92.
80. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med*. 2004;23(9):1351-75.
81. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med*. 2003;22(17):2693-710.
82. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol*. 2014;14:25.
83. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods*. 2016;7(1):55-79.
84. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open*. 2016;6(7):e010247.
85. Petho B, Vancsa S, Varadi A, Agocs G, Matrai A, Zaszkaliczky-Iker F, et al. Very young and advanced maternal age strongly elevates the occurrence of nonchromosomal

congenital anomalies: a systematic review and meta-analysis of population-based studies. *Am J Obstet Gynecol*. 2024.

86. Agopian A, Marengo L, Mitchell LE. Descriptive epidemiology of nonsyndromic omphalocele in Texas, 1999-2004. *American Journal of Medical Genetics, Part A*. 2009;149(10):2129-33.

87. Baer RJ, Chambers CD, Jones KL, Shew SB, MacKenzie TC, Shaw GM, et al. Maternal factors associated with the occurrence of gastroschisis. *Am J Med Genet A*. 2015;167(7):1534-41.

88. Beckman L, Nordstrom M. Population studies in northern Sweden. VIII. Frequencies of congenital malformations by region, time, sex and maternal age. *Hereditas*. 1976;84(1):35-40.

89. Bergman JE, Loane M, Vrijheid M, Pierini A, Nijman RJ, Addor MC, et al. Epidemiology of hypospadias in Europe: a registry-based study. *World journal of urology*. 2015;33(12):2159-67.

90. Baird PA, Sadovnick AD, Yee IM. Maternal age and oral cleft malformations: data from a population-based series of 576,815 consecutive livebirths. *Teratology*. 1994;49(6):448-51.

91. Bodnár L. The effect of maternal age and birth order on the incidence of congenital abnormalities. *Orvosi hetilap*. 1970;111(11):625-8.

92. Borman GB, Smith AH, Howard JK. Risk factors in the prevalence of anencephalus and spina bifida in New Zealand. *Teratology*. 1986;33(2):221-30.

93. Bourque DK, Meng L, Dougan S, Momoli F, Riddell C, Walker M, et al. Gastroschisis in Ontario, Canada: 2012–2018. *Birth Defects Research*. 2021;113(14):1044-51.

94. Bugge M, Drachmann G, Kern P, Budtz-Jørgensen E, Eiberg H, Olsen B, et al. Abdominal Wall Defects in Greenland 1989-2015. *Birth Defects Res*. 2017;109(11):836-42.

95. Byron-Scott R, Haan E, Chan A, Bower C, Scott H, Clark K. A population-based study of abdominal wall defects in South Australia and Western Australia. *Paediatric and Perinatal Epidemiology*. 1998;12(2):136-51.



96. Canfield MA, Marengo L, Ramadhani TA, Suarez L, Brender JD, Scheuerle A. The prevalence and predictors of anencephaly and spina bifida in Texas. *Paediatric and Perinatal Epidemiology*. 2009;23(1):41-50.
97. Canon S, Mosley B, Chipollini J, Purifoy JA, Hobbs C. Epidemiological assessment of hypospadias by degree of severity. *Journal of Urology*. 2012;188(6):2362-6.
98. Croen LA, Shaw GM. Young maternal age and congenital malformations: A population-based study. *American Journal of Public Health*. 1995;85(5):710-3.
99. DeRoo LA, Gaudino JA, Edmonds LD. Orofacial cleft malformations: associations with maternal and infant characteristics in Washington State. *Birth Defects Res A Clin Mol Teratol*. 2003;67(9):637-42.
100. Dott MM, Wong LY, Rasmussen SA. Population-based study of congenital diaphragmatic hernia: risk factors and survival in Metropolitan Atlanta, 1968-1999. *Birth Defects Res A Clin Mol Teratol*. 2003;67(4):261-7.
101. Dudin A. Neural tube defect among Palestinians: A hospital-based study. *Annals of Tropical Paediatrics*. 1997;17(3):217-22.
102. Fedrick J. Anencephalus in Scotland 1961-72. *Br J Prev Soc Med*. 1976;30(2):132-7.
103. Feldman JG, Stein SC, Klein RJ, Kohl S, Casey G. The prevalence of neural tube defects among ethnic groups in Brooklyn, New York. *J Chronic Dis*. 1982;35(1):53-60.
104. Forrester MB, Merz RD. Descriptive epidemiology of oral clefts in a multiethnic population, Hawaii, 1986-2000. *Cleft Palate-Craniofacial Journal*. 2004;41(6):622-8.
105. Forrester MB, Merz RD. Epidemiology of abdominal wall defects, Hawaii, 1986-1997. *Teratology*. 1999;60(3):117-23.
106. Forrester MB, Merz RD. Epidemiology of neural tube defects, Hawaii, 1986-1997. *Hawaii medical journal*. 2000;59(8):323-7, 41.
107. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, Wright JD. Gastroschisis: epidemiology and mode of delivery, 2005–2013. *American Journal of Obstetrics and Gynecology*. 2016;215(3):348.e1-.e9.
108. Gupta B, Antia AU. Incidence of congenital heart disease in Nigerian children. *British heart journal*. 1967;29(6):906-9.

109. Hansen M, Greenop K, Yim D, Ramsay J, Thomas Y, Baynam GS. Birth prevalence of congenital heart defects in Western Australia, 1990-2016. *J Paediatr Child Health*. 2021;57(10):1672-80.
110. Hay S. Incidence of selected congenital malformations in Iowa. *American journal of epidemiology*. 1971;94(6):572-84.
111. Hollier LM, Leveno KJ, Kelly MA, McIntire DD, Cunningham FG. Maternal age and malformations in singleton births. *Obstetrics and Gynecology*. 2000;96(5):701-6.
112. Jaikrishan G, Sudheer KR, Andrews VJ, Koya PK, Madhusoodhanan M, Jagadeesan CK, et al. Study of stillbirth and major congenital anomaly among newborns in the high-level natural radiation areas of Kerala, India. *J Community Genet*. 2013;4(1):21-31.
113. Janerich DT. Maternal age and spina bifida: longitudinal versus cross-sectional analysis. *Am J Epidemiol*. 1972;96(6):389-95.
114. Janerich DT. Anencephaly and maternal age. *Am J Epidemiol*. 1972;95(4):319-26.
115. Jaruratanasirikul S, Chicharoen V, Chakranon M, Sriplung H, Limpitikul W, Dissaneevate P, et al. Population-based study of prevalence of cleft lip/palate in southern Thailand. *Cleft Palate-Craniofacial Journal*. 2016;53(3):351-6.
116. Jones AM, Isenburg J, Salemi JL, Arnold KE, Mai CT, Aggarwal D, et al. Increasing Prevalence of Gastroschisis--14 States, 1995-2012. *MMWR Morbidity and mortality weekly report*. 2016;65(2):23-6.
117. Kazaura M, Lie RT, Skjærven R. Paternal age and the risk of birth defects in Norway. *Annals of Epidemiology*. 2004;14(8):566-70.
118. Kirby RS, Marshall J, Tanner JP, Salemi JL, Feldkamp ML, Marengo L, et al. Prevalence and correlates of gastroschisis in 15 states, 1995 to 2005. *Obstet Gynecol*. 2013;122(2 Pt 1):275-81.
119. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. *Circulation*. 2013;128(6):583-9.
120. Liu S, Evans J, MacFarlane AJ, Ananth CV, Little J, Kramer MS, et al. Association of maternal risk factors with the recent rise of neural tube defects in Canada. *Paediatr Perinat Epidemiol*. 2019;33(2):145-53.

121. Li ZY, Chen YM, Qiu LQ, Chen DQ, Hu CG, Xu JY, et al. Prevalence, types, and malformations in congenital anomalies of the kidney and urinary tract in newborns: a retrospective hospital-based study. *Ital J Pediatr*. 2019;45(1):50.
122. Vo LU, Langlois PH. Time trends in prevalence of gastroschisis in Texas, 1999 to 2011: Subgroup analyses by maternal and infant characteristics. *Birth Defects Res A Clin Mol Teratol*. 2015;103(11):928-40.
123. Luo YL, Wang W, Gao XH, Huang YH, Xu Q, Cheng YL. Birth prevalence of orofacial clefts among perinatal infants: A register-based study in Bao'an district, Shenzhen, China. *Birth Defects Res*. 2019;111(7):353-9.
124. Martínez Frías ML, Salvador J, Prieto L, Zaplana J. Incidence of gastroschisis and omphalocele in Spain. *Revista de sanidad e higiene pública*. 1982;56(1-2):107-18.
125. Materna-Kiryluk A, Wisniewska K, Badura-Stronka M, Mejnartowicz J, Wieckowska B, Balcar-Boron A, et al. Parental age as a risk factor for isolated congenital malformations in a Polish population. *Paediatr Perinat Epidemiol*. 2009;23(1):29-40.
126. McGivern MR, Best KE, Rankin J, Wellesley D, Greenlees R, Addor MC, et al. Epidemiology of congenital diaphragmatic hernia in Europe: A register-based study. *Archives of Disease in Childhood: Fetal and Neonatal Edition*. 2015;100(2):F137-F44.
127. Miller A, Riehle-Colarusso T, Siffel C, Frías JL, Correa A. Maternal age and prevalence of isolated congenital heart defects in an urban area of the United States. *American Journal of Medical Genetics, Part A*. 2011;155(9):2137-45.
128. Mucat Baron Y, Gatt M, Calleja N, Collicot M. Advanced maternal age and neonatal outcomes in Malta. *Clinical and Experimental Obstetrics and Gynecology*. 2019;46(2):265-9.
129. Nazer J, Aravena T, Cifuentes L. Congenital malformations in Chile. An emerging problem (period 1995-1999). *Revista médica de Chile*. 2001;129(8):895-904.
130. Nazer H J, Cifuentes O L. [Congenital malformations among newborns of teenage mothers]. *Revista médica de Chile*. 2013;141(10):1300-6.
131. Parkes B, Hansell AL, Ghosh RE, Douglas P, Fecht D, Wellesley D, et al. Risk of congenital anomalies near municipal waste incinerators in England and Scotland: Retrospective population-based cohort study. *Environ Int*. 2020;134:104845.
132. Paśnicki M, Wiśniewska K, Materna-Kiryluk A, Latos-Bieleńska A, Krawczyński M. The congenital malformations in children aged 0-2 in Zielona Góra province (1988-

1997) and Lubuskie province (1998-2007) according to the Polish Registry of Congenital Malformations. Part 3. Age of mother and frequency of congenital malformations in children. *Pediatrics Polska*. 2013;88(1):48-56.

133. Persson M, Razaz N, Edstedt Bonamy AK, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk of Congenital Heart Defects. *J Am Coll Cardiol*. 2019;73(1):44-53.

134. Petrova JG, Vaktskjold A. The incidence of neural tube defects in Norway and the Arkhangelskaja Oblast in Russia and the association with maternal age. *Acta Obstetricia et Gynecologica Scandinavica*. 2009;88(6):667-72.

135. Pradat P. Epidemiology of major congenital heart defects in Sweden, 1981-1986. *Journal of Epidemiology and Community Health*. 1992;46(3):211-5.

136. Purkey NJ, Axelrod DM, McElhinney DB, Rigdon J, Qin F, Desai M, et al. Birth Location of Infants with Critical Congenital Heart Disease in California. *Pediatr Cardiol*. 2019;40(2):310-8.

137. Rankin J, Dillon E, Wright C. Congenital anterior abdominal wall defects in the North of England, 1986-1996: Occurrence and outcome. *Prenatal Diagnosis*. 1999;19(7):662-8.

138. Rankin J, Glinianaia S, Brown R, Renwick M. The changing prevalence of neural tube defects: a population-based study in the north of England, 1984-96. Northern Congenital Abnormality Survey Steering Group. *Paediatr Perinat Epidemiol*. 2000;14(2):104-10.

139. Rider RA, Stevenson DA, Rinsky JE, Feldkamp ML. Association of twinning and maternal age with major structural birth defects in Utah, 1999 to 2008. *Birth Defects Res A Clin Mol Teratol*. 2013;97(8):554-63.

140. Roeper PJ, Harris J, Lee G, Neutra R. Secular rates and correlates for gastroschisis in California (1968-1977). *Teratology*. 1987;35(2):203-10.

141. Salihu HM, Pierre-Louis BJ, Druschel CM, Kirby RS. Omphalocele and gastroschisis in the State of New York, 1992-1999. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2003;67(9):630-6.

142. Salim TR, Soares GP, Klein CH, Oliveira GMM. Fetal and maternal factors are associated with mortality due to circulatory system disorders in children. *Rev Saude Publica*. 2019;53:31.

143. Sarkar S, Patra C, Dasgupta MK, Nayek K, Karmakar PR. Prevalence of congenital anomalies in neonates and associated risk factors in a tertiary care hospital in eastern India. *Journal of Clinical Neonatology*. 2013;2(3):131-4.
144. Sever LE. An epidemiologic study of neural tube defects in Los Angeles County II. Etiologic factors in an area with low prevalence at birth. *Teratology*. 1982;25(3):323-34.
145. Shields ED, Bixler D, Fogh-Andersen P. Cleft palate: A genetic and epidemiologic investigation. *Clinical Genetics*. 1981;20(1):13-24.
146. Short TD, Stallings EB, Isenburg J, O'Leary LA, Yazdy MM, Bohm MK, et al. Gastroschisis Trends and Ecologic Link to Opioid Prescription Rates - United States, 2006-2015. *MMWR Morb Mortal Wkly Rep*. 2019;68(2):31-6.
147. St Louis AM, Kim K, Browne ML, Liu G, Liberman RF, Nembhard WN, et al. Prevalence trends of selected major birth defects: A multi-state population-based retrospective study, United States, 1999 to 2007. *Birth Defects Res*. 2017;109(18):1442-50.
148. Tan KH, Kilby MD, Whittle MJ, Beattie BR, Booth IW, Botting BJ. Congenital anterior abdominal wall defects in England and Wales 1987-93: Retrospective analysis of OPCS data. *British Medical Journal*. 1996;313(7062):903-6.
149. Pregnancy outcomes in women of very advanced maternal age: Editorial comment. *Obstetrical and Gynecological Survey*. 2005;60(9):562-3.
150. Tan KB, Tan KH, Chew SK, Yeo GS. Gastroschisis and omphalocele in Singapore: a ten-year series from 1993 to 2002. *Singapore Med J*. 2008;49(1):31-6.
151. Williams LJ, Kucik JE, Alverson CJ, Olney RS, Correa A. Epidemiology of gastroschisis in metropolitan Atlanta, 1968 through 2000. *Birth Defects Res A Clin Mol Teratol*. 2005;73(3):177-83.
152. Xie D, Yang T, Liu Z, Wang H. Epidemiology of birth defects based on a birth defect surveillance system from 2005 to 2014 in Hunan Province, China. *PLoS ONE*. 2016;11(1).
153. Xie D, Fang J, Liu Z, Wang H, Yang T, Sun Z, et al. Epidemiology and major subtypes of congenital heart defects in Hunan Province, China. *Medicine (Baltimore)*. 2018;97(31):e11770.

154. Xu LL, Yuan XQ, Zhu J, Li XH, Wang YP, Zhou GX, et al. [Incidence and its trends on gastroschisis in some parts of China, 1996 - 2007]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2011;32(3):268-70.
155. Zhang X, Li S, Wu S, Hao X, Guo S, Suzuki K, et al. Prevalence of birth defects and risk-factor analysis from a population-based survey in Inner Mongolia, China. *BMC Pediatr*. 2012;12:125.
156. Yang W, Carmichael SL, Harris JA, Shaw GM. Epidemiologic characteristics of congenital diaphragmatic hernia among 2.5 million California births, 1989-1997. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2006;76(3):170-4.
157. Zhou Y, Mao X, Zhou H, Qin Z, Wang L, Cai Z, et al. Epidemiology of birth defects based on a birth defect surveillance system in Southern Jiangsu, China, 2014-2018. *J Matern Fetal Neonatal Med*. 2020:1-7.
158. Ahn D, Kim J, Kang J, Kim YH, Kim K. Congenital anomalies and maternal age: A systematic review and meta-analysis of observational studies. *Acta Obstet Gynecol Scand*. 2022;101(5):484-98.
159. Moges N, Anley DT, Zemene MA, Adella GA, Solomon Y, Bantie B, et al. Congenital anomalies and risk factors in Africa: a systematic review and meta-analysis. *BMJ Paediatr Open*. 2023;7(1).
160. Cleary-Goldman J, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Impact of maternal age on obstetric outcome. *Obstet Gynecol*. 2005;105(5 Pt 1):983-90.
161. Hwang SS, Dukhovny D, Gopal D, Cabral H, Missmer S, Diop H, et al. Health of Infants After ART-Treated, Subfertile, and Fertile Deliveries. *Pediatrics*. 2018;142(2).
162. Yu HT, Yang Q, Sun XX, Chen GW, Qian NS, Cai RZ, et al. Association of birth defects with the mode of assisted reproductive technology in a Chinese data-linkage cohort. *Fertil Steril*. 2018;109(5):849-56.
163. Hoorsan H, Mirmiran P, Chaichian S, Moradi Y, Hoorsan R, Jesmi F. Congenital Malformations in Infants of Mothers Undergoing Assisted Reproductive Technologies: A Systematic Review and Meta-analysis Study. *J Prev Med Public Health*. 2017;50(6):347-60.
164. Chen M, Heilbronn LK. The health outcomes of human offspring conceived by assisted reproductive technologies (ART). *J Dev Orig Health Dis*. 2017;8(4):388-402.

165. Riskin A, Itzhaki O, Bader D, Iofe A, Toropine A, Riskin-Mashiah S. Perinatal Outcomes in Infants of Mothers with Diabetes in Pregnancy. *Isr Med Assoc J*. 2020;22(9):569-75.
166. Lemaitre M, Bourdon G, Bruandet A, Lenne X, Subtil D, Rakza T, et al. Pre-gestational diabetes and the risk of congenital heart defects in the offspring: A French nationwide study. *Diabetes Metab*. 2023;49(4):101446.
167. Chen LJ, Chiu CH, Huang JY, Chen PJ, Su PH, Yang SF, et al. Maternal diabetes mellitus and birth defects in Taiwan: A 5-year nationwide population-based cohort study. *J Chin Med Assoc*. 2023;86(6):589-95.
168. Ravindra K, Chanana N, Mor S. Exposure to air pollutants and risk of congenital anomalies: A systematic review and metaanalysis. *Sci Total Environ*. 2021;765:142772.
169. Peyvandi S, Baer RJ, Chambers CD, Norton ME, Rajagopal S, Ryckman KK, et al. Environmental and Socioeconomic Factors Influence the Live-Born Incidence of Congenital Heart Disease: A Population-Based Study in California. *J Am Heart Assoc*. 2020;9(8):e015255.
170. Okmen Ozkan B, Koroglu N, Turkgeldi LS, Cetin BA, Aslan H. Advanced maternal age and risk of non-chromosomal anomalies: data from a tertiary referral hospital in Turkey. *J Matern Fetal Neonatal Med*. 2019;32(5):749-52.
171. Yang J, Carmichael SL, Canfield M, Song J, Shaw GM, National Birth Defects Prevention S. Socioeconomic status in relation to selected birth defects in a large multicentered US case-control study. *Am J Epidemiol*. 2008;167(2):145-54.
172. Goetzinger K, Shanks A, Odibo A, Macones G, Cahill A. Advanced maternal age and the risk of major congenital anomalies: Survival of the fittest? *American Journal of Obstetrics and Gynecology*. 2014;210(1):S23.
173. Croen LA, Shaw GM. Young maternal age and congenital malformations: a population-based study. *Am J Public Health*. 1995;85(5):710-3.
174. De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev*. 2015;2015(12):CD007950.
175. Borman GB, Smith AH, Howard JK. Risk factors in the prevalence of anencephalus and spina bifida in New Zealand. *Teratology*. 1986;33(2):221-30.

176. Dudin A. Neural tube defect among Palestinians: a hospital-based study. *Ann Trop Paediatr*. 1997;17(3):217-22.
177. Forrester MB, Merz RD. Epidemiology of neural tube defects, Hawaii, 1986-1997. *Hawaii Med J*. 2000;59(8):323-7, 41.
178. Wen S, Ethen M, Langlois PH, Mitchell LE. Prevalence of encephalocele in Texas, 1999-2002. *Am J Med Genet A*. 2007;143A(18):2150-5.
179. Escobar VAP, Wyant WA, Debs LH, Jamshidi A, Kiehna EN, McCrea HJ. Evaluating the potential role of determinants of health on encephalocele patient outcomes - a combined retrospective study and systematic review. *Childs Nerv Syst*. 2024;40(6):1751-63.
180. Ali TM, Elwy R, Abdelrazik B, Soliman MAR, Alsawy MF, Abdullah A, et al. Risk factors of congenital hydrocephalus: a case-control study in a lower-middle-income country (Egypt). *J Neurosurg Pediatr*. 2023;31(5):397-405.
181. Yi L, Wan C, Deng C, Li X, Deng K, Mu Y, et al. Changes in prevalence and perinatal outcomes of congenital hydrocephalus among Chinese newborns: a retrospective analysis based on the hospital-based birth defects surveillance system. *BMC Pregnancy Childbirth*. 2017;17(1):406.
182. Tully HM, Capote RT, Saltzman BS. Maternal and infant factors associated with infancy-onset hydrocephalus in Washington State. *Pediatr Neurol*. 2015;52(3):320-5.
183. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM. Spina bifida. *Nat Rev Dis Primers*. 2015;1:15007.
184. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. *Lancet*. 2004;364(9448):1885-95.
185. Salari N, Fatahi B, Fatahian R, Mohammadi P, Rahmani A, Darvishi N, et al. Global prevalence of congenital anencephaly: a comprehensive systematic review and meta-analysis. *Reprod Health*. 2022;19(1):201.
186. Agopian AJ, Tinker SC, Lupo PJ, Canfield MA, Mitchell LE, National Birth Defects Prevention S. Proportion of neural tube defects attributable to known risk factors. *Birth Defects Res A Clin Mol Teratol*. 2013;97(1):42-6.
187. Eros FR, Beke A. [Effectiveness of prenatal ultrasound in fetal and neonatal malformations and examination of difficulty and uncertainty factors]. *Orv Hetil*. 2017;158(45):1794-801.



188. You SJ, Kang D, Sung JH, Park H, Cho J, Choi SJ, et al. The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 years. *Obstet Gynecol Sci.* 2024;67(4):380-92.
189. Ooki S. Maternal age and birth defects after the use of assisted reproductive technology in Japan, 2004-2010. *International Journal of Women's Health.* 2013;5(1):65-77.
190. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. *Circulation.* 2014;129(21):2183-242.
191. AIUM Practice Parameter for the Performance of Fetal Echocardiography. *J Ultrasound Med.* 2020;39(1):E5-E16.
192. Khalilipalandi S, Lemieux A, Lauzon-Schnitka J, Perreault L, Dubois M, Tousignant A, et al. Systematic review and meta-analysis of prenatal risk factors for congenital heart disease: maternal chronic diseases and parental exposures. *Can J Cardiol.* 2024.
193. Robinson R, Stavsky M, Yitshak Sade M, Krymko H, Slanovic L, Novack V, et al. Risk factors for congenital heart defects in two populations residing in the same geographic area: A long-term population-based study, Southern Israel. *Cardiology in the Young.* 2019;29(8):1040-4.
194. Mamasoula C, Bigirumurame T, Chadwick T, Addor MC, Cavero-Carbonell C, Dias CM, et al. Maternal age and the prevalence of congenital heart defects in Europe, 1995-2015: A register-based study. *Birth Defects Res.* 2023;115(6):583-94.
195. Varela MM, Nohr EA, Llopis-Gonzalez A, Andersen AM, Olsen J. Socio-occupational status and congenital anomalies. *Eur J Public Health.* 2009;19(2):161-7.
196. Shaw GM, Croen LA, Curry CJ. Isolated oral cleft malformations: associations with maternal and infant characteristics in a California population. *Teratology.* 1991;43(3):225-8.
197. Vieira AR, Orioli IM, Murray JC. Maternal age and oral clefts: a reappraisal. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2002;94(5):530-5.

198. Martelli DR, Cruz KW, Barros LM, Silveira MF, Swerts MS, Martelli Júnior H. Maternal and paternal age, birth order and interpregnancy interval evaluation for cleft lip-palate. *Brazilian journal of otorhinolaryngology*. 2010;76(1):107-12.
199. Herkrath AP, Herkrath FJ, Rebelo MA, Vettore MV. Parental age as a risk factor for non-syndromic oral clefts: a meta-analysis. *J Dent*. 2012;40(1):3-14.
200. Fisch H, Golden RJ, Libersen GL, Hyun GS, Madsen P, New MI, et al. Maternal age as a risk factor for hypospadias. *Journal of Urology*. 2001;165(3):934-6.
201. Porter MP, Faizan MK, Grady RW, Mueller BA. Hypospadias in Washington State: maternal risk factors and prevalence trends. *Pediatrics*. 2005;115(4):e495-9.
202. Shnorhavorian M, Bittner R, Wright JL, Schwartz SM. Maternal risk factors for congenital urinary anomalies: results of a population-based case-control study. *Urology*. 2011;78(5):1156-61.
203. Mesas Burgos C, Ehrén H, Conner P, Frenckner B. Maternal Risk Factors and Perinatal Characteristics in Congenital Diaphragmatic Hernia: A Nationwide Population-Based Study. *Fetal Diagn Ther*. 2019;46(6):385-91.
204. Peppas M, De Stavola BL, Loukogeorgakis S, Zylbersztejn A, Gilbert R, De Coppi P. Congenital diaphragmatic hernia subtypes: Comparing birth prevalence, occurrence by maternal age, and mortality in a national birth cohort. *Paediatr Perinat Epidemiol*. 2023;37(2):143-53.
205. Marshall J, Salemi JL, Tanner JP, Ramakrishnan R, Feldkamp ML, Marengo LK, et al. Prevalence, Correlates, and Outcomes of Omphalocele in the United States, 1995-2005. *Obstet Gynecol*. 2015;126(2):284-93.
206. Frolov P, Alali J, Klein MD. Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature. *Pediatr Surg Int*. 2010;26(12):1135-48.
207. Curry JJ, McKinney P, Thornton JG, Stringer MD. The aetiology of gastroschisis. *BJOG*. 2000;107(11):1339-46.
208. Baldacci S, Santoro M, Coi A, Mezzasalma L, Bianchi F, Pierini A. Lifestyle and sociodemographic risk factors for gastroschisis: a systematic review and meta-analysis. *Arch Dis Child*. 2020;105(8):756-64.
209. Feldkamp ML, Canfield MA, Krikov S, Prieto-Merino D, Sipek A, Jr., LeLong N, et al. Gastroschisis prevalence patterns in 27 surveillance programs from 24 countries,

International Clearinghouse for Birth Defects Surveillance and Research, 1980-2017. Birth Defects Res. 2024;116(2):e2306.

210. Hegyi P, Eross B, Izbeki F, Parniczky A, Szentesi A. Accelerating the translational medicine cycle: the Academia Europaea pilot. Nat Med. 2021;27(8):1317-9.

211. Hegyi P, Petersen OH, Holgate S, Eross B, Garami A, Szakacs Z, et al. Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits. J Clin Med. 2020;9(5).

212. D'Antonio F, Di Mascio D, Rizzo G. Should we expand indications for targeted fetal neurosonography? Ultrasound Obstet Gynecol. 2022;59(2):274-6.

213. Malinger G, Paladini D, Haratz KK, Monteagudo A, Pilu GL, Timor-Tritsch IE. ISUOG Practice Guidelines (updated): sonographic examination of the fetal central nervous system. Part 1: performance of screening examination and indications for targeted neurosonography. Ultrasound Obstet Gynecol. 2020;56(3):476-84.

## 16 BIBLIOGRAPHY

### 16.1 Publications related to the thesis

1. **Pethő B**, Mátrai Á, Agócs G, Veres DS, Harnos A, Váncsa S, Bánhidy F, Hegyi P, Ács N

Maternal age is highly associated with non-chromosomal congenital anomalies: Analysis of a population-based case-control database

**BJOG: AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY**

2023; 130: 10 pp. 1217-1225. DOI: doi.org/10.1111/1471-0528.17461

**D1, IF: 4,7**

2. **Pethő B**, Váncsa Sz, Váradi A, Agócs G, Mátrai Á, Zászkaliczky-Iker F, Balogh Z, Bánhidy F, Hegyi P, Ács N

Very Young and Advanced Maternal Age Strongly Elevates the Occurrence of Non-Chromosomal Congenital Anomalies: A Systematic Review and Meta-Analysis of Population-Based Studies

**AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY**

2024; 17:S0002-9378(24)00592

DOI:10.1016/j.ajog.2024.05.010

**D1, IF: 8,71**

## 16.2 Publications not related to the thesis

1. Galamb Á, **Pethő B**, Fekete D, Petrányi G, Pajor A.

Uterine anomalies in women with recurrent pregnancy loss

**ORVOSI HETILAP** 2015 Jul;156(27):1081-1084.

DOI: 10.1556/650.2015.30136. PMID: 26122902.

**Q3, IF: 0,291**

2. Mátrai Á, Teutsch B, Váradi A, Hegyi P, **Pethő B**, Fujisawa A, Váncsa S, Lintner B, Melczer Z, Ács N.

First-Trimester Influenza Infection Increases the Odds of Non-Chromosomal Birth Defects: A Systematic Review and Meta-Analysis. **VIRUSES**

2022; 14(12):2708.

DOI: doi.org/10.3390/v14122708

**Q2, IF: 4.7**

3. Mátrai Á, Teutsch B, **Pethő B**, Kaposi A, Hegyi P, Ács N

Reducing the Risk of Birth Defects Associated with Maternal Influenza: Insights from a Hungarian Case-Control Study

**JOURNAL OF CLINICAL MEDICINE**

2023; 12: 21 Paper: 6934, 10 p.

DOI: 10.3390/jcm12216934

**Q1, IF: 3,0**

## 17 ACKNOWLEDGEMENTS

First and foremost, I would like to express my heartfelt gratitude to all those whose support made this scientific work possible.

I extend my deepest thanks to my supervisor, Nándor Ács, M.D., Ph.D., D.Sc. Without his invaluable guidance, this research and dissertation would not have been possible. His unwavering professional and personal support from the very beginning encouraged me throughout this journey. His dedication to both research and high-quality patient care has been a continuous source of motivation and inspiration. I am particularly grateful for his flexibility and commitment during the time of my baby's birth, which enabled me to continue my scientific work both during pregnancy and afterward.

I am deeply grateful to Péter Hegyi, M.D., Ph.D., D.Sc., MAE, director of the Centre for Translational Medicine Ph.D. Program, for his irreplaceable support and guidance. He provided me with the opportunity to join a dynamic and cohesive research community, where I not only gained a deep understanding of experiential learning but also found continuous inspiration in the collaborative environment. The methodological support from the Institute was instrumental in producing high-quality research and manuscripts that meet rigorous publication standards. I am especially thankful to him not only for the support in my own work but also for imparting practical knowledge that has guided me through the scientific landscape.

I am truly grateful to my methodological supervisor, Szilárd Váncsa, M.D., Ph.D. His exceptional professionalism, sharp insights, and thoughtful guidance were instrumental in shaping my academic journey and the successful completion of this dissertation. His personal example has been a constant source of inspiration.

I am profoundly grateful to Gergely Agócs, Pharm.D., Ph.D., whose analytical thinking, excellent insights and innovative ideas have supported me from the very beginning. His constructive criticism has significantly influenced the direction of my research and enhanced the quality of my work. These contributions were invaluable not only in his role as a statistician but also in providing constant support throughout my research.

A special thanks is extended to my co-investigators Ferenc Bánhidý, M.D., Ph.D., Ákos Mátrai, M.D., Alex Váradi, Andrea Harnos, Ph.D., Dániel Veres, Ph.D., Franciska Zászkaliczky-Iker, and Zita Balogh, without whose collaboration this research would not have been possible.

Finally, I express my heartfelt thanks to my adaptable and supportive family, friends, and especially my little one, who have been my steadfast foundation throughout this Ph.D. journey. Their encouragement and flexibility have been invaluable.

## RESEARCH ARTICLE

## Epidemiology

# Maternal age is highly associated with non-chromosomal congenital anomalies: Analysis of a population-based case-control database

Boglárka Pethő<sup>1,2</sup> | Ákos Mátrai<sup>1,2,3</sup> | Gergely Agócs<sup>2,4</sup> | Dániel Sándor Veres<sup>2,4</sup> |  
Andrea Harnos<sup>2,5</sup> | Szilárd Váncsa<sup>2,6,7</sup> | Ferenc Bánhidý<sup>1,2</sup> | Péter Hegyi<sup>2,6,7</sup> |  
Nándor Ács<sup>1,2</sup>

<sup>1</sup>Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary

<sup>2</sup>Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

<sup>3</sup>Faculty of Health Sciences, University of Pécs, Pécs, Hungary

<sup>4</sup>Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary

<sup>5</sup>Department of Biostatistics, University of Veterinary Medicine Budapest, Budapest, Hungary

<sup>6</sup>Institute for Translational Medicine, Szentágotthai Research Centre, Medical School, University of Pécs, Pécs, Hungary

<sup>7</sup>Institute for Pancreatic Diseases, Semmelweis University, Budapest, Hungary

## Correspondence

N. Ács, Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Ulloi ut 78/a, Hungary.  
Email: [acsndor@hotmail.hu](mailto:acsndor@hotmail.hu)

## Abstract

**Objective:** The role of maternal age in the development of non-chromosomal congenital anomalies (NCAs) is under debate. Therefore, the primary aim of this study was to identify the age groups at risk for NCAs. The secondary aim was to perform a detailed analysis of the relative frequency of various anomalies.

**Design:** National population-based study.

**Setting:** The Hungarian Case-Control Surveillance of Congenital Anomalies (CAs) between 1980 and 2009.

**Population or Sample:** A cohort of 31 128 cases with confirmed NCAs was compared with Hungary's total of 2 808 345 live births.

**Methods:** Clinicians prospectively reported cases after delivery. Data were analysed by non-linear logistic regression. Risk-increasing effect of young and advanced maternal age was determined by each NCA group.

**Main outcome measures:** These were the total number of NCAs: cleft lip and palate, circulatory, genital, musculoskeletal, digestive, urinary, eye, ear, face, and neck, nervous system, and respiratory system anomalies.

**Results:** The occurrence of NCAs in our database was lowest between 23 and 32 years of maternal age at childbirth. The relative risk (RR) of any NCA was 1.2 (95% CI 1.17–1.23) and 1.15 (95% CI 1.11–1.19) in the very young and advanced age groups, respectively. The respective results for the circulatory system were RR = 1.07 (95% CI 1.01–1.13) and RR = 1.33 (95% CI 1.24–1.42); for cleft lip and palate RR = 1.09 (95% CI 1.01–1.19) and RR = 1.45 (95% CI 1.26–1.67); for genital organs RR = 1.15 (95% CI 1.08–1.22) and RR = 1.16 (95% CI 1.04–1.29); for the musculoskeletal system RR = 1.17 (95% CI 1.12–1.23) and RR = 1.29 (95% CI 1.14–1.44); and for the digestive system RR = 1.23 (95% CI 1.14–1.31) and RR = 1.16 (95% CI 1.04–1.29).

**Conclusion:** Very young and advanced maternal ages are associated with different types of NCAs. Therefore, screening protocols should be adjusted for these risk groups.

## KEYWORDS

ageing, congenital abnormalities, maternal age, non-chromosomal anomalies, pregnancy, screening



## 1 | INTRODUCTION

Worldwide, 3–5% of births are affected by a congenital anomaly (CA),<sup>1</sup> representing a leading cause of infant mortality.<sup>2</sup> Based on the EUROCAT survey, the average European relative frequency of birth defects is 23.9 per 1000 births.<sup>3</sup> According to the 2010 Global Burden of Disease study, congenital anomalies (CAs) are responsible for 6% of infant deaths worldwide,<sup>4</sup> whereas other studies suggest that around 20% of neonatal and infant mortality is caused by CAs.<sup>5,6</sup>

CAs have a significant burden on society as a whole, namely, the affected families and both health and social care systems. In addition, CA-related hospitalisations are extremely costly, accounting for 3.0% of total hospitalisations and 5.2% of total hospital costs, with an estimated annual cost of \$22.9 billion in the USA in 2013.<sup>7</sup> These facts highlight the importance of CAs globally for healthcare systems, research, prevention and screening. Appropriate intervention must be considered a public health priority.

For several known maternal lifestyle risk factors and chronic illnesses, there is a clear association with the occurrence of CAs. For example, according to a meta-analysis, maternal smoking during pregnancy increases the odds of CAs (odds ratio [OR] = 1.18, 95% CI 1.03–1.34).<sup>8</sup> The risk-increasing effect of maternal diabetes is also considered in genetic screening. The effect of pre-gestational diabetes is indeed pronounced according to a meta-analysis (relative risk [RR] = 2.66, 95% CI 2.04–3.47).<sup>9</sup>

There is also a well-known correlation between maternal age and chromosomal anomalies, but we have much less information about maternal age as a risk factor in the case of non-chromosomal congenital anomalies (NCAs). The significant role of maternal age in their development is probably established, but the exact details are still the subject of active research. In addition, age distributions of NCAs in the literature are inconsistent. Some studies show a risk-increasing effect either only for the young<sup>10</sup> (generally defined as under 20 years) or only for the advanced<sup>11</sup> (generally defined 35 years or more); others show an effect for both age groups.

We aimed to identify maternal age-related risk groups without arbitrary age categories and to focus on screening options based on maternal age – an approach which is currently missing in the protocols for NCAs. Our hypothesis was that very young (expected to be <20 years) and advanced maternal age (expected to be ≥35 years) increase the risk of NCAs.

## 2 | METHODS

### 2.1 | Study design

Our population-based study investigated the relative frequency of CAs in relation to maternal age over a period of almost 30 years in Hungary. This study obtained cases from

the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA) and the total number of live births during the study period from the Central Statistical Office (KSH).

We identified high- and low-risk maternal age groups using the restricted cubic spline model instead of comparing arbitrary age categories.<sup>12</sup>

We report our population-based study according to the recommendations of the STROBE guideline (Table S1).<sup>13</sup>

### 2.2 | Setting

Our study is an analysis of the HCCSCA (established in 1980, and terminated in 2009).<sup>14</sup> Data collection was changed in 1997 (affecting only the collection of matched controls that were not used in the current study), slightly modifying the structure of the HCCSCA. Data collected through the HCCSCA between 1980 and 2009 were unified into one large validated database.<sup>15</sup> In 2002, after one mother's objections, the legal background of data privacy was questioned, and data collection was suspended until 2005.


Since 1962, reporting patients as cases with CA to the Hungarian Congenital Abnormality Registry (HCAR) has been obligatory for physicians in Hungary, from birth until the end of the first postnatal year. The HCAR was founded in 1962 as the first national-based registry of CAs globally.<sup>16</sup> Since 1984, the prenatal diagnostic centres have also been asked to report malformed fetuses diagnosed prenatally with or without elective termination of pregnancy to the HCAR. Cases have been enrolled in the HCCSCA from the HCAR since 1980.

### 2.3 | Ethics and patient consent

Ethics approval for data analysis was obtained from the Scientific and Research Ethics Committee of the Medical Research Council, Hungary (BMEÜ/920-3/2022/EKU). There are no identifiable registry data reported in our study. National legislation does not require informed consent to register a baby with a congenital anomaly.<sup>17</sup> Patients were not involved in the design and conduct of this research.

### 2.4 | Participants

Cases with CAs in the HCAR were enrolled to the HCCSCA if they met all the following selection criteria: (1) reported to the HCAR within 3 months after birth or elective termination of pregnancy, (2) none of the three mild CAs (hip dislocation, congenital inguinal hernia and large haemangioma) was present alone, and (3) CA syndromes were not caused by gene mutations or chromosomal anomalies with preconceptional origin. In our analysis, we excluded cases with incomplete data or the co-presence of chromosomal anomalies (Figure 1). The main task of the HCCSCA has been the detection of teratogenic/



**FIGURE 1** (A) Study plan. (B) Age distribution of cases and total population by age.

fetotoxic agents and other environmental effects during pregnancy resulting in the development of birth defects.

The case group contains live births, stillbirths and elective terminations of pregnancies following prenatal malformation diagnosis. For the total number of cases and controls, the total number of live births by maternal age in Hungary during the study period was obtained from the Hungarian Central Statistical Office (KSH).

## 2.5 | Variables and data sources

The following information about every patient was recorded during data collection: NCA(s), gender, maternal age, paternal age, birth date, birthweight, gestational age, area of mother's residence, birth order, mother's and father's qualifications, employment status and type of employment, mother's marital status, outcome of previous pregnancies, maternal diseases during pregnancy (by month of pregnancy), medication during pregnancy (by month of pregnancy), and the mother's smoking habits and alcohol consumption patterns.<sup>15</sup>

Maternal age was recorded at the time of delivery or termination of pregnancy due to fetal anomaly.

Data on maternal diseases, lifestyle factors and medication during pregnancy were collected in multiple ways. Mothers provided all their medical documentation about their ongoing pregnancy, and professionals recorded it (prospective, medically recorded data). A questionnaire was then mailed to the mothers containing questions about maternal diseases, pregnancy-related drug treatments and pregnancy

supplements (retrospective, maternal self-reported information). Lastly, regional nurses visited all mothers. The nurses helped mothers collect and present their medical records and answer the questionnaire (Table S1).

We performed our analysis by disease categories as defined by the International Classification of Diseases (ICD)-10, which ensures an accurate categorisation. Even though the definition of certain anomalies may have changed during the study period, their ICD categorisation at the level of our analysis remained consistent.

## 2.6 | Bias and evidence synthesis

The maternal ages were recorded based on birth certificates, ensuring a very high level of data accuracy. The unique nature of data collection and verification further enhances the reliability of the data. However, the classification of outcomes was not consistent over the long study period. When converting different ICD categories to each other, the groupings used do not always match with complete accuracy.

We used the GRADEPRO tool to assess the level of evidence for our results.<sup>18</sup>

## 2.7 | Statistical methods

Primary data extraction and organisation were carried out in Microsoft EXCEL. Statistical analysis was carried out in R (v4.1.3).<sup>19</sup>

The aim of our analysis was to determine the high-risk maternal age for each non-chromosomal anomaly (NCA) category. We used a two-way approach.

First, we identified the best 10-year period of maternal age corresponding to the anomaly's lowest relative frequency. Risk was calculated as: number of cases among live births + stillbirths + elective terminations of pregnancies following prenatal diagnosis of malformation/total number of live births in the population. Risk ratios for each year were determined by taking the best 10-year period as a 'reference risk'. Note that, despite the case-control approach, RR could be used because data collection included the whole population). Cases with a maternal age <13 (one case) and >45 years (nine cases) were excluded because the very low number of cases in these maternal age ranges would have made the regression unreliable. The confidence interval of relative frequency was estimated according to Agresti & Coull.<sup>20</sup>

Secondly, we fitted a non-linear, non-parametric logistic regression model on the original data (namely, a restricted cubic splines model using five knots at the 0.05, 0.275, 0.5, 0.725 and .95 quantiles, as recommended in the literature; explanatory variable: maternal age; response variable: presence or absence of NCAs) using the 'rms' R package (v6.2.0).<sup>21</sup> The resulting relative frequency estimates of the regression were transformed to the RR scale to enable graphical representation in the figure showing the year-by-year risk estimates calculated above.

A grouping of NCA categories based on high-risk maternal age was done by considering the confidence bands in addition to assessing the shape of the curves: a curve may appear U-shaped at first glimpse but the risk increase is not necessarily statistically substantiated in both directions, i.e. the confidence band may contain the RR = 1 line corresponding to zero effect.

All confidence intervals were calculated at a confidence level (1- $\alpha$ ) of 95%.

### 3 | RESULTS

#### 3.1 | Participants

A total of 31 128 cases with NCAs were identified in Hungary (Table S2); during the study period there were 2 808 345 live births in the country (Figure 1). Figure 1 presents the age distribution of the study population, showing that 7.66% of births fell into the very young ( $\leq 19$ ) and 6.62% into the advanced ( $\geq 35$ ) maternal age categories. Within this group, 1.11% of births represented mothers over 40. This means that 14.28% of births were in the maternal age groups expected to pose an increased risk.

Mean maternal age was practically the same among cases (26.0 years; SD = 5.4) and in the reference population (26.1 years; SD = 5.1).

#### 3.2 | Descriptive data

Thanks to the population-wide data collection, we had individual information about the cases. In the table below, we

have summarized some of this information (Table 1). The most notable is the sex of the fetuses, which is around 65% male.

#### 3.3 | Outcome data

The relative frequency of NCAs in the study period was 1.1% after excluding cases with only mild anomalies and chromosomal anomalies.


#### 3.4 | The risk-increasing effect of advanced and very young maternal age

In the first step, all NCAs were analysed together (Figure 2). The lowest risk 10-year period was between 23 and 32 years (light grey shading); lower (RR = 1.2; 95% CI 1.17–1.23) and higher (RR = 1.15; 95% CI 1.11–1.19) maternal age pose an almost identically increased risk of anomalies. The year-by-year RRs (circle markers) imply an increasing trend in both directions. The fitted regression line (black, with a dark grey confidence band) stresses that both very young and

**TABLE 1** Baseline characteristics table.

|                         | Maternal age: All (13–45 years; total 31 118) |            |     |
|-------------------------|---|------------|-----|
|                         | Total   | Mean       | SD  |
| Birth mass, g           | 30 908  | 3018       | 707 |
| Gestation period, weeks | 30 995  | 38.5       | 3.2 |
| Paternal age, years     | 1851  | 32.1       | 6.4 |
|                         | Count   | Proportion |     |
| Gender                  |   |            |     |
| Male                    | 20 046  | 65.64%     |     |
| Female                  | 10 492  | 34.36%     |     |
| NA                      | 580   |            |     |
| Birth order             |   |            |     |
| Primiparous             | 16 309  | 55.76%     |     |
| Multiparous             | 12 939  | 44.24%     |     |
| NA                      | 1870  |            |     |
| Maternal smoking        |   |            |     |
| Smoker                  | 2776  | 35.51%     |     |
| Nonsmoker               | 5041  | 64.49%     |     |
| NA                      | 23 301  |            |     |
| Maternal education      |   |            |     |
| Managerial              | 1377  | 15.26%     |     |
| Professional            | 2450  | 27.14%     |     |
| Skilled worker          | 2376  | 26.32%     |     |
| Semiskilled             | 2327  | 25.78%     |     |
| Unskilled               | 496   | 5.50%      |     |
| NA                      | 22 092  |            |     |

NA, not available.



**FIGURE 2** Analysis of all NCAs by maternal age. The figure shows the estimated risk ratios of NCAs as a function of maternal age with the best 10-year period as 'reference risk' (circle markers). The best 10-year-period is highlighted in light grey. The black curve shows the result of the restricted cubic splines regression; the dark grey area is its confidence range.

advanced maternal age increase risk even more. Even though the confidence range becomes wider in the very young and old maternal age groups due to the low number of cases, the trend is still clear.

In the next step, NCAs were analysed by ICD category (Figure 3). In the case of certain ICD categories, both lower and higher maternal ages exert a risk-increasing effect, namely: circulatory system (Q20–Q28), cleft lip and palate (Q35–Q37), genital organ system (Q50–Q56), musculoskeletal system (Q65–Q79) and digestive system (Q38–Q45). A U-shaped regression curve can describe the relation. Observing the regression line in the case of musculoskeletal and digestive system anomalies, there is an increased risk of birth defects in very young mothers. In cases of circulatory system anomalies and cleft lip/palate, the increased risk is more pronounced for advanced age mothers. There is no expressed difference in the risk-increasing effect when comparing the lower and higher maternal age ranges in the case of the genital organ system.

### 3.5 | The risk-increasing effect of advanced maternal age only

In the case of CAs of the urinary system (Q60–Q64) and malformations of the eye, ear, face and neck (Q10–Q18), advanced maternal age exerts a risk-increasing effect while

young age does not. However, looking at the figure regarding the malformations of the eye, ear, face and neck (Q10–Q18), the results are somewhat inconsistent, and the increase in risk becomes clearly significant only >40 years.

### 3.6 | The risk-increasing effect of very young maternal age only

The nervous system anomalies (Q00–Q07) category is the only one where only young maternal age is associated with increased risk. Looking at the entire low-age group, the risk increase is 25%. For the very young (<20), there is an apparent increase in risk that is even higher.

### 3.7 | Congenital anomalies not related to maternal age

According to our analysis, respiratory system anomalies (Q30–Q34) could not be proven to be associated with maternal age.


### 3.8 | Level of evidence

When all NCAs were analysed according to maternal age, the young and advanced age groups were found to have moderate certainty of NCAs (Figure S1).

## 4 | DISCUSSION

The main findings of this study confirm our hypothesis. The relative frequency of NCAs strongly depends on maternal age. Our data are of clinical importance because, based on these results, preventive and screening interventions can be applied according to maternal age groups. Furthermore, our research shows that very young and advanced maternal age increase risk when all NCAs are examined together. This finding is particularly important, considering that chromosomal anomalies (with a well-known correlation to maternal age) were excluded from the analysis.

Although the topic has been eagerly investigated, age distributions of various NCAs are inconsistent in the literature. In line with our findings, Reefhuis et al.<sup>22</sup> showed that women <20 and ≥35 years are at increased risk of having a fetus with an NCA. Croen et al.<sup>23</sup> also found this association in their data analysis from the California Birth Defects Monitoring Program, excluding the Afro-American population. Looking at all the NCA categories combined, other studies have shown a risk-increasing effect of older maternal age.<sup>11</sup> This may be due to the risk-increasing effect of chromosomal anomalies that occur more frequently with advanced maternal age. Hollier et al.<sup>11</sup> suggest that the accumulation of environmental exposures over time may also have a risk-increasing effect.



**FIGURE 3** Summary results for the NCA categories. For the interpretation of the figure, see the caption to [Figure 2](#).

Analysing data from the EUROCAT database, Loane et al.<sup>10</sup> point out that more emphasis should be placed on screening very young mothers, who are more likely to have several risk factors. Zhang et al. found an increase in risk for extremely young mothers and mothers younger than 25 years. The authors emphasise that statistically significant differences in NCA relative frequency were found between different levels of maternal education.

Based on the current guidelines, there is no recommendation for screening NCAs with regard to maternal age.<sup>24-26</sup> Maternal age has previously been shown to be a relevant risk factor for chromosomal anomalies, and this pressure for age-based screening has significantly increased the detection rate.

Neural tube defects (NTDs) and congenital heart defects (CHDs) should be discussed separately, as fetal



neurosonography and fetal echocardiography are complementary screening options.

Looking at the NTDs (ICD-10 Q00–Q07) together, we observed an increased risk in very young mothers. The literature is not consistent on the age effect. Most studies have suggested a ‘U-shaped’ association between maternal age and the relative frequency of NTDs.<sup>27,28</sup> Other groups suggest that a higher risk of NTD is likely associated with increased maternal age.<sup>29</sup> The heterogeneous results may be the consequence of inappropriate NTD definition, as grouping was not uniformly applied across studies. Some anomalies were explicitly associated with young maternal age (e.g. anencephaly),<sup>30,31</sup> whereas other isolated anomalies were more common with older maternal age (e.g. spina bifida, encephalocele).<sup>31</sup>

From a clinical point of view, finding a clear association between maternal age and the relative frequency of CHDs (ICD-10 Q20–Q28) is an important task. Currently, there is no maternal age-related indication for fetal echocardiography.<sup>32,33</sup>

This finding is of particular significance because the effects of chromosomal anomalies did not modify the relative frequency found in our study. Various studies have been published about the risk-increasing effect of older maternal age, but it is important to note that the co-occurrence of chromosomal anomalies is most significant at this age.<sup>34</sup>

As there is no additional screening opportunity for the other NCA groups, age-adjusted ultrasound examinations in these age groups must focus on these organ systems.

Particular attention should be paid to more frequent differences in the low or high maternal age categories. Examining what may be behind the risk-increasing effects of each age group can help identify the right prevention options. The teratogenic effects associated with the lifestyle of mothers becoming pregnant at a very young age and the lack of primary prevention options may largely explain the vulnerability of this age group, including smoking, drug and alcohol abuse (substance abuse together 41.0%), lower social status, lower educational attainment<sup>35</sup> and the lack of adequate folic acid supplementation typical of conscious childbearing.<sup>36</sup> This investigation of socioeconomic differences in the use of supplements found inequalities that benefit the wealthier and more highly educated white mothers. The lack of folic acid intake is clearly associated with a higher risk of NTDs.<sup>37</sup> In contrast, it is worth investigating the possible correlations between maternal chronic diseases and conditions relating to the risk-increasing effect of advanced maternal age. The age-related decline in oocyte quality and deteriorating repair processes could be the subject of basic research regarding CAs of the urinary system and facial malformations.

Our results suggest that incorporating the age aspect into screening protocols can increase the possibility of early detection of NCAs. Although the present study is not sufficient to confirm an isolated evidence of age effects, and the influence of lifestyle factors typically associated with age categories may be significant, and age alone may represent a well-defined, clear risk factor.

## 4.1 | Strengths and limitations

The strengths of our analysis are the large number of cases, the unique database and data collection methods, and that the collection of data on maternal age is highly accurate. In addition, the novel statistical approach employed may better reflect reality without using arbitrary groups.

Considering the limitations of this work, slight changes in screening methods and detection rates during the long study period could be mentioned. In addition, the definitions of some individual anomalies differed between the years or were even missing. These documents were also structured for the ICD-10 categories; however, it was impossible to identify them precisely in some cases. Finally, the main limitation is the lack of a multivariate model. However, this stemmed from the nature of the population-based study.

The generalisation of our result is substantiated, as the enrolled patients represent the entire selected geographical region.

## 4.2 | Implications for practice and research

Based on our results, we suggest maternal age-based screening for CHDs.

Further prospective data collection is needed to assess the problem more accurately and to consider confounders. For example, an international congenital anomaly registry that collects all pregnancy data prospectively and allows multivariate analysis or observational clinical research with longer follow-up periods might give additional insight into this topic. In addition, screening protocol modifications require further health-economic studies, but the risk-increasing effect of maternal age can already be considered for individual cases using our results.

## 5 | CONCLUSION

Our results show that certain NCAs are strongly associated with maternal age: a clear increase in risk can be observed for very young or advanced maternal age, or both – exact age limits varying by disease. Taking this into consideration, improved screening protocols should be implemented. Current protocols do not include maternal age-based recommendations for either fetal echocardiography or fetal neurosonography, which would be useful in detecting the respective NCAs. Moreover, in addition to mothers of advanced age, due attention should also be paid to very young groups.

## AUTHOR CONTRIBUTIONS

BP: conceptualisation, project administration, writing – original draft. ÁM: conceptualisation, writing – review & editing. GA: conceptualisation, formal analysis; visualisation. DSV: conceptualisation, formal analysis, visualisation. AH: conceptualisation, formal analysis, visualisation. SV:

conceptualisation, methodology, writing – review & editing. FB: conceptualisation, writing – review & editing. PH: conceptualisation, writing – review & editing. NÁ: conceptualisation, supervision, writing – original draft. All authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the paper's concept, design, analysis, writing and revision.

## ACKNOWLEDGEMENTS

None to declare.

## CONFLICT OF INTEREST STATEMENT

None declared. Completed disclosure of interest forms are available to view online as supporting information.

## DATA AVAILABILITY STATEMENT

All data were included in the manuscript.

## FUNDING STATEMENT

Sponsors had no role in the design, data collection, analysis, interpretation or article preparation.

## ETHICAL APPROVAL

In our study, cases were obtained from the Hungarian Case-Control Surveillance of Congenital Anomalies (HCCSCA) and the control group comprised live births from the Central Statistical Office (KSH) during the study period. Ethics approval for data analysis was obtained from the Scientific and Research Ethics Committee of the Medical Research Council, Hungary (BMEÜ/920-3 /2022/EKU). The study was conducted in accordance with the Declaration of Helsinki. Patients were not involved in the design or conduct of this research.

## REFERENCES

- Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, et al. National population-based estimates for major birth defects, 2010–2014. *Birth Defects Res*. 2019;111(18):1420–35.
- Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999–2001. *Birth Defects Res A Clin Mol Teratol*. 2006;76(11):747–56.
- Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. *Adv Exp Med Biol*. 2010;686:349–64.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *Lancet*. 2012;380(9859):2095–128.
- Almli LM, Ely DM, Ailes EC, Abouk R, Grosse SD, Isenburg JL, et al. Infant mortality attributable to birth defects - United States, 2003–2017. *Morb Mortal Wkly Rep*. 2020;69(2):25–9.
- Roncancio CP, Misnaza SP, Pena IC, Prieto FE, Cannon MJ, Valencia D. Trends and characteristics of fetal and neonatal mortality due to congenital anomalies, Colombia 1999–2008. *J Matern Fetal Neonatal Med*. 2018;31(13):1748–55.
- Arth AC, Tinker SC, Simeone RM, Ailes EC, Cragan JD, Grosse SD. Inpatient hospitalization costs associated with birth defects among persons of all ages - United States, 2013. *Morb Mortal Wkly Rep*. 2017;66(2):41–6.
- Salmasi G, Grady R, Jones J, McDonald SD, Knowledge Synthesis Group. Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. *Acta Obstet Gynecol Scand*. 2010;89(4):423–41.
- Balsells M, Garcia-Patterson A, Gich I, Corcoy R. Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2012;28(3):252–7.
- Loane M, Dolk H, Morris JK, EUROCAT Working Group. Maternal age-specific risk of non-chromosomal anomalies. *BJOG*. 2009;116(8):1111–9.
- Hollier LM, Leveno KJ, Kelly MA, McIntire DD, Cunningham FG. Maternal age and malformations in singleton births. *Obstet Gynecol*. 2000;96(5):701–6.
- Lusa L, Ahlin C. Restricted cubic splines for modelling periodic data. *PLoS One*. 2020;15(10):e0241364.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573–7.
- Czeizel AE, Rockenbauer M, Siffel C, Varga E. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980–1996. *Teratology*. 2001;63(5):176–85.
- Acs N, Matrai A, Kaposi A. First data from the new, unified database of the Hungarian case-control surveillance of congenital abnormalities. *J Matern Fetal Neonatal Med*. 2021;34(17):2887–92.
- Czeizel AE, Metneki J, Beres J. 50 years of the Hungarian congenital abnormality registry. *Congenit Anom (Kyoto)*. 2014;54(1):22–9.
- (Platform) EPoDRER. Hungary. [cited 2022 June 16]. Available from: [https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-members/registrieshungary\\_en#:~:text=The%20Hungarian%20Congenital%20Abnormality%20Registry,Health%20Development%20under%20government%20financing](https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-members/registrieshungary_en#:~:text=The%20Hungarian%20Congenital%20Abnormality%20Registry,Health%20Development%20under%20government%20financing)
- GRADEpro. Available from: <https://www.grade-pro.org/>
- R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing; 2022. Available from: <https://www.R-project.org/>
- Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. *The American Statistician*. 1998;52(2):119–26.
- Harrell J, Frank E. Rms: Regression Modeling Strategies. 2021 Available from: <https://CRAN.R-project.org/package=rms>
- Reefhuis J, Honein MA. Maternal age and non-chromosomal birth defects, Atlanta--1968–2000: teenager or thirty-something, who is at risk? *Birth Defects Res A Clin Mol Teratol*. 2004;70(9):572–9.
- Croen LA, Shaw GM. Young maternal age and congenital malformations: a population-based study. *Am J Public Health*. 1995;85(5):710–3.
- RCOG. Non-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma DNA. Available from: [https://www.rcog.org.uk/media/gecpbqau/sip\\_15\\_04032014.pdf](https://www.rcog.org.uk/media/gecpbqau/sip_15_04032014.pdf)
- GUIDELINE JS-CCP. Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies. Available from: [https://www.jogc.com/article/S1701-2163\(16\)34961-1/pdf](https://www.jogc.com/article/S1701-2163(16)34961-1/pdf)
- Guidance A. NIPT Summary of Recommendations. Available from: <https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance>
- Borman GB, Smith AH, Howard JK. Risk factors in the prevalence of anencephalus and spina bifida in New Zealand. *Teratology*. 1986;33(2):221–30.
- Feldman JG, Stein SC, Klein RJ, Kohl S, Casey G. The prevalence of neural tube defects among ethnic groups in Brooklyn, New York. *J Chronic Dis*. 1982;35(1):53–60.
- Dudin A. Neural tube defect among Palestinians: a hospital-based study. *Ann Trop Paediatr*. 1997;17(3):217–22.

30. Fedrick J. Anencephalus in Scotland 1961-72. *Br J Prev Soc Med.* 1976;30(2):132-7.
31. Forrester MB, Merz RD. Epidemiology of neural tube defects, Hawaii, 1986-1997. *Hawaii Med J.* 2000;59(8):323-7.
32. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. *Circulation.* 2014;129(21):2183-242.
33. AIUM practice parameter for the performance of fetal echocardiography. *J Ultrasound Med.* 2020;39(1):E5-E16.
34. Best KE, Rankin J. Is advanced maternal age a risk factor for congenital heart disease? *Birth Defects Res A Clin Mol Teratol.* 2016;106(6):461-7.
35. Wong SPW, Twynstra J, Gilliland JA, Cook JL, Seabrook JA. Risk factors and birth outcomes associated with teenage pregnancy: a Canadian sample. *J Pediatr Adolesc Gynecol.* 2020;33(2):153-9.
36. Miranda VIA, da Silva Dal Pizzol T, Silveira MPT, Mengue SS, da Silveira MF, Lutz BH, et al. The use of folic acid, iron salts and other vitamins by pregnant women in the 2015 Pelotas birth cohort: is there socioeconomic inequality? *BMC Public Health.* 2019;19(1):889.
37. van Gool JD, Hirche H, Lax H, De Schaepdrijver L. Folic acid and primary prevention of neural tube defects: a review. *Reprod Toxicol.* 2018;80:73-84.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Pethő B, Mátrai Á, Agócs G, Veres DS, Harnos A, Váncsa S, et al. Maternal age is highly associated with non-chromosomal congenital anomalies: Analysis of a population-based case-control database. *BJOG.* 2023;130(10):1217-1225. <https://doi.org/10.1111/1471-0528.17461>



# Very young and advanced maternal age strongly elevates the occurrence of nonchromosomal congenital anomalies: a systematic review and meta-analysis of population-based studies

Boglárka Pethő, MD; Szilárd Váncsa, MD, PhD; Alex Váradi; Gergely Agócs, PharmD, PhD; Ákos Mátrai, MD; Franciska Zászkaliczky-Iker; Zita Balogh; Ferenc Bánhid, MD, PhD; Péter Hegyi, MD, PhD; Nándor Ács, MD, PhD

## Introduction

Congenital anomalies are structural or functional abnormalities that occur during intrauterine life and can be

From the Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary (Pethő, Mátrai, Zászkaliczky-Iker, Balogh, Bánhid, and Ács); Centre for Translational Medicine, Semmelweis University, Budapest, Hungary (Pethő, Váncsa, Váradi, Agócs, Mátrai, Zászkaliczky-Iker, Balogh, Bánhid, Hegyi, and Ács); Institute of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary (Agócs); Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary (Váncsa, Hegyi); Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary (Váncsa, Hegyi); Department of Metagenomics, University of Debrecen, Debrecen, Hungary (Váradi); Department of Laboratory Medicine, University of Pécs, Pécs, Hungary (Váradi).

Received Jan. 17, 2024; revised May 2, 2024; accepted May 11, 2024.

The authors report no conflict of interest.

Ethical approval: No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct or interpretation of our study.

The datasets used in this study can be found in the full-text articles included in the systematic review and meta-analysis.

Corresponding author: Nándor Ács, MD, PhD. [acs.nandor@gmail.com](mailto:acs.nandor@gmail.com)

0002-9378

© 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>). <https://doi.org/10.1016/j.ajog.2024.05.010>



Click Supplemental Materials and Video under article title in Contents at [ajog.org](https://ajog.org)

**BACKGROUND:** Nonchromosomal congenital anomalies (NCAs) are the most common cause of infant mortality and morbidity. The role of maternal age is well known, although the specifics are not thoroughly elucidated in the literature.

**OBJECTIVE:** To evaluate the role of maternal age in the incidence of NCAs and to pinpoint age groups at higher risk to refine screening protocols.

**STUDY DESIGN:** A systematic review and meta-analysis were conducted following the PRISMA 2020 guidelines and *Cochrane Handbook*. Searches were performed on October 19, 2021, across MEDLINE (via PubMed), Cochrane Library (CENTRAL), and Embase. Population-based studies assessing the impact of maternal age on the incidence of NCAs in pregnant women were included, without restrictions on age range, country, or comorbidities. A random-effects model was used for pooling effect sizes, considering the heterogeneity across studies.

**RESULTS:** From 15,547 studies, 72 were synthesized. Maternal age >35 showed an increased NCA risk (risk ratio [RR]: 1.31, confidence interval [CI]: 1.07 -1.61), rising notably after >40 (RR: 1.44, CI: 1.25 -1.66). The latter changes to 1.25 (CI: 1.08 -1.46) if the co-occurrence of chromosomal aberrations is excluded. Specific anomalies like cleft lip/palate (>40, RR: 1.57, CI: 1.11 -2.20) and circulatory system defects (>40, RR: 1.94, CI: 1.28 -2.93) were significantly associated with advanced maternal age. Conversely, gastroschisis was linked to mothers <20 (RR: 3.08, CI: 2.74 -3.47).

**CONCLUSION:** The study confirms that both very young and advanced maternal ages significantly increase the risk of NCAs. There is a pressing need for age-specific prenatal screening protocols to better detect these anomalies, especially considering the current trend of delayed childbearing. Further research is required to fully understand the impact of maternal age on the prevalence of rarer NCAs.

**Key words:** aging, congenital abnormalities, maternal age, nonchromosomal anomalies, pregnancy, screening

identified intrauterinely, at birth, or, less often, only during infancy.<sup>1</sup> Congenital anomalies are the most common cause of infant mortality and morbidity, accounting for the loss of 25.3 to 38.8 million disability-adjusted life years worldwide.<sup>2</sup> According to data provided by the World Health Organization, 6% of babies are born with a congenital anomaly.<sup>3</sup> Maternal age is included among the many known

risk factors, and the significance of advanced maternal age (AMA) ( $\geq 35$ ) particularly appears to be supported.

Over the last few decades, there has been an increasing trend in women's average delivery age.<sup>4</sup> An increasing portion of couples are having their first child over the maternal age of 30 to 35 years.<sup>5</sup> Many studies have associated the postponement of childbearing with various pregnancy and fetal complications<sup>6-8</sup> and made

## AJOG at a Glance

**Why was this study conducted?**

This study was conducted to investigate how maternal age affects the risk of nonchromosomal congenital anomalies by analyzing data from numerous population-based studies.

**Key findings**

Very young and advanced maternal ages are linked to a higher incidence of these anomalies. Specifically, risks increase significantly for those over 40 years old, with elevated risks for conditions affecting the circulatory system and cleft lip/palate, and for those under 20, with a notable rise in gastroschisis cases.

**What does this add to what is known?**

First in-depth meta-analysis of the age dependence of the risk of nonchromosomal congenital anomalies by anomaly category. This highlights the necessity for age-specific prenatal screening protocols to better detect congenital anomalies.

recommendations on managing these high-risk pregnancies.<sup>9</sup> Among congenital anomalies, chromosomal abnormalities (CAs) are clearly associated with AMA,<sup>10–13</sup> a long-established fact that has led to the current professional screening protocols that are widely used worldwide and constantly evolving.<sup>14,15</sup> However, the etiology of nonchromosomal congenital anomalies (NCAs) is far from being fully understood. While the role of maternal age in the development of NCAs is well known and is the subject of active research, the literature is inconsistent in its assessment of the risk of NCAs in different age groups. This is a major issue not only because of the trend towards delayed childbearing but also because of the emerging risks of adolescent pregnancies.

**Objective**

Considering the disagreement in the literature, we aimed to investigate the role of maternal age in the occurrence of NCAs in a meta-analysis. There are currently no meta-analyses or other comprehensive studies that specifically and exclusively examine the association of NCAs with maternal age. We hypothesized that both very young and AMAs increase the risk of NCAs. We aimed to identify high-risk age groups to improve screening protocols and reach a better detection rate for NCAs.

**Methods**

We reported our systematic review and meta-analysis based on the recommendation of the PRISMA 2020 guideline<sup>16</sup> (see [Supplemental Table 1](#)), and we followed the Cochrane Handbook for Systematic Reviews of Interventions.<sup>17</sup> The protocol of the study was prospectively registered on International Prospective Register of Systematic Reviews<sup>18</sup> (registration number CRD42021283593), and we adhered to it, with some deviations: title adjustment for clarity and summary purposes; subgroup analyses were conducted but not prespecified; searches included screening reference lists of eligible articles; only population-based studies with exact NCA counts were included to enable risk assessment; risk ratios (RRs) were used instead of odds ratios for ease of interpretation; publication bias assessed only visually. However, these modifications are fundamentally technical in nature and do not alter the conceptual framework of the study.

**Information sources**

The systematic search was conducted in 3 comprehensive medical databases: MEDLINE (via PubMed), the Cochrane Library (CENTRAL), and Embase on October 19, 2021.

**Search strategy**

We used for the systematic search the following search key: (“maternal age” OR “maternal ages” OR “mother age” OR “mother ages”) AND (((congenital OR birth) AND (anomaly OR anomalies OR disorder OR disorders OR malformation OR malformations OR defect OR defects)) OR congenital abnormalities. No language restrictions or filters were applied during the search. We also screened the reference list of eligible articles.

**Eligibility criteria**

We formulated our research question using the population, exposure, comparator, outcome framework. We included population-based studies reporting on pregnant women (P). We did not have predefined exclusion criteria (eg, age range, country, comorbidities) for our population. Eligible studies compared different maternal age groups (E and C) regarding NCAs. We examined every predefined age group reported by the eligible studies. Our primary outcome (O) was the rate of total NCAs, while we considered as secondary outcomes the various structural defects regarding different organ systems (eg, congenital heart defects [CHDs]) and common birth defects separately. We did not have predefined diagnostic criteria for the NCAs. Studies not reporting on the exact number of NCAs in the different age groups and the total number of patients were not eligible. The following exclusion criteria were predefined: CAs as target outcomes; case-control or cohort studies; case series; and case reports, because our concept was to analyze relative frequency.

**Study selection**

After removing duplicates, the selection was performed independently by 3 review authors (B.P., F.I., and Z.B.), first by title, then by abstract, and finally based on full text according to the aforementioned criteria. Endnote v20 (Clarivate Analytics, Philadelphia, PA) reference manager software was used for the selection. We calculated Cohen's kappa coefficient ( $\kappa$ ) after each selection

process to measure interrater reliability.<sup>19</sup> Disagreements were resolved by consensus; if consensus was not reached, a final decision was made with involvement from a fourth independent review author (S.V.). The study selection process is shown using PRISMA 2020 flowchart (Figure 1).

### Data extraction

Three authors (B.P., F.I., and Z.B.) independently collected data from the eligible articles. In the case of disagreement, the decision was based on consensus. If consensus was not reached, a final decision was made by involving a fourth author (S.V.).

The following data were extracted with a standardized collection method to an Excel sheet (Office 365, Microsoft, Redmond, WA): first author, the year of publication, study population, study period, study site (country), study design, demographic data of the patients, total number of patients in the age groups, number of NCAs in the age

groups, and information for assessing the risk of bias in the studies.

We extracted the total number of live births and events involving birth defects from each study. To investigate which maternal age increases the probability of particular birth defects, we used the age categories from the included studies or defined new ones by merging 2 or more age groups. The age group of 20- to 30-year-old mothers was used as a reference group. In defining the age groups, the ideal 10-year period was based on other studies, including our own work.<sup>20</sup> We aimed to look at AMA (35 or older), as commonly defined; very young mothers (under 20); and mothers over 40. In addition, between 30 and 40 years of age, we created additional groupings with a 5-year split to investigate at which stage the risk increase occurs for each anomaly. We only included studies for each outcome in the analysis if the reference and at least 1 more age category could be formed. For maximum accuracy, we grouped the endpoints

according to the International Classification of Diseases-10 (ICD-10) categories.

### Assessment of risk of bias


Two authors (B.P., Á.M.) performed the risk of bias assessment independently with the help of the Quality in Prognostic Studies tool.<sup>21</sup> Disagreements were resolved by a third review author (S.V.) (Supplementary Table 3). The specific methodological details are described in Supplemental Appendix 1. The web-based version of the Risk-of-Bias VISualization tool was used to visualization of the results (Supplementary Table 4).<sup>22</sup>

### Data synthesis

We carried out a mathematical synthesis if there were at least 3 homogenous articles regarding the age groups and NCAs.

All statistical analyses were made with R<sup>23</sup> using the meta (Schwarzer 2022, v5.5.0; University of Freiburg, Freiburg, Germany) and dmetar (Cuijpers

**FIGURE 1**  
**PRISMA 2020 flowchart representing the study selection process**



[Amsterdam, Netherlands], Furukawa [Tokyo, Japan], and Ebert [Zurich, Switzerland] 2022, v0.0.9000) packages.<sup>24</sup>

We anticipated considerable between-study heterogeneity in the study population; therefore, a random-effects model was used to pool effect sizes. RR with 95% confidence interval (CI) was calculated as a random effects estimate with the meta-bin function of the meta (Schwarzer 2022, v5.5.0) R package. The Mantel-Haenszel method<sup>25–27</sup> was used to pool RRs. Since the exact Mantel-Haenszel method was used, we did not apply continuity correction to handle 0 cell counts.<sup>28</sup>

For outcomes with at least 5 studies, a Hartung-Knapp adjustment was used.<sup>29,30</sup>

We applied the Paule-Mandel method<sup>31</sup> to estimate the between-study variance ( $\tau^2$ ).

Additionally, between-study heterogeneity was investigated by Cochrane's Q test. Significant heterogeneity was considered at  $P < .1$ . Higgins & Thompson's I<sup>2</sup> statistics and 95% CI (30) were reported to illustrate the total variation across studies due to between-study heterogeneity.

Following the recommendations of Int'Hout et al,<sup>32</sup> where applicable, we also reported the prediction intervals (ie, the expected range of effects of future studies) of the pooled estimates.

A Cochrane Q test was used between subgroups to assess the age group differences. The null hypothesis was rejected at a 5% significance level. We used forest plots to summarize the results graphically. All statistical analyses were made with R (R Core Team 2022, v4.2.0) using the meta (Schwarzer 2022, v5.5.0) and dmetar (Cuijpers, Furukawa, Ebert 2022, v0.0.9000) packages.

## Results

### Study selection

Altogether 15,547 studies were identified by our search, from which 72 full-text articles were included in our synthesis following the selection process described above (Figure 1).

### Study characteristics

The baseline characteristics of the enrolled studies are detailed in Supplemental Table 1.

Our meta-analysis includes population-based studies from around the world. A precise geographic location is indicated in the baseline table. From the American continent, 37 articles were included; from Europe, 17; from Asia, 14; from Australia, 3; and from Africa 1. In terms of the study's examination period, the included articles encompass an overall timeframe between 1940 and 2018. All studies are population-based, with 36 studies carried out at the national level, 34 at the subnational level, and 2 at the multinational level, mostly based on the corresponding registries.

### Risk of bias assessment

The results of the risk of bias assessment are presented in Supplemental Table 2.

Publication bias and heterogeneity: Most of our analyses showed high heterogeneity. This is attributable to the diversity of geographical regions, population sizes, date, and duration of the study periods represented by the included studies.

Based on the visual inspection of the funnel plots we did not find significant publication bias. The inspection of funnel plots was used to assess publication bias when a minimum of 10 articles were available for 1 outcome (Supplemental Figures 18–37).

### Synthesis of results

*The role of maternal age in the occurrence of NCAs*

Table summarizes our results, while in the Supplementary Materials, we detail each of our forest plots. By default forest plots and summary statistics were prepared including all eligible studies regardless concomitant CAs.

Regarding our primary outcome, when we analyzed the total NCAs, we found that age  $>35$  (RR 1.31, CI: 1.07–1.61) and especially age  $>40$  (RR 1.44, CI: 1.25–1.66) increase the risk of NCAs (Figure 2). On this topic, we conducted 2 subgroup analyses to investigate this question more deeply. When we examined the age risk of total NCAs without the co-occurrence and influence effects of CAs, we found significant results for the  $>40$  age category (RR 1.25, CI: 1.08–1.46). Furthermore, in the analysis

where the influence of the chromosome abnormality was present, the risk of NCAs was found to increase in relation to maternal age  $>35$  (RR 1.26, CI: 1.12–1.42) and  $>40$  (RR 1.63, CI: 1.26–2.09), with risk increasing each year. *Congenital malformations of the nervous system (Q00–Q07)*

Analyzing 5 to 10 articles from different age groups, we found no effect between maternal age and congenital nervous system malformations.

*Congenital malformations of the circulatory system (Q20–Q28)*

We found a risk-increasing effect of AMA ( $>40$ , RR 1.94, CI: 1.28–2.93). Among the diseases of the circulatory system, we highlighted the group of CHDs, where we also found the risk-increasing effect of AMA ( $>35$ , RR 1.50, CI: 1.11–2.04 and  $>40$ , RR 1.75, CI: 1.32–2.32), while the preventive effect of young maternal age was observed ( $<20$ , RR 0.87, CI: 0.78–0.97; Figure 3). *Cleft lip and cleft palate (Q35–Q37)*

AMA ( $>40$ , RR 1.57, CI: 1.11–2.20) increased the risk of cleft lip and cleft palate. Regarding cleft palate separately, we found an even higher risk with AMA, which appears as early as the 35th maternal age (age  $>35$ , RR 1.78, CI: 1.16–2.73, and age  $>40$ , RR 1.77, CI: 1.48–2.11).

*Congenital malformations of the digestive system (Q38–Q45)*

We found a risk-increasing effect of AMA (age  $>40$ , RR 2.16, CI: 1.34–3.49). *Congenital malformations of the urinary system (Q60–Q64)*

We could not show an association between maternal age and congenital malformations of the urinary system after analyzing 3 eligible population-based articles with homogeneous age categories.

*Congenital malformations and deformations of the musculoskeletal system (Q65–Q79)*

We did not find an association with maternal age. However, this can also be explained by the low number of articles, the heterogeneity, and the diverse nature of the group.

*Other malformations*

On the other hand, we found a clear association between maternal age and

TABLE

## Summary of our results based on International Classification of Diseases-10 groups

| Congenital anomaly              | ICD-10 category | Age<20            | N  | Age 30–35         | N  | Age 35–40          | N  | Age>35            | N  | Age>40            | N  |
|---------------------------------|-----------------|-------------------|----|-------------------|----|--------------------|----|-------------------|----|-------------------|----|
| All NCAs (with or without CAs)  | Q00–Q89         | 1.08 (0.89; 1.32) | 14 | 1.23 (0.85; 1.78) | 13 | 1.47 (0.87; 2.49)  | 9  | 1.31 (1.06; 1.61) | 13 | 1.44 (1.25; 1.66) | 11 |
| All NCAs (without CAs)          | Q00–Q89         | 1.21 (0.59; 2.49) | 5  | 1.54 (0.55; 4.32) | 6  | 1.73 (0.45; 6.70)  | 5  | 1.37 (0.76; 2.45) | 6  | 1.25 (1.08; 1.46) | 6  |
| All NCAs (with CAs)             | Q00–Q89         | 1.15 (0.87; 1.52) | 10 | 1.02 (0.99; 1.06) | 7  | 1.20 (0.99; 1.44)  | 4  | 1.26 (1.12; 1.42) | 7  | 1.63 (1.26; 2.09) | 6  |
| <b>Nervous system</b>           | Q00–Q07         | 1.16 (0.74; 1.81) | 10 | 1.64 (0.70; 3.81) | 8  | 2.56 (0.64; 10.32) | 5  | 1.53 (0.80; 2.94) | 8  | 1.56 (0.67; 3.62) | 7  |
| Encephalocele                   | Q01             | 1.76 (0.44; 7.12) | 3  | 1.51 (0.33; 6.83) | 3  | No data            |    | 1.43 (0.57; 3.60) | 3  | No data           |    |
| Congenital hydrocephalus        | Q03             | 1.19 (1.02; 1.38) | 2  | No data           |    | No data            |    | No data           |    | No data           |    |
| Spina bifida                    | Q05             | 1.30 (0.93; 1.82) | 9  | 1.15 (0.65; 2.06) | 8  | 1.79 (0.61; 5.31)  | 5  | 1.39 (0.75; 2.59) | 8  | 1.96 (0.72; 5.31) | 5  |
| Anencephaly                     | Q00.0           | 1.40 (0.98; 1.99) | 9  | 1.15 (0.72; 1.84) | 8  | 1.20 (0.53; 2.72)  | 6  | 1.02 (0.60; 1.72) | 8  | 1.30 (0.71; 2.38) | 6  |
| <b>Circulatory system</b>       | Q20–Q28         | 0.87 (0.68; 1.11) | 3  | 1.09 (1.00; 1.20) | 3  | 1.18 (0.94; 1.49)  | 3  | 1.33 (0.97; 1.82) | 3  | 1.94 (1.28; 2.93) | 4  |
| Congenital heart defects        | Q20–Q26         | 0.87 (0.78; 0.97) | 10 | 1.45 (0.83; 2.52) | 10 | 1.91 (0.65; 5.62)  | 6  | 1.50 (1.11; 2.04) | 10 | 1.75 (1.32; 2.32) | 6  |
| <b>Cleft lip and palate</b>     | Q35–Q37         | 0.93 (0.76; 1.14) | 6  | 1.58 (0.77; 3.22) | 6  | 1.85 (0.59; 5.75)  | 4  | 1.47 (0.95; 2.28) | 6  | 1.57 (1.11; 2.20) | 4  |
| Cleft palate                    | Q35             | 0.99 (0.56; 1.73) | 6  | 1.42 (0.66; 3.06) | 8  | 2.08 (0.54; 7.99)  | 5  | 1.78 (1.16; 2.73) | 8  | 1.77 (1.48; 2.11) | 5  |
| <b>Digestive system</b>         | Q38–Q45         | 0.98 (0.71; 1.37) | 2  | No data           |    | No data            |    | No data           |    | 2.16 (1.34; 3.49) | 2  |
| <b>Urinary system</b>           | Q60–Q64         | No data           |    | 0.97 (0.75; 1.26) | 3  | No data            |    | 0.86 (0.57; 1.29) | 3  | No data           |    |
| Hypospadiasis                   | Q54             | 0.99 (0.91; 1.07) | 5  | 1.06 (0.96; 1.17) | 4  | No data            |    | 1.11 (0.88; 1.39) | 4  | No data           |    |
| <b>Musculoskeletal system</b>   | Q65–Q79         | 0.88 (0.72; 1.08) | 2  | No data           |    | 0.93 (0.71; 1.22)  | 2  | 0.94 (0.65; 1.37) | 2  | 0.90 (0.55; 1.46) | 3  |
| Congenital diaphragmatic hernia | Q79.0           | 0.96 (0.88; 1.06) | 5  | 1.74 (0.52; 5.80) | 4  | No data            |    | 1.52 (0.79; 2.91) | 5  | No data           |    |
| Omphalocele                     | Q79.2           | 1.44 (1.08; 1.92) | 14 | 1.13 (0.85; 1.50) | 14 | 1.35 (0.98; 1.87)  | 13 | 1.47 (1.20; 1.79) | 14 | 2.57 (1.77; 3.73) | 13 |
| Gastroschisis                   | Q79.3           | 3.08 (2.74; 3.47) | 22 | 0.32 (0.23; 0.44) | 17 | 0.27 (0.16; 0.47)  | 12 | 0.22 (0.15; 0.32) | 17 | 0.41 (0.23; 0.74) | 11 |

N—numbers represent the number of studies included in the analysis.


The reference group for each comparison was pregnant women between the age of 20–30.

CA, chromosomal abnormality; ICD-10, International Classification of Diseases-10; NCA, nonchromosomal congenital anomaly.



FIGURE 2


Forest plot representing the RR with 95% CI of all nonchromosomal anomalies (ICD-10: Q00–Q89) in different age groups compared to the 20–30 age group



CI, confidence interval; RR, risk ratio.

FIGURE 3

Forest plot representing the RR with 95% CI of congenital heart defects (ICD-10: Q20–Q26) in different age groups compared to the 20–30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

some individual malformations. The risk of omphalocele was higher in both very young (age<20, RR 1.44, CI: 1.08–1.92) and AMA (age>40, RR 2.57, CI: 1.77–3.73) women. Based on 22 eligible articles (age<20, RR 3.08, CI 2.74–3.47), gastroschisis shows a strong association with very young maternal age. The analyses of the ICD-10 main groups and certain individual anomalies can be found in the supplementary material ([Supplementary Figures 1–17](#)).

Regarding the congenital malformations of the eye, ear, face, and neck (Q10–Q18), congenital malformations of the respiratory system (Q30–Q34), and congenital malformations of genital organs (Q50–Q56), we did not find enough studies with homogenous age groups and NACs to carry out a mathematical synthesis.

Additionally, we also resorted our study-level outcomes by year of publication to showcase any apparent trend in case of outcomes where sufficient number of articles were available to have any chance to reliably assess any effect ([Supplemental Figures 38–47](#)) and we could not see any convincing trend. We also analyzed the subset of studies published from 2005 onward ([Supplemental Figures 48–57](#)): no clear and convincing trend could be identified, only weak trends in a few cases (summarized in [Supplemental Table 6](#)).

## Comment

The present study aimed to investigate the influence of maternal age on the risk of NCAs. Overall, our results suggest that maternal age plays a significant role in NCAs, with notable variations observed across different age groups. This finding is particularly important given that the focus of the analysis was specifically on the NCAs, while CAs were excluded from the analysis. The coexistence of CAs occurred in several established studies, but examining maternal age associations of CAs was not the subject of our present study.

## Principal findings and comparison with existing literature

One key finding of our study is the association between AMA ( $\geq 35$  years and

$\geq 40$  years) and an increased risk of NCAs. This finding is consistent with previous research,<sup>33–35</sup> highlighting the importance of considering AMA as a risk factor in prenatal care and genetic counseling. The meta-analysis written on the subject in 2022 also considered AMA as a risk.<sup>36</sup> However, the significance of our present study is given by the fact that we specifically and exclusively examined NCAs and grouped them according to the International Classification of Diseases. We separately analyzed the main groups and some individual deviations. In addition, during our study, we examined the risk of several age groups compared to the reference age group. The increased risk observed in older mothers may be attributed to various factors, including increased rate of in vitro fertilization,<sup>37–40</sup> increased prevalence of comorbidities especially pregestational diabetes mellitus,<sup>41–43</sup> and a higher likelihood of exposure to environmental factors<sup>44,45</sup> over an extended period. Contrary to our findings, some research has questioned the risk-increasing effect of AMA.<sup>46,47</sup> This may be explained by the fact that the increase in maternal age in Europe is especially associated with women of higher social status, which may have led to a decrease in the risk of NCA in this age group compared to previous trends.<sup>47,48</sup> Some studies show that AMA is associated with a reduced risk of NCAs, with researchers hypothesizing that the “all-or-nothing” phenomenon plays a stronger role in embryonic development as the egg ages and that anatomically normal fetuses are more likely to survive.<sup>49</sup>

Our findings support and strengthen previous research that has suggested a significant association between maternal age and the risk of different NCAs.<sup>20,50,51</sup> By pooling data from multiple studies, our meta-analysis demonstrates a consistent pattern of increased risk among older and younger mothers. This finding adds to the body of evidence and underscores the importance of considering maternal age as a critical factor in assessing the risk of these anomalies.

Interestingly, we also observed an elevated risk of NCAs among younger

maternal age groups (<20 years), but this association is not statistically significant. This finding is consistent with previous studies and suggests that a very young maternal age may also be a significant risk factor for these anomalies.<sup>47</sup> Possible explanations for this increased risk among younger mothers include inadequate prenatal care, a higher prevalence of socioeconomic disadvantages, and increased susceptibility to nutritional deficiencies during pregnancy.<sup>52</sup>

It is known that in addition to CAs, the incidence of NCAs also increases with age, which is why it is worthwhile to examine the relationship even without their copresence. We found that the increased risk persisted in subgroup analyses excluding coincident chromosomal anomalies (see [Supplemental Table 5](#)). The RR for NCAs between mothers aged 20 to 30 and those aged >40, without coincidence of chromosomal anomalies, was 1.25 (95% CI: 1.08–1.46), indicating a 25% higher risk of nonchromosomal anomalies in older mothers when chromosomal anomalies were not present. This finding aligns with our recent population-based study,<sup>20</sup> which demonstrated an increased risk of nonchromosomal anomalies in older mothers even after excluding CAs from the analysis. According to the current guidelines, there is no specific recommendation for screening for NCAs based on maternal age. However, it has been previously demonstrated that maternal age is a significant risk factor for chromosomal anomalies. Consequently, there has been a growing emphasis on age-based screening, which has led to a notable improvement in the detection rate. While CAs are well-established in the etiology of developmental disorders, NCAs can also arise from gene abnormalities. However, no routine screening protocol is currently available for these; thus, their presence could not be excluded in this study. Moreover, their incidence is less associated with maternal age.<sup>53,54</sup>

A further aim of the present meta-analysis was to investigate the effect of maternal age on the prevalence of NCA using data classified by ICD-10



categories. By analyzing data from 5 different age groups (<20; 30–35; >35; 35–40; >40) and comparing them to a control age group of 20 to 30 years, we sought to provide a comprehensive understanding of the relationship between maternal age and specific types of NCAs. CHDs and neural tube defects (NTDs) should be addressed separately, as fetal echocardiography and neurosonography serve as complementary screening methods for these conditions.

In the circulatory system category, the risk of nonchromosomal anomalies was significantly higher in mothers aged >40. Specifically, CHDs within this category showed a similarly increased risk, with a 75% risk-increasing effect for mothers aged >40 compared to those aged 20 to 30. When comparing mothers aged >35 to those aged 20 to 30 a 50% increased risk was indicated in the older age group. These are significant findings from a clinical point of view, because there is currently no maternal age-related indication for fetal echocardiography.<sup>55,56</sup>

No association with maternal age was found for NTDs. The literature does not provide consistent findings regarding the effect of age. Most studies also highlight the role of both very young and AMA.<sup>57,58</sup> While other researchers suggest that a higher risk of NTD is associated with increased maternal age,<sup>59</sup> the diverse outcomes observed in studies may be attributed to the inconsistent definition of NTDs, as grouping was not uniformly applied across different research studies.

The included studies have span a long time period (1940–2018) during which substantial changes in lifestyle, prevention strategies,<sup>60</sup> and diagnostics may have happened; hence, the incidence of certain NCAs may have also changed over time. However, this shift does not appear to have impacted the dependence of RRs on maternal age.

Since no specific additional screening options are available for other NCA groups, ultrasound examinations adjusted for age in these particular age groups should prioritize the assessment of these organ systems. Special attention should be dedicated to the more frequent

disparities observed in the low and high maternal age categories. Exploring the underlying causes of the risk-increasing effects within each age group can aid the identification of appropriate preventive options. Our findings indicate that the inclusion of age in screening protocols can enhance the likelihood of early detection of NCAs. While this study alone does not provide conclusive evidence regarding the isolated impact of age, it is important to consider the potential influence of lifestyle factors commonly associated with different age categories. Nevertheless, age alone can still be considered a distinct and significant risk factor.

### Strengths and limitation

Regarding the strengths of our analysis, we followed our protocol, which was registered in advance. A rigorous methodology was applied. We included population-based articles, which gave us a comprehensive view of all NCAs. We included articles from around the world with a large number of cases, enabling the generalizability of the result.

However, there are several limitations. All included studies had a retrospective design that limited our ability to establish causality and precluded the assessment of certain confounding variables. The quality and heterogeneity of the included studies may have introduced some biases and limitations in interpreting our results. As with any meta-analysis, publication bias may be a concern, as studies with nonsignificant results are less likely to be published. Additionally, the sample sizes, the long study period with changing screening methods, and data reporting across the included studies may have introduced some degree of heterogeneity.

### Conclusions and implication

The importance of immediate implementation of the results has been previously proven.<sup>61,62</sup> Based on our study, we suggest advanced ultrasound screening and additional screening methods (fetal echocardiography) in high-risk age groups, and considering this knowledge in family planning due to the clear

advantages of the rapid integration of the results into clinical practice. Our results suggest that introducing fetal echocardiography may be a priority for AMA.

Further prospective data collection is needed to assess the problem in question more accurately and to understand the role of maternal age in the case of rare NCAs.

In conclusion, our meta-analysis of population-based articles provides compelling evidence of the influence of maternal age (especially AMA) on the risk of NCAs. These findings have important clinical implications, emphasizing the need for age-specific prenatal care and genetic counseling to mitigate the risk of these anomalies. ■

### REFERENCES

1. WHO. Birth defects/key facts 2022. Available at: <https://www.who.int/news-room/fact-sheets/detail/birth-defects>. Accessed October 25, 2023.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197–223.
3. WHO. Congenital anomalies. Available at: [https://www.who.int/health-topics/congenital-anomalies#tab=tab\\_1](https://www.who.int/health-topics/congenital-anomalies#tab=tab_1). Accessed October 25, 2023.
4. United Nations, Department of Economic and Social Affairs, Population Division. World fertility patterns 2015—data booklet (ST/ESA/SER. A/370). New York, NY: United Nations; 2015.
5. Stone L. Declining fertility in America. American Enterprise Institute: Washington, D.C.; 2018.
6. Frick AP. Advanced maternal age and adverse pregnancy outcomes. *Best Pract Res Clin Obstet Gynaecol* 2021;70:92–100.
7. Frederiksen LE, Ernst A, Brix N, et al. Risk of adverse pregnancy outcomes at advanced maternal age. *Obstet Gynecol* 2018;131:457–63.
8. Cao J, Xu W, Liu Y, et al. Trends in maternal age and the relationship between advanced age and adverse pregnancy outcomes: a population-based register study in Wuhan, China, 2010–2017. *Public Health* 2022;206:8–14.
9. Glick I, Kadish E, Rottenstreich M. Management of pregnancy in women of advanced maternal age: improving outcomes for mother and baby. *Int J Womens Health* 2021;13:751–9.
10. Polani PE, Alberman E, Berry AC, Blunt S, Singer JD. Chromosome abnormalities and maternal age. *Lancet* 1976;1:516–7.

11. Ferguson-Smith MA. Maternal age and Down syndrome. *Lancet* 1978;2:213.
12. Cuckle H. Maternal age-standardisation of prevalence of Down's syndrome. *Lancet* 1999;354:529–30.
13. Ma JY, Li S, Chen LN, Schatten H, Ou XH, Sun QY. Why is oocyte aneuploidy increased with maternal aging? *J Genet Genomics* 2020;47:659–71.
14. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226. *Obstet Gynecol* 2020; 136:e48–69.
15. Fiorentino DG, Hughes F. Fetal screening for chromosomal abnormalities. *Neoreviews* 2021;22:e805–18.
16. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)* 2021;74:790–9.
17. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 2019;10:14651858.
18. PROSPERO. Available at: <https://www.crd.york.ac.uk/prospero/>. Accessed May 11, 2023.
19. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med* 2012;22:276–82.
20. Petho B, Matrai A, Agocs G, et al. Maternal age is highly associated with non-chromosomal congenital anomalies: analysis of a population-based case-control database. *BJOG* 2023;130:1217–25.
21. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:14898.
22. McGuinness LA, Higgins JP. Risk-of-bias Visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2021;12:55–61.
23. R Core Team. R Foundation for Statistical Computing. R: A language and environment for statistical computing. Vienna, Austria, 2023.
24. Egger M, Higgins JPT, & Smith GD, (eds). G. S. Meta-Analysis in R. Systematic reviews in health research: meta-analysis in context. Chapman and Hall/CRC, Boca Raton, FL, 2022: 510–34.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22: 719–48.
26. Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. *Am J Epidemiol* 1986;124:719–23.
27. Thompson SG, Turner RM, Wain DE. Multilevel models for meta-analysis, and their application to absolute risk differences. *Stat Methods Med Res* 2001;10:375–92.
28. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med* 2004;23:1351–75.
29. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* 2003;22:2693–710.
30. Int'Hout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014;14:25.
31. Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods* 2016;7:55–79.
32. Int'Hout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open* 2016;6:e010247.
33. Hollier LM, Leveno KJ, Kelly MA, McIntire DD, Cunningham FG. Maternal age and malformations in singleton births. *Obstet Gynecol* 2000;96:701–6.
34. Moges N, Anley DT, Zemene MA, et al. Congenital anomalies and risk factors in Africa: a systematic review and meta-analysis. *BMJ Paediatr Open* 2023;7:e002022.
35. Cleary-Goldman J, Malone FD, Vidaver J, et al. Impact of maternal age on obstetric outcome. *Obstet Gynecol* 2005;105:983–90.
36. Ahn D, Kim J, Kang J, Kim YH, Kim K. Congenital anomalies and maternal age: a systematic review and meta-analysis of observational studies. *Acta Obstet Gynecol Scand* 2022;101:484–98.
37. Hwang SS, Dukhovny D, Gopal D, et al. Health of infants after ART-treated, subfertile, and fertile deliveries. *Pediatrics* 2018;142: e20174069.
38. Yu HT, Yang Q, Sun XX, et al. Association of birth defects with the mode of assisted reproductive technology in a Chinese data-linkage cohort. *Fertil Steril* 2018;109:849–56.
39. Hoorsan H, Mirmiran P, Chaichian S, Moradi Y, Hoorsan R, Jesmi F. Congenital malformations in infants of mothers undergoing assisted reproductive technologies: a systematic review and meta-analysis study. *J Prev Med Public Health* 2017;50:347–60.
40. Chen M, Heilbronn LK. The health outcomes of human offspring conceived by assisted reproductive technologies (ART). *J Dev Orig Health Dis* 2017;8:388–402.
41. Riskin A, Itzhaki O, Bader D, Iofe A, Toropine A, Riskin-Mashiah S. Perinatal outcomes in infants of mothers with diabetes in pregnancy. *Isr Med Assoc J* 2020;22:569–75.
42. Lemaître M, Bourdon G, Bruandet A, et al. Pre-gestational diabetes and the risk of congenital heart defects in the offspring: a French nationwide study. *Diabetes Metab* 2023;49:101446.
43. Chen LJ, Chiu CH, Huang JY, et al. Maternal diabetes mellitus and birth defects in Taiwan: a 5-year nationwide population-based cohort study. *J Chin Med Assoc* 2023;86:589–95.
44. Ravindra K, Chanana N, Mor S. Exposure to air pollutants and risk of congenital anomalies: a systematic review and metaanalysis. *Sci Total Environ* 2021;765:142772.
45. Peyvandi S, Baer RJ, Chambers CD, et al. Environmental and socioeconomic factors influence the live-born incidence of congenital heart disease: a population-based study in California. *J Am Heart Assoc* 2020;9:e015255.
46. Okmen Ozkan B, Koroglu N, Turkogeldi LS, Cetin BA, Aslan H. Advanced maternal age and risk of non-chromosomal anomalies: data from a tertiary referral hospital in Turkey. *J Matern Fetal Neonatal Med* 2019;32:749–52.
47. Loane M, Dolk H, Morris JK, Group EW. Maternal age-specific risk of non-chromosomal anomalies. *BJOG* 2009;116:1111–9.
48. Yang J, Carmichael SL, Canfield M, Song J, Shaw GM, National Birth Defects Prevention Study. Socioeconomic status in relation to selected birth defects in a large multicentered US case-control study. *Am J Epidemiol* 2008;167:145–54.
49. Goetzinger K, Shanks A, Odibo A, Macones G, Cahill A. Advanced maternal age and the risk of major congenital anomalies: survival of the fittest? *Am J Obstet Gynecol* 2014;210:S23.
50. Reefhuis J, Honein MA. Maternal age and non-chromosomal birth defects, Atlanta–1968–2000: teenager or thirty-something, who is at risk? *Birth Defects Res A Clin Mol Teratol* 2004;70:572–9.
51. Gill SK, Broussard C, Devine O, et al. Association between maternal age and birth defects of unknown etiology: United States, 1997–2007. *Birth Defects Res A Clin Mol Teratol* 2012;94:1010–8.
52. Miranda VIA, da Silva Dal Pizzol T, Silveira MPT, et al. The use of folic acid, iron salts and other vitamins by pregnant women in the 2015 Pelotas birth cohort: is there socioeconomic inequality? *BMC Public Health* 2019;19: 889.
53. Wojcik MH, Agrawal PB. Deciphering congenital anomalies for the next generation. *Cold Spring Harb Mol Case Stud* 2020;6: a005504.
54. Donahoe PK, Noonan KM, Lage K. Genetic tools and algorithms for gene discovery in major congenital anomalies. *Birth Defects Res A Clin Mol Teratol* 2009;85:6–12.
55. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. *Circulation* 2014;129:2183–242.
56. AIUM practice parameter for the performance of fetal echocardiography. *J Ultrasound Med* 2020;39:E5–16.
57. Feldman JG, Stein SC, Klein RJ, Kohl S, Casey G. The prevalence of neural tube defects among ethnic groups in Brooklyn, New York. *J Chronic Dis* 1982;35:53–60.
58. Borman GB, Smith AH, Howard JK. Risk factors in the prevalence of anencephalus and

spina bifida in New Zealand. *Teratology* 1986;33:221–30.

**59.** Dudin A. Neural tube defect among Palestinians: a hospital-based study. *Ann Trop Paediatr* 1997;17:217–22.

**60.** Oakley GP Jr, Bell KN, Weber MB. Recommendations for accelerating global action to

prevent folic acid-preventable birth defects and other folate-deficiency diseases: meeting of experts on preventing folic acid-preventable neural tube defects. *Birth Defects Res A Clin Mol Teratol* 2004;70:835–7.

**61.** Hegyi P, Eross B, Izbeki F, Parniczky A, Szentesi A. Accelerating the translational

medicine cycle: the Academia Europaea pilot. *Nat Med* 2021;27:1317–9.

**62.** Hegyi P, Petersen OH, Holgate S, et al. Academia Europaea position paper on translational medicine: the cycle model for translating scientific results into community benefits. *J Clin Med* 2020;9:1532.

## Appendix Supplementary Appendix 1. Risk of bias assessment methodology

Overall ratings for each domain were assigned as carrying 'low' (green), 'moderate' (yellow), or 'high' (red) risk of bias, based on the items included in each domain.

**Study design:** (1) low risk of bias was attributed if the proportion of baseline sample was available, also if the reason for lost to follow-up was detailed; (2) moderate risk of bias was attributed if a part of the above listed criteria were missing; (3) high risk of bias was attributed if data was missing for the above mentioned criteria.

**Study participation measurement:** (1) low risk of bias was attributed if authors adequately described the source population, including methods to identify patients and eligibility criteria; (2) moderate risk of bias was attributed if a part of the above listed descriptions were missing; (3) high risk of bias was attributed if baseline characteristics, eligibility criteria, time and place of recruitment were not described.

**Prognostic factor measurement:** (1) low risk of bias was attributed if clear and detailed age categories were used covering all age groups; (2) moderate risk of bias was attributed if clear categories were defined but some age groups were missing; (3) high risk of bias was attributed if only 1 group was examined.

**Outcome measurement:** (1) low risk of bias was attributed if there was clear definition of outcome, if the study used International Classification of Diseases-10 (ICD-10) category; (2) moderate risk of bias was attributed if a mentioned criteria were missing but can be matched to ICD-10 category; (3) high risk of bias was attributed if the anomaly could not be precisely identified or it was inadequate.

**Study confounding measurement:** (1) low risk of bias was attributed if important potential confounders were described and accounted for in the analysis; (2) moderate risk of bias was attributed if some of the important confounders were not measured; (3) high risk of bias was attributed if studies did not provide data on confounding factors.

**Statistical analysis measurement:** (1) low risk of bias was attributed if there is clear, raw data (no or negligible contradiction); (2) moderate risk of bias was attributed if requires some calculation or reading from a graph (minor contradiction); (3) high risk of bias was attributed if only approximate data can be obtained (serious contradiction).

## SUPPLEMENTAL REFERENCES

1. Agopian A, Marengo L, Mitchell LE. Descriptive epidemiology of nonsyndromic omphalocele in Texas, 1999-2004. *Am J Med Genet A* 2009;149:2129-33.
2. Baer RJ, Chambers CD, Jones KL, et al. Maternal factors associated with the occurrence of gastroschisis. *Am J Med Genet A* 2015;167:1534-41.
3. Beckman L, Nordstrom M. Population studies in northern Sweden. VIII. Frequencies of congenital malformations by region, time, sex and maternal age. *Hereditas* 1976;84:35-40.
4. Bergman JE, Loane M, Vrijheid M, et al. Epidemiology of hypospadias in Europe: a registry-based study. *World J Urol* 2015;33:2159-67.
5. Baird PA, Sadovnick AD, Yee IM. Maternal age and oral cleft malformations: data from a population-based series of 576,815 consecutive livebirths. *Teratology* 1994;49:448-51.
6. Bodnár L. The effect of maternal age and birth order on the incidence of congenital abnormalities. *Orv Hetil* 1970;111:625-8.
7. Borman GB, Smith AH, Howard JK. Risk factors in the prevalence of anencephalus and spina bifida in New Zealand. *Teratology* 1986;33:221-30.
8. Bourque DK, Meng L, Dougan S, et al. Gastroschisis in Ontario, Canada: 2012-2018. *Birth Defects Res* 2021;113:1044-51.
9. Bugge M, Drachmann G, Kern P, et al. Abdominal wall defects in Greenland 1989-2015. *Birth Defects Res* 2017;109:836-42.
10. Byron-Scott R, Haan E, Chan A, Bower C, Scott H, Clark K. A population-based study of abdominal wall defects in South Australia and Western Australia. *Paediatr Perinat Epidemiol* 1998;12:136-51.
11. Canfield MA, Marengo L, Ramadhani TA, Suarez L, Brender JD, Scheuerle A. The prevalence and predictors of anencephaly and spina bifida in Texas. *Paediatr Perinat Epidemiol* 2009;23:41-50.
12. Canon S, Mosley B, Chipollini J, Purifoy JA, Hobbs C. Epidemiological assessment of hypospadias by degree of severity. *J Urol* 2012;188:2362-6.
13. Croen LA, Shaw GM. Young maternal age and congenital malformations: a population-based study. *Am J Public Health* 1995;85:710-3.
14. DeRoo LA, Gaudino JA, Edmonds LD. Orofacial cleft malformations: associations with

maternal and infant characteristics in Washington state. *Birth Defects Res A Clin Mol Teratol* 2003;67:637-42.


15. Dott MM, Wong LY, Rasmussen SA. Population-based study of congenital diaphragmatic hernia: risk factors and survival in Metropolitan Atlanta, 1968-1999. *Birth Defects Res A Clin Mol Teratol* 2003;67:261-7.
16. Dudin A. Neural tube defect among Palestinians: a hospital-based study. *Ann Trop Paediatr* 1997;17:217-22.
17. Fedrick J. Anencephalus in Scotland 1961-72. *Br J Prev Soc Med* 1976;30:132-7.
18. Feldman JG, Stein SC, Klein RJ, Kohl S, Casey G. The prevalence of neural tube defects among ethnic groups in Brooklyn, New York. *J Chronic Dis* 1982;35:53-60.
19. Forrester MB, Merz RD. Descriptive epidemiology of oral clefts in a multiethnic population, Hawaii, 1986-2000. *Cleft Palate Craniofac J* 2004;41:622-8.
20. Forrester MB, Merz RD. Epidemiology of abdominal wall defects, Hawaii, 1986-1997. *Teratology* 1999;60:117-23.
21. Forrester MB, Merz RD. Epidemiology of neural tube defects, Hawaii, 1986-1997. *Hawaii Med J* 2000;59:323-7. 41.
22. Friedman AM, Ananth CV, Siddiq Z, D'Alton ME, Wright JD. Gastroschisis: epidemiology and mode of delivery, 2005-2013. *Am J Obstet Gynecol* 2016;215:348.e1-e9.
23. Gupta B, Antia AU. Incidence of congenital heart disease in Nigerian children. *Br Heart J* 1967;29:906-9.
24. Hansen M, Greenop K, Yim D, Ramsay J, Thomas Y, Baynam GS. Birth prevalence of congenital heart defects in Western Australia, 1990-2016. *J Paediatr Child Health* 2021;57:1672-80.
25. Hay S. Incidence of selected congenital malformations in Iowa. *Am J Epidemiol* 1971;94:572-84.
26. Hollier LM, Leveno KJ, Kelly MA, McIntire DD, Cunningham FG. Maternal age and malformations in singleton births. *Obstet Gynecol* 2000;96:701-6.
27. Jaikrishan G, Sudheer KR, Andrews VJ, et al. Study of stillbirth and major congenital anomaly among newborns in the high-level natural radiation areas of Kerala, India. *J Community Genet* 2013;4:21-31.
28. Janerich DT. Maternal age and spina bifida: longitudinal versus cross-sectional analysis. *Am J Epidemiol* 1972;96:389-95.
29. Janerich DT. Anencephaly and maternal age. *Am J Epidemiol* 1972;95:319-26.
30. Jaruratanasirikul S, Chicharoen V, Chakranon M, et al. Population-based study of prevalence of cleft lip/palate in southern Thailand. *Cleft Palate Craniofac J* 2016;53:351-6.
31. Jones AM, Isenburg J, Salemi JL, et al. Increasing prevalence of gastroschisis-14 states, 1995-2012. *MMWR Morbid Mortal Wkly Rep* 2016;65:23-6.
32. Kazaura M, Lie RT, Skjærven R. Paternal age and the risk of birth defects in Norway. *Ann Epidemiol* 2004;14:566-70.



33. Kirby RS, Marshall J, Tanner JP, et al. Prevalence and correlates of gastroschisis in 15 states, 1995 to 2005. *Obstet Gynecol* 2013;122:275–81.
34. Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. *Circulation* 2013;128:583–9.
35. Liu S, Evans J, MacFarlane AJ, et al. Association of maternal risk factors with the recent rise of neural tube defects in Canada. *Paediatr Perinat Epidemiol* 2019;33:145–53.
36. Li ZY, Chen YM, Qiu LQ, et al. Prevalence, types, and malformations in congenital anomalies of the kidney and urinary tract in newborns: a retrospective hospital-based study. *Ital J Pediatr* 2019;45:50.
37. Vo LU, Langlois PH. Time trends in prevalence of gastroschisis in Texas, 1999 to 2011: subgroup analyses by maternal and infant characteristics. *Birth Defects Res A Clin Mol Teratol* 2015;103:928–40.
38. Luo YL, Wang W, Gao XH, Huang YH, Xu Q, Cheng YL. Birth prevalence of orofacial clefts among perinatal infants: a register-based study in Bao'an district, Shenzhen, China. *Birth Defects Res* 2019;111:353–9.
39. Martínez Frías ML, Salvador J, Prieto L, Zaplana J. Incidence of gastroschisis and omphalocele in Spain. *Rev Sanid Hig Pública (Madr)* 1982;56:107–18.
40. Materna-Kiryluk A, Wisniewska K, Badura-Stronka M, et al. Parental age as a risk factor for isolated congenital malformations in a Polish population. *Paediatr Perinat Epidemiol* 2009;23:29–40.
41. McGivern MR, Best KE, Rankin J, et al. Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study. *Arch Dis Child Fetal Neonatal Ed* 2015;100:F137–44.
42. Miller A, Riehle-Colarusso T, Siffel C, Frías JL, Correa A. Maternal age and prevalence of isolated congenital heart defects in an urban area of the United States. *Am J Med Genet A* 2011;155:2137–45.
43. Mucat Baron Y, Gatt M, Calleja N, Collicot M. Advanced maternal age and neonatal outcomes in Malta. *Clin Exp Obstet Gynecol* 2019;46:265–9.
44. Nazer J, Aravena T, Cifuentes L. Congenital malformations in Chile. An emerging problem (period 1995-1999). *Rev Med Chile* 2001;129:895–904.
45. Nazer HJ, Cifuentes OL. [Congenital malformations among newborns of teenage mothers]. *Rev Med Chile* 2013;141:1300–6.
46. Parkes B, Hansell AL, Ghosh RE, et al. Risk of congenital anomalies near municipal waste incinerators in England and Scotland: retrospective population-based cohort study. *Environ Int* 2020;134:104845.
47. Paśnicki M, Wiśniewska K, Materna-Kiryluk A, Latos-Bieleńska A, Krawczyński M. The congenital malformations in children aged 0-2 in Zielona Góra province (1988-1997) and Lubuskie province (1998-2007) according to the Polish Registry of Congenital Malformations. Part 3. Age of mother and frequency of congenital malformations in children. *Pediatr Pol* 2013;88:48–56.
48. Persson M, Razaz N, Edstedt Bonamy AK, Villamor E, Cnattingius S. Maternal overweight and obesity and risk of congenital heart defects. *J Am Coll Cardiol* 2019;73:44–53.
49. Petrova JG, Vaktiskjold A. The incidence of neural tube defects in Norway and the Arkhangelskaja Oblast in Russia and the association with maternal age. *Acta Obstet Gynecol Scand* 2009;88:667–72.
50. Pradat P. Epidemiology of major congenital heart defects in Sweden, 1981-1986. *J Epidemiol Community Health* 1992;46:211–5.
51. Purkey NJ, Axelrod DM, McElhinney DB, et al. Birth location of infants with critical congenital heart disease in California. *Pediatr Cardiol* 2019;40:310–8.
52. Rankin J, Dillon E, Wright C. Congenital anterior abdominal wall defects in the North of England, 1986-1996: occurrence and outcome. *Prenat Diagn* 1999;19:662–8.
53. Rankin J, Glinianaia S, Brown R, Renwick M. The changing prevalence of neural tube defects: a population-based study in the north of England, 1984-96. Northern Congenital Abnormality Survey Steering Group. *Paediatr Perinat Epidemiol* 2000;14:104–10.
54. Rider RA, Stevenson DA, Rinsky JE, Feldkamp ML. Association of twinning and maternal age with major structural birth defects in Utah, 1999 to 2008. *Birth Defects Res A Clin Mol Teratol* 2013;97:554–63.
55. Roeper PJ, Harris J, Lee G, Neutra R. Secular rates and correlates for gastroschisis in California (1968-1977). *Teratology* 1987;35:203–10.
56. Salihi HM, Pierre-Louis BJ, Druschel CM, Kirby RS. Omphalocele and gastroschisis in the State of New York, 1992-1999. *Birth Defects Res A Clin Mol Teratol* 2003;67:630–6.
57. Salim TR, Soares GP, Klein CH, Oliveira GMM. Fetal and maternal factors are associated with mortality due to circulatory system disorders in children. *Rev Saude Publica* 2019;53:31.
58. Sarkar S, Patra C, Dasgupta MK, Nayek K, Karmakar PR. Prevalence of congenital anomalies in neonates and associated risk factors in a tertiary care hospital in eastern India. *J Clin Neonatol* 2013;2:131–4.
59. Sever LE. An epidemiologic study of neural tube defects in Los Angeles County II. Etiologic factors in an area with low prevalence at birth. *Teratology* 1982;25:323–34.
60. Shields ED, Bixler D, Fogh-Andersen P. Cleft palate: a genetic and epidemiologic investigation. *Clin Genet* 1981;20:13–24.
61. Short TD, Stallings EB, Isenburg J, et al. Gastroschisis trends and ecologic link to opioid prescription rates - United States, 2006-2015. *MMWR Morb Mortal Wkly Rep* 2019;68:31–6.
62. St Louis AM, Kim K, Browne ML, et al. Prevalence trends of selected major birth defects: a multi-state population-based retrospective study, United States, 1999 to 2007. *Birth Defects Res* 2017;109:1442–50.
63. Tan KH, Kilby MD, Whittle MJ, Beattie BR, Booth IW, Botting BJ. Congenital anterior abdominal wall defects in England and Wales 1987-93: retrospective analysis of OPCS data. *Br Med J* 1996;313:903–6.
64. Pregnancy outcomes in women of very advanced maternal age: editorial comment. *Obstet Gynecol Surv* 2005;60:562–3.
65. Tan KB, Tan KH, Chew SK, Yeo GS. Gastroschisis and omphalocele in Singapore: a ten-year series from 1993 to 2002. *Singap Med J* 2008;49:31–6.
66. Williams LJ, Kucik JE, Alverson CJ, Olney RS, Correa A. Epidemiology of gastroschisis in metropolitan Atlanta, 1968 through 2000. *Birth Defects Res A Clin Mol Teratol* 2005;73:177–83.
67. Xie D, Yang T, Liu Z, Wang H. Epidemiology of birth defects based on a birth defect surveillance system from 2005 to 2014 in Hunan Province, China. *PLoS One* 2016;11:e0147280.
68. Xie D, Fang J, Liu Z, et al. Epidemiology and major subtypes of congenital heart defects in Hunan Province, China. *Medicine (Baltimore)* 2018;97:e11770.
69. Xu LL, Yuan XQ, Zhu J, et al. [Incidence and its trends on gastroschisis in some parts of China, 1996 - 2007]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2011;32:268–70.
70. Zhang X, Li S, Wu S, et al. Prevalence of birth defects and risk-factor analysis from a population-based survey in Inner Mongolia, China. *BMC Pediatr* 2012;12:125.
71. Yang W, Carmichael SL, Harris JA, Shaw GM. Epidemiologic characteristics of congenital diaphragmatic hernia among 2.5 million California births, 1989-1997. *Birth Defects Res A Clin Mol Teratol* 2006;76:170–4.
72. Zhou Y, Mao X, Zhou H, et al. Epidemiology of birth defects based on a birth defect surveillance system in Southern Jiangsu, China, 2014-2018. *J Matern Fetal Neonatal Med* 2022;35:745–51.

## SUPPLEMENTAL FIGURE 1


Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies (only studies excluding concomitant chromosomal anomalies)* (ICD-10 Q00–Q89) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 2


Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies (only studies including concomitant chromosomal anomalies)* (ICD-10: Q00–Q89 with Q90–Q99) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 3

Forest plot representing the RR with 95% CI of *congenital anomalies of the nervous system* (ICD-10: Q00–Q07) in different age groups compared to the 20 to 30 age group




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



**SUPPLEMENTAL FIGURE 4**


Forest plot representing the RR with 95% CI of *encephalocele* (ICD-10: Q01) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

**SUPPLEMENTAL FIGURE 5**


Forest plot representing the RR with 95% CI of *congenital hydrocephalus* (ICD-10: Q03) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 6

Forest plot representing the RR with 95% CI of *spina bifida* (ICD-10: Q05) in different age groups compared to the 20 to 30 age group




Lower with Comparator Higher with Comparator

CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 7


Forest plot representing the RR with 95% CI of *anencephaly* (ICD-10: Q00.0) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 8

Forest plot representing the RR with 95% CI of *congenital anomalies of the circulatory system* (ICD-10: Q20–Q28) in different age groups compared to the 20 to 30 age group




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 9


Forest plot representing the RR with 95% CI of *cleft lip and cleft palate* (ICD-10: Q35–Q37) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 10

Forest plot representing the RR with 95% CI of *cleft palate* (ICD-10: Q35) in different age groups compared to the 20 to 30 age group




Lower with Comparator Higher with Comparator

CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

**SUPPLEMENTAL FIGURE 11**

Forest plot representing the RR with 95% CI of *congenital anomalies of the digestive system* (ICD-10: Q38–Q45) in different age groups compared to the 20 to 30 age group




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 12


Forest plot representing the RR with 95% CI of *hypospadias* (ICD-10: Q54) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 13


Forest plot representing the RR with 95% CI of *congenital anomalies of the urinary system* (ICD-10: Q60–Q64) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 14


Forest plot representing the RR with 95% CI of *congenital anomalies of the musculoskeletal system* (ICD-10: Q65–Q79) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 15


Forest plot representing the RR with 95% CI of *congenital diaphragma hernia* (ICD-10 Q79.0) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 16

Forest plot representing the RR with 95% CI of *omphalocele* (ICD-10: Q79.2) in different age groups compared to the 20 to 30 age group




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 17


Forest plot representing the RR with 95% CI of *gastroschisis* (ICD-10: Q79.3) in different age groups compared to the 20 to 30 age group



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

**SUPPLEMENTAL FIGURE 18**


**Funnel plot for the association between maternal age and *all nonchromosomal anomalies* (ICD-10: Q00–Q89) (<20 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.


**SUPPLEMENTAL FIGURE 19**

**Funnel plot for the association between maternal age and *all nonchromosomal anomalies* (ICD-10: Q00–Q89) (>35 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.




**SUPPLEMENTAL FIGURE 20****Funnel plot for the association between maternal age and *all nonchromosomal anomalies* (ICD-10: Q00–Q89) (>40 vs 20–30 age groups)**

ICD-10, International Classification of Diseases-10.

## SUPPLEMENTAL FIGURE 21


Funnel plot for the association between maternal age and *all nonchromosomal anomalies* (ICD-10: Q00–Q89) (30–35 vs 20–30 age groups)



ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 22**


**Funnel plot for the association between maternal age and *all nonchromosomal anomalies (only studies including concomitant chromosomal anomalies)* (ICD-10: Q00–Q99 with Q90–Q99) (<20 vs 20–30 age groups)**




ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 23**

**Funnel plot for the association between maternal age and *congenital heart defects* (ICD-10: Q20–Q26) (<20 vs 20–30 age groups)**




ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 24****Funnel plot for the association between maternal age and *congenital heart defects* (ICD-10: Q20–Q26) (>35 vs 20–30 age groups)**

ICD-10, International Classification of Diseases-10.


**Funnel plot for the association between maternal age and *congenital heart defects* (ICD-10: Q20–Q26) (30–35 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 26**


**Funnel plot for the association between maternal age and *congenital anomalies of the nervous system* (ICD-10: Q00–Q07) (<20 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 27**

**Funnel plot for the association between maternal age and *anencephaly* (ICD-10: Q00.0) (<20 vs 20–30 age groups)**




ICD-10, International Classification of Diseases-10.



**SUPPLEMENTAL FIGURE 28**


**Funnel plot for the association between maternal age and *omphalocele* (ICD-10: Q79.2) (<20 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.


## SUPPLEMENTAL FIGURE 29

Funnel plot for the association between maternal age and *omphalocele* (ICD-10: Q79.2) (>35 vs 20–30 age groups)



ICD-10, International Classification of Diseases-10.


## SUPPLEMENTAL FIGURE 30

Funnel plot for the association between maternal age and *omphalocele* (ICD-10: Q79.2) (>40 vs 20–30 age groups)

ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 31**


**Funnel plot for the association between maternal age and *omphalocele* (ICD-10: Q79.2) (30–35 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.


**SUPPLEMENTAL FIGURE 32**

**Funnel plot for the association between maternal age and *omphalocele* (ICD-10: Q79.2) (35–40 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.


**Funnel plot for the association between maternal age and *gastroschisis* (ICD-10: Q79.3) (<20 vs 20–30 age groups)**



*ICD-10*, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 34**


**Funnel plot for the association between maternal age and *gastroschisis* (ICD-10: Q79.3) (>35 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 35**

**Funnel plot for the association between maternal age and *gastroschisis* (ICD-10: Q79.3) (>40 vs 20–30 age groups)**




ICD-10, International Classification of Diseases-10.



**SUPPLEMENTAL FIGURE 36**


**Funnel plot for the association between maternal age and *gastroschisis* (ICD-10: Q79.3) (30–35 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.

**SUPPLEMENTAL FIGURE 37**


**Funnel plot for the association between maternal age and *gastroschisis* (ICD-10: Q79.3) (35–40 vs 20–30 age groups)**



ICD-10, International Classification of Diseases-10.

## SUPPLEMENTAL FIGURE 38


Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies* (ICD-10: Q00–Q89) in different age groups compared to the 20 to 30 age group and sorted by year of publication



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 39

Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies (only studies excluding concomitant chromosomal anomalies)* (ICD-10: Q00–Q89) in different age groups compared to the 20 to 30 age group and sorted by year of publication




0.1 0.51 2 10

Lower with Comparator Higher with Comparator

CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 40


Forest plot representing the RR with 95% CI of *congenital anomalies of the nervous system* (ICD-10: Q00–Q07) in different age groups compared to the 20 to 30 age group and sorted by year of publication



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 41

Forest plot representing the RR with 95% CI of *anencephaly* (ICD-10: Q00.0) in different age groups compared to the 20 to 30 age group and sorted by year of publication




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 42


Forest plot representing the RR with 95% CI of *spina bifida* (ICD-10: Q05) in different age groups compared to the 20 to 30 age group and sorted by year of publication



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 43

Forest plot representing the RR with 95% CI of *congenital heart defects* (ICD-10: Q20–Q26) in different age groups compared to the 20 to 30 age group and sorted by year of publication




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 44


Forest plot representing the RR with 95% CI of *cleft lip and cleft palate* (ICD-10: Q35–Q37) in different age groups compared to the 20 to 30 age group and sorted by year of publication



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 45


Forest plot representing the RR with 95% CI of *cleft palate* (ICD-10: Q35) in different age groups compared to the 20 to 30 age group and sorted by year of publication



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 46

Forest plot representing the RR with 95% CI of *omphalocele* (ICD-10: Q79.2) in different age groups compared to the 20 to 30 age group and sorted by year of publication




Lower with Comparator Higher with Comparator

CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 47

Forest plot representing the RR with 95% CI of *gastroschisis* (ICD-10: Q79.3) in different age groups compared to the 20 to 30 age group and sorted by year of publication




Lower with Comparator Higher with Comparator

CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 48

Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies* (ICD-10: Q00–Q89) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 49


Forest plot representing the RR with 95% CI of *all nonchromosomal anomalies (only studies excluding concomitant chromosomal anomalies)* (ICD-10: Q00–Q89) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 50


Forest plot representing the RR with 95% CI of *congenital anomalies of the nervous system* (ICD-10: Q00–Q07) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 51

Forest plot representing the RR with 95% CI of *anencephaly* (ICD-10: Q00.0) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 52


Forest plot representing the RR with 95% CI of *spina bifida* (ICD-10: Q05) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 53


Forest plot representing the RR with 95% CI of *congenital heart defects* (ICD-10: Q20–Q26) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

## SUPPLEMENTAL FIGURE 54


Forest plot representing the RR with 95% CI of *cleft lip and cleft palate* (ICD-10: Q35–Q37) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.


## SUPPLEMENTAL FIGURE 55

Forest plot representing the RR with 95% CI of *cleft palate* (ICD-10: Q35) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



## SUPPLEMENTAL FIGURE 56

Forest plot representing the RR with 95% CI of *omphalocele* (ICD-10: Q79.2) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005




CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.



## SUPPLEMENTAL FIGURE 57

Forest plot representing the RR with 95% CI of *gastroschisis* (ICD-10: Q79.3) in different age groups compared to the 20 to 30 age group and sorted by year of publication but only including studies published since 2005



CI, confidence interval; ICD-10, International Classification of Diseases-10; RR, risk ratio.

**SUPPLEMENTAL TABLE 1**  
**PRISMA checklist**

| Section and topic             | Item # | Checklist item   | Location where item is reported |
|-------------------------------|--------|--|---------------------------------|
| Title                         |        |  |                                 |
| Title                         | 1      | Identify the report as a systematic review.  |                                 |
| Abstract                      |        |  |                                 |
| Abstract                      | 2      | See the PRISMA 2020 for Abstracts checklist.   |                                 |
| Introduction                  |        |  |                                 |
| Rationale                     | 3      | Describe the rationale for the review in the context of existing knowledge.  |                                 |
| Objectives                    | 4      | Provide an explicit statement of the objective(s) or question(s) the review addresses.   |                                 |
| Methods                       |        |  |                                 |
| Eligibility criteria          | 5      | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.  |                                 |
| Information sources           | 6      | Specify all databases, registers, websites, organizations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.  |                                 |
| Search strategy               | 7      | Present the full search strategies for all databases, registers and websites, including any filters and limits used.   |                                 |
| Selection process             | 8      | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.                     |                                 |
| Data collection process       | 9      | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. |                                 |
| Data items                    | 10a    | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (eg, for all measures, time points, analyses), and if not, the methods used to decide which results to collect.                         |                                 |
|                               | 10b    | List and define all other variables for which data were sought (eg, participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.  |                                 |
| Study risk of bias assessment | 11     | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.                                    |                                 |

(continued)

**SUPPLEMENTAL TABLE 1**  
**PRISMA checklist** (continued)

| Section and topic             | Item # | Checklist item  | Location where item is reported |
|-------------------------------|--------|---|---------------------------------|
| Effect measures               | 12     | Specify for each outcome the effect measure(s) (eg, risk ratio, mean difference) used in the synthesis or presentation of results.  |                                 |
| Synthesis methods             | 13a    | Describe the processes used to decide which studies were eligible for each synthesis (eg, tabulating the study intervention characteristics and comparing against the planned groups for each synthesis [item #5]).   |                                 |
|                               | 13b    | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.   |                                 |
|                               | 13c    | Describe any methods used to tabulate or visually display results of individual studies and syntheses.  |                                 |
|                               | 13d    | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. |                                 |
|                               | 13e    | Describe any methods used to explore possible causes of heterogeneity among study results (eg, subgroup analysis, meta-regression).   |                                 |
|                               | 13f    | Describe any sensitivity analyses conducted to assess robustness of the synthesized results.  |                                 |
| Reporting bias assessment     | 14     | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).   |                                 |
| Certainty assessment          | 15     | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.   |                                 |
| <b>Results</b>                |        |   |                                 |
| Study selection               | 16a    | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram (see <a href="#">Figure 1</a> ).                                |                                 |
|                               | 16b    | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.   |                                 |
| Study characteristics         | 17     | Cite each included study and present its characteristics.   |                                 |
| Risk of bias in studies       | 18     | Present assessments of risk of bias for each included study.  |                                 |
| Results of individual studies | 19     | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (eg, confidence/credible interval), ideally using structured tables or plots.                             |                                 |

(continued)



**SUPPLEMENTAL TABLE 1**  
**PRISMA checklist** (continued)

| Section and topic                               | Item # | Checklist item  | Location where item is reported |
|---|--------|---|---------------------------------|
| Results of syntheses                            | 20a    | For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.  |                                 |
|   | 20b    | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (eg, confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. |                                 |
|   | 20c    | Present results of all investigations of possible causes of heterogeneity among study results.  |                                 |
|   | 20d    | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.  |                                 |
| Reporting biases                                | 21     | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.   |                                 |
| Certainty of evidence                           | 22     | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.   |                                 |
| Discussion                                      |        |   |                                 |
| Discussion                                      | 23a    | Provide a general interpretation of the results in the context of other evidence.   |                                 |
|   | 23b    | Discuss any limitations of the evidence included in the review.   |                                 |
|   | 23c    | Discuss any limitations of the review processes used.   |                                 |
|   | 23d    | Discuss implications of the results for practice, policy, and future research.  |                                 |
| Other information                               |        |   |                                 |
| Registration and protocol                       | 24a    | Provide registration information for the review, including register name and registration number, or state that the review was not registered.  |                                 |
|   | 24b    | Indicate where the review protocol can be accessed, or state that a protocol was not prepared.  |                                 |
|   | 24c    | Describe and explain any amendments to information provided at registration or in the protocol.   |                                 |
| Support   | 25     | Describe sources of financial or nonfinancial support for the review, and the role of the funders or sponsors in the review.  |                                 |
| Competing interests                             | 26     | Declare any competing interests of review authors.  |                                 |
| Availability of data, code, and other materials | 27     | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.  |                                 |

SUPPLEMENTAL TABLE 2

## Basic characteristics of the included studies

| Author (year)  | Ref           | Country                    | Study period | Total      | Cases    | Age category                                | Congenital anomalies   |
|----------------|---------------|----------------------------|--------------|------------|----------|---|--|
| Agopian 2009   | <sup>1</sup>  | Texas (USA)                | 1999–2004    | 2,208,758  | 325      | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Omhalocele   |
| Baer 2014      | <sup>2</sup>  | California (USA)           | 2005–2010    | 3,070,957  | 1279     | <19, 20–24, 25–29, 30–34, ≥35               | Gastroschisis  |
| Beckman 1976   | <sup>3</sup>  | Sweden                     | 1950–1973    | 61,061     | 280      | <24, 25–29, 30–34, ≥35                      | Cleft palate, cleft lip with or without cleft palate, polydactyly, syndactyly, clubfoot                      |
| Bergman 2015   | <sup>4</sup>  | Europe                     | 2001–2010    | 5,871,855  | 10,929   | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Hypospadias  |
| Baird 1994     | <sup>5</sup>  | Canada                     | 1966–1981    | 576,815    | 702      | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Isolated cleft palate, cleft lip and cleft palate  |
| Bodnár 1970    | <sup>6</sup>  | Hungary                    | 1958–1967    | 115,215    | 2100     | <19, 20–24, 25–29, 30–39, ≥40               | All NCAs, nervous system, circulatory system, urogenital anomalies, musculoskeletal system, digestive system |
| Borman 1986    | <sup>7</sup>  | New Zeland                 | 1978         | 52,143     | 104      | <20, 20–24, 25–29, ≥30                      | Anencephlaus, spina bifida   |
| Borque 2021    | <sup>8</sup>  | Canada                     | 2012–2018    | 1,001,080  | 231      | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Gastroschisis  |
| Bugge 2017     | <sup>9</sup>  | Greenland                  | 1989–2015    | 26,666     | 33       | <20, 20–24, 25–29, 30–34, 35–39, 40–44, ≥45 | Gastroschisis, omphalocele   |
| Byron 1998     | <sup>10</sup> | Australia                  | 1980–1990    | 358,679    | 59; 104  | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Gastroschisis, omphalocele   |
| Canfield 2009  | <sup>11</sup> | Texas (USA)                | 1999–2003    | 1,827,317  | 514; 643 | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Anencephlaus, spina bifida   |
| Canon 2012     | <sup>12</sup> | Arkansas (USA)             | 1998–2007    | 196,050    | 1455     | <20, 20–24, 25–29, 30–34, ≥35               | Hypospadias  |
| Croen 1995     | <sup>13</sup> | California (USA)           | 1983–1988    | 1,028,255  | 29,848   | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | All NCAs   |
| DeRoo 2003     | <sup>14</sup> | Washington (USA)           | 1987–1990    | 298,138    | 608      | <20, 20–24, 25–29, 30–34, 35–39, ≥40        | Cleft lip and cleft palate   |
| Dott 2003      | <sup>15</sup> | Metropolitan Atlanta (USA) | 1968–1999    | 1,029,143  | 249      | <20, 20–24, 25–34, ≥35                      | Diaphragmatic hernia   |
| Dudin 1997     | <sup>16</sup> | Palestina                  | 1986–1993    | 26,934     | 148      | 15–19, 20–24, 25–29, 30–39, ≥40             | Neural tube defects  |
| Fedrick 1976   | <sup>17</sup> | Scotland                   | 1961–1972    | 1,162,939  | 3246     | <20, 20–24, 25–29, 30–34, 35–39, 40–44, ≥45 | Anencephlaus   |
| Feldman 1982   | <sup>18</sup> | New York, Brooklyn (USA)   | 1968–1976    | 173,670    | 179      | <20, 20–24, 25–29, 30–34, ≥35               | Neural tube defects  |
| Forrester 2004 | <sup>19</sup> | Hawaii (USA)               | 1986–2000    | 281,866    | 544      | <19, 20–24, 25–29, 30–34, 35–39, ≥40        | Cleft lip and cleft palate   |
| Forrester 1999 | <sup>20</sup> | Hawaii (USA)               | 1986–1997    | 229,584    | 150      | 19≥, 20–24, 25–29, 30–34, 35–39, ≥40        | Omphalocele, gastroschisis   |
| Forrester 2000 | <sup>21</sup> | Hawaii (USA)               | 1986–1997    | 246,231    | 245      | 19≥, 20–24, 25–29, 30–34, 35–39, ≥40        | Anencephaly, spina bifida, encephalocele   |
| Friedman 2016  | <sup>22</sup> | USA                        | 2005–2013    | 24,836,777 | 5985     | <20, 20–24, 25–29, 30–34, ≥35               | Gastroschisis  |

(continued)

## SUPPLEMENTAL TABLE 2

## Basic characteristics of the included studies (continued)

| Author (year)          | Ref | Country   | Study period | Total      | Cases  | Age category                             | Congenital anomalies   |
|------------------------|-----|---|--------------|------------|--------|--|--|
| Gupta 1967             | 23  | Nigeria   | 1964         | 4220       | 15     | 15–19 20–24, 25–29, 30–34, 35–39, 40–44  | CHD  |
| Hansen 2021            | 24  | Australia                                       | 1990–2016    | 765,419    | 8173   | <20, 20–24, 25–29, 30–34, 35–39, ≥40     | CHD  |
| Hay 1972               | 25  | USA   | 1961–1966    | 8,475,600  | 1063   | <20, 20–24, 25–29, 30–34, 35–39, ≥40     | Anencephaly, spina bifida, hydrocephalus, congenital heart defects, cleft lip without cleft palate, cleft lip and palate, cleft palate without cleft lip, tracheoesophageal fistula and other esophageal defects, omhalocele, imperforate anus and other anorectal defects, hypospadias, position foot defects, polydactyly, syndactyly, reduction deformities |
| Hollier 2000           | 26  | Dallas (Texas, USA)                             | 1988–1994    | 102,728    | 3466   | <20, 20–24, 25–29, 30–34, 35–39, ≥40     | All NCAs   |
| Jaikrishan 2012        | 27  | India   | 1995–2011    | 141,540    | 1370   | 15–19, 20–29, ≥30                        | Clubfoot, CHD, cleft palate/lip, NTD, hypospadias  |
| Janerich 1972          | 28  | New York State (USA)                            | 1945–1970    | 4,555,614  | 4450   | 15–19; 20–24; 25–29; 30–34; 35–39; 40–44 | Spina bifida   |
| Janerich 1972          | 29  | New York State (USA)                            | 1945–1967    | 4,074,079  | 3090   | 15–19; 20–24; 25–29; 30–34; 35–39; 40–44 | Anencephaly  |
| Jaruratanasirikul 2016 | 30  | Southern Thailand                               | 2009–2013    | 186,393    | 269    | <20; 20–<25; 25–<30; 30–<35; ≥35         | Oral clefts  |
| Jones 2016             | 31  | USA   | 1995–2012    | 21,040,437 | 8866   | <20; 20–24; 25–29; 30–34; 35–39          | Gastroschisis  |
| Kazaura 2004           | 32  | Norway  | 1967–1998    | 1,869,388  | 699    | <20; 20–24; 25–29; 30–34; 35–39; ≥40     | Gastroschisis, omphalocele   |
| Kirby 2013             | 33  | USA   | 1995–2005    | 13,233,235 | 4713   | <20; 20–24; 25–29; 30–34; 35–39          | Gastroschisis  |
| Liu 2013               | 34  | Canada  | 2002–2010    | 2,283,223  | 26,488 | <19; 20–24; 25–29; 30–34; 35–39; 40–44   | CHD  |
| Liu 2019               | 35  | Canada  | 2004–2015    | 3,327,762  | 1517   | <19; 20–24; 25–29; 30–34; 35–39; 40–44   | Spina bifida, anencephaly/encephalocele  |
| Li 2019                | 36  | Zhejiang Province (China, People's Republic of) | 2010–2016    | 1,748,023  | 2790   | <20; 20–25; 30–35; ≥35                   | Kidney and urinary tract defects   |
| Loc-Uyen 2015          | 37  | USA-Texas                                       | 1999–2011    | 4,970,525  | 2549   | <19; 20–24; 25–29; 30–34                 | Gastroschisis  |
| Luo 2019               | 38  | China-Shenzhen                                  | 2003–2017    | 591,024    | 777    | <25; 25–; 30–; 35–                       | Cleft lip and palate   |
| Martinez-Frias 1984    | 39  | Spain   | 1976         | 264,502    | 52     | <19; 20–24; 25–29; 30–34; 35–39; 40–44   | Gastroschisis, omphalocele   |

(continued)

## SUPPLEMENTAL TABLE 2

## Basic characteristics of the included studies (continued)

| Author (year)         | Ref                | Country                                   | Study period | Total      | Cases  | Age category                                       | Congenital anomalies   |
|-----------------------|--------------------|---|--------------|------------|--------|--|--|
| Materna-Kirylyuk 2009 | <a href="#">40</a> | Poland                                    | 1998–2002    | 716,089    | 8683   | <19; 20–24; 25–29; 30–34; 35–39; 40<               | All NCAs (excluded muskuloskeletal defects), diaphragmatic hernia, gastroschisis, omphalocele, neural tube defects, microcephalus, hydrocephalus, congenital heart defects, hypospadias, renal agenesis or hypoplasia, cystic kidney disease, hydronephrosis, cleft palate, cleft lip with or without cleft palate, oesophageal atresia, small intestinal/large intestinal atresia or stenosis, anal atresia or stenosis |
| McGivern 2015         | <a href="#">41</a> | Europe                                    | 1980–2009    | 11,478,586 | 3373   | <20; 20–24; 25–29; 30–34; 35<                      | Diaphragmatic hernia   |
| Miller 2011           | <a href="#">42</a> | Atlanta (Georgia, USA)                    | 1968–2005    | 1,301,340  | 5289   | <35; 35<   | CHD  |
| Mucat 2019            | <a href="#">43</a> | Malta                                     | 2000–2014    | 55,943     |        | 20–24; 25–29; 30–34; 35–39; 40<                    | All NCAs, nervous system, eye, ear, face, neck, circulatory system, respiratory system, digestive system, genital organs, urinary system, muskuloskeletal system   |
| Nazer 2007            | <a href="#">44</a> | Chile                                     | 1996–2005    | 21,083     | 1767   | <15; 15–19; 20–24; 25–29; 30–34; 35–39; 40–44; 45< | All NCAs   |
| Nazer 2013            | <a href="#">45</a> | Chile                                     | 2002–2011    | 15,636     | 1174   | <15; 15–19; 20–24; 25–29; 30–34; 35–39; 40–44; 45< | All NCAs   |
| Parkes 2020           | <a href="#">46</a> | England, Scotland (UK)                    | 2003–2010    | 219,486    |        | <19; 20–29; 30–39; 40<                             | All NCAs   |
| Pasnicki 2013         | <a href="#">47</a> | Poland                                    | 1988–2007    | 192,438    | 2769   | <18; 20–24; 25–29; 30–34; 35–39; 40<               | All NCAs, nervous system, circulatory system, cleft lip and cleft palate, digestive system, genital organs, urinary system, muskuloskeletal system, other  |
| Persson 2019          | <a href="#">48</a> | Sweden                                    | 1992–2012    | 2,050,491  | 28,628 | >24; 25–29; 30–34; 35<                             | CHD  |
| Petrova 2009          | <a href="#">49</a> | Norway and Arkhangelskaja Oblast (Russia) | 1995–2004    | 434,567    | 615    | <19; 20–24; 25–29; 30–34; 35<                      | Neural tube defects: anencephalus, spina bifida  |
| Pradat 1992           | <a href="#">50</a> | Sweden                                    | 1981–1986    | 573,422    | 1605   | <20; 20–24; 25–29; 30–34; 35–39; 40–44; >44        | CHD  |
| Purkey 2019           | <a href="#">51</a> | California (USA)                          | 2008–2012    | 2,054,516  | 6325   | <19; 20–24; 25–29; 30–34; 35<                      | CHD  |
| Rankin 1999           | <a href="#">52</a> | North of England                          | 1986–1996    | 426,694    | 296    | 11–19; 20–24; 25–29; 30–34; 35–39; >40             | Gastroschisis, omphalocele, omphalocele  |

(continued)

## SUPPLEMENTAL TABLE 2

## Basic characteristics of the included studies (continued)

| Author (year) | Ref                | Country                              | Study period | Total                   | Cases   | Age category                                       | Congenital anomalies  |
|---------------|--------------------|--------------------------------------|--------------|-------------------------|---------|--|---|
| Rankin 2000   | <a href="#">53</a> | North of England                     | 1984–1996    | 507,405                 | 934     | 11–19; 20–24; 25–29; 30–34; 35–39; >40             | Neural tube defects   |
| Rider 2013    | <a href="#">54</a> | Utah (USA)                           | 1999–2008    | 480,125                 | 8510    | <24; 25–29; 30–34; 35–39; 40–60                    | All NCAs  |
| Roeper 1987   | <a href="#">55</a> | California (USA)                     | 1968–1977    | 3,297,071               | 166     | <19; 20–24; 25–29; 30–34; 35–39; 40<               | Gastroschisis, omphalocele  |
| Salihu 2003   | <a href="#">56</a> | NewYork State (USA)                  | 1992–1999    | 2,153,955;<br>2,149,340 | 595     | <19; 20–24; 25–29; 30–34; 35–39; 40<               | Omphalocele, gastroschisis  |
| Salim 2019    | <a href="#">57</a> | Brazil                               | 1996–2014    | 4,270,114               | 5062    | <19; 20–29; 30–34; 35–39; 40<                      | Circulatory system  |
| Sarkar 2013   | <a href="#">58</a> | India                                | 2011–2012    | 12,896                  | 286     | <20; 20–30; 30<                                    | All NCAs  |
| Sever 1982    | <a href="#">59</a> | Los Angeles County (California, USA) | 1966–1972    | 2,945,555               | 962     | <14; 15–19; 20–24; 25–29; 30–34; 35–39; 40–44; 45< | Anencephalus, spina bifida, encephalocele, neural tube defects, all NCAs  |
| Shields 1981  | <a href="#">60</a> | Denmark                              | 1940–1971    | 2,406,654               | 548     | <19; 20–24; 25–29; 30–34; 35–39; 40–44; 45<        | Cleft palate  |
| Short 2019    | <a href="#">61</a> | USA                                  | 2006–2015    | 17,686,317              | 3489    | <19; 20–24; 25–29; 30<                             | Gastroschisis   |
| StLouis 2017  | <a href="#">62</a> | USA                                  | 1999–2007    | 13,105,878              | 138,999 | <19; 20–24; 25–29; 30–34; 35<                      | All NCAs, anencephalus, spina bifida, encephalocele, anotia/microtia, common truncus CHD, transposition of the great arteries, tetralogy of fallot, atrioventricular septal defect without down syndrome, hypoplastic left heart syndrome, coarctation of the aorta, aortic valve stenosis, cleft palate without cleft lip, cleft lip with and without cleft palate, esophageal atresia/tracheoesophageal fistula, pyloric stenosis, rectal and large intestinal atresia/stenosis, hypospadiasis, upper limb deficiency, lower limb deficiency, any limb deficiency, diaphragmatic hernia, gastroschisis, omphalocele |
| Tan 1996      | <a href="#">63</a> | England, Wales (UK)                  | 1987–1993    | 4,873,547               | 1043    | <20; 20–24; 25–29; 30–34; 35–39; >40               | Gastroschisis, omphalocele  |
| Tan 2005      | <a href="#">64</a> | Singapore                            | 1994–2000    | 328,077                 | 7870    | <20; 20–24; 25–29; 30–34; 35–39; >40               | All NCAs  |
| Tan 2008      | <a href="#">65</a> | Singapore                            | 1993–2002    | 460,532                 | 121     | <20; 20–24; 25–29; 30–34; 35–39; >40               | Gastroschisis, omphalocele  |
| Williams 2005 | <a href="#">66</a> | Atlanta (USA)                        | 1968–2000    | 877,604                 | 211     | <20; 20–24; 24<                                    | Gastroschisis   |
| Xie 2016      | <a href="#">67</a> | China-Hunan Province                 | 2005–2014    | 925,413                 | 17,753  | <20; 20–24; 25–29; 30–34; 35<                      | All NCAs  |
| Xie 2018      | <a href="#">68</a> | China (People's Republic of)         | 2012–2016    | 673,060                 | 6289    | <20, 20–24, 25–29, 30–34, ≥35                      | Congenital heart defects  |

(continued)

**SUPPLEMENTAL TABLE 2****Basic characteristics of the included studies** *(continued)*

| Author (year) | Ref                | Country   | Study period | Total     | Cases | Age category                           | Congenital anomalies |
|---------------|--------------------|---|--------------|-----------|-------|--|----------------------|
| Xu 2011       | <a href="#">69</a> | China (People's Republic of)                      | 1996–2007    | 6,308,594 | 1601  | <19; 20–24; 25–29; 30–34; 35<          | Gastroschisis        |
| Zhang 2012    | <a href="#">70</a> | China (People's Republic of)                      | 2012         | 62,526    | 976   | <25; 25–30; 35<                        | All NCAs             |
| Yang 2006     | <a href="#">71</a> | California (USA)                                  | 1989–1997    | 2,506,188 | 550   | <20; 20–24; 25–29; 30–34; 35–39; 40–55 | Diaphragmatic hernia |
| Zhou 2020     | <a href="#">72</a> | China (People's Republic of),<br>Southern Jiangsu | 2014–2018    | 238,712   | 1707  | <19; 20–24; 25–29; 30–34; 35<          | All NCAs             |

*CHD*, congenital heart defect; *NCAs*, nonchromosomal congenital anomalies; *NTD*, neural tube defect.

**SUPPLEMENTAL TABLE 3**  
**Risk of bias assessment using the QUIPS tool**

|               | D1  | D2  | D3   | D4   | D5  | D6   |  |
|---------------|---|---|--|--|---|--|--|
|               | Low-risk: table or detailed text about population<br>Moderate: moderate information about population<br>High risk: limited information about study population | Low risk: population—based study—whole country/region/hospital<br>Moderate risk: case-control study—high-case numbers<br>High risk: case-control study—low case numbers or just descriptive information about cases | Low risk: clear and detailed age categories covering all age groups<br>Moderate risk: clear categories, but some age groups are missing<br>High risk: only 1 group is examined | Low risk: clear definition of outcome—exact ICD-10 category<br>Moderate risk: can be matched to ICD-10 category<br>High risk: unclear definition | Low risk: clear information about confounders/multivariate models<br>Moderate risk: limited information<br>High risk: no information about relevant confounders | Low risk: clear, raw data; no or negligible contradiction<br>Moderate risk: needs some calculation or reading from graph; minor contradiction<br>High risk: only approximate data can be obtained; serious contradiction | High quality: max. ++<br>Acceptable: max. ++<br>+/+<br>Low quality: ++ or more |
| Code          | Study population  | Study design  | Prognostic factor measurement  | Outcome  | Study confounding   | Data Quality—statistics  | Overall rate   |
| Agopian_2009  | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Baer_2014     | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Beckman_1976  | Moderate risk   | Low risk  | Low risk   | Moderate risk  | Low risk  | Moderate risk  | Acceptable   |
| Bergman_2015  | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Baird_1994    | Moderate risk   | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | Acceptable   |
| Bodnár_1970   | Moderate risk   | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | Acceptable   |
| Borman_1986   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Borque_2021   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | Acceptable   |
| Bugge_2017    | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Byron_1998    | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Moderate risk  | High quality   |
| Canfield_2009 | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Canon_2012    | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Croen_1995    | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Moderate risk  | Acceptable   |
| DeRoo_2003    | Moderate risk   | Low risk  | Low risk   | Moderate risk  | Low risk  | Low risk   | High quality   |
| Donghua_2018  | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Dott_2003     | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | Acceptable   |
| Dudin_1997    | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Fedrick_1976  | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |

(continued)

SUPPLEMENTAL TABLE 3

Risk of bias assessment using the QUIPS tool (continued)

|                        | D1  | D2  | D3   | D4   | D5  | D6   |  |
|------------------------|---|---|--|--|---|--|--|
|                        | Low-risk: table or detailed text about population<br>Moderate: moderate information about population<br>High risk: limited information about study population | Low risk: population—based study—whole country/region/hospital<br>Moderate risk: case-control study—high-case numbers<br>High risk: case-control study—low case numbers or just descriptive information about cases | Low risk: clear and detailed age categories covering all age groups<br>Moderate risk: clear categories, but some age groups are missing<br>High risk: only 1 group is examined | Low risk: clear definition of outcome—exact ICD-10 category<br>Moderate risk: can be matched to ICD-10 category<br>High risk: unclear definition | Low risk: clear information about confounders/multivariate models<br>Moderate risk: limited information<br>High risk: no information about relevant confounders | Low risk: clear, raw data; no or negligible contradiction<br>Moderate risk: needs some calculation or reading from graph; minor contradiction<br>High risk: only approximate data can be obtained; serious contradiction | High quality: max. ++<br>Acceptable: max. ++<br>+/+<br>Low quality: ++ or more |
| Code                   | Study population  | Study design  | Prognostic factor measurement  | Outcome  | Study confounding   | Data Quality—statistics  | Overall rate   |
| Feldman_1982           | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Forrester_2004C        | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Forrester_1999         | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Forrester_2000         | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Friedman_2016          | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Gupta_1967             | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Hansen_2021            | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | High quality   |
| Hay_1972               | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Hollier_2000           | Low risk  | Low risk  | Low risk   | Moderate risk  | Low risk  | Low risk   | High quality   |
| Jaikrishan_2012        | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Janerich_1972          | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Janerich_1972          | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Jaruratanasirikul_2016 | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Jones_2016             | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | Acceptable   |
| Kazaura_2004           | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Kirby_2013             | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Liu_2013               | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | High quality   |
| Liu_2019               | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |

(continued)



SUPPLEMENTAL TABLE 3

Risk of bias assessment using the QUIPS tool (continued)

|               | D1  | D2  | D3   | D4   | D5  | D6   |  |
|---------------|---|---|--|--|---|--|--|
|               | Low-risk: table or detailed text about population<br>Moderate: moderate information about population<br>High risk: limited information about study population | Low risk: population—based study—whole country/region/hospital<br>Moderate risk: case-control study—high-case numbers<br>High risk: case-control study—low case numbers or just descriptive information about cases | Low risk: clear and detailed age categories covering all age groups<br>Moderate risk: clear categories, but some age groups are missing<br>High risk: only 1 group is examined | Low risk: clear definition of outcome—exact ICD-10 category<br>Moderate risk: can be matched to ICD-10 category<br>High risk: unclear definition | Low risk: clear information about confounders/multivariate models<br>Moderate risk: limited information<br>High risk: no information about relevant confounders | Low risk: clear, raw data; no or negligible contradiction<br>Moderate risk: needs some calculation or reading from graph; minor contradiction<br>High risk: only approximate data can be obtained; serious contradiction | High quality: max. ++<br>Acceptable: max. ++<br>+/+<br>Low quality: ++ or more |
| Code          | Study population  | Study design  | Prognostic factor measurement  | Outcome  | Study confounding   | Data Quality—statistics  | Overall rate   |
| Liz_2019      | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Loc_2015      | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Luo_2019      | Low risk  | Low risk  | Low risk   | Moderate risk  | Low risk  | Low risk   | High quality   |
| Martinez_1984 | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Materna_2009  | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| McGivern_2015 | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | High quality   |
| Miller_2011   | Low risk  | Low risk  | Low risk   | Moderate risk  | Low risk  | Moderate risk  | High quality   |
| Mucat_2019    | Low risk  | Low risk  | Low risk   | Moderate risk  | Moderate risk   | Low risk   | High quality   |
| Nazer_2007    | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Parkes_2020   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Pasnicky_2013 | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Persson_2019  | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Petrova_2009  | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Pradat_1992   | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Purkey_2019   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Rankin_1999   | Low risk  | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Rankin_2000   | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Rider_2013    | Low risk  | Low risk  | Low risk   | Moderate risk  | Low risk  | Low risk   | High quality   |

(continued)


SUPPLEMENTAL TABLE 3

Risk of bias assessment using the QUIPS tool (continued)

|               | D1  | D2  | D3   | D4   | D5  | D6   |  |
|---------------|---|---|--|--|---|--|--|
|               | Low-risk: table or detailed text about population<br>Moderate: moderate information about population<br>High risk: limited information about study population | Low risk: population—based study—whole country/region/hospital<br>Moderate risk: case-control study—high case numbers<br>High risk: case-control study—low case numbers or just descriptive information about cases | Low risk: clear and detailed age categories covering all age groups<br>Moderate risk: clear categories, but some age groups are missing<br>High risk: only 1 group is examined | Low risk: clear definition of outcome—exact ICD-10 category<br>Moderate risk: can be matched to ICD-10 category<br>High risk: unclear definition | Low risk: clear information about confounders/multivariate models<br>Moderate risk: limited information<br>High risk: no information about relevant confounders | Low risk: clear, raw data; no or negligible contradiction<br>Moderate risk: needs some calculation or reading from graph; minor contradiction<br>High risk: only approximate data can be obtained; serious contradiction | High quality: max. ++<br>Acceptable: max. ++<br>+/+<br>Low quality: ++ or more |
| Code          | Study population  | Study design  | Prognostic factor measurement  | Outcome  | Study confounding   | Data Quality—statistics  | Overall rate   |
| Roeper_1987   | Moderate risk   | Low risk  | Low risk   | Low risk   | Low risk  | Low risk   | High quality   |
| Salihu_2003   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | Acceptable   |
| Salim_2019    | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Salinas_2018  | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Sarkar_2013   | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Sever_1982    | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Shields_1981  | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Short_2019    | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Moderate risk  | Acceptable   |
| StLouis_2014  | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Tan_2008      | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Tan_2005      | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Tan_1996      | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Williams_2005 | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Xie_2016      | Low risk  | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Xu_2011       | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Yang_2006     | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Zhang_2012    | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |
| Zhou_2020     | Moderate risk   | Low risk  | Low risk   | Low risk   | Moderate risk   | Low risk   | High quality   |

Colors represent: Green: low risk of bias, Yellow: moderate risk of bias, Red: high risk of bias.

ICD-10, International Classification of Diseases-10; QUIPS, Quality in Prognostic Studies.

**SUPPLEMENTAL TABLE 4****Overall risk of bias including all studies using the Risk-of-Bias VISualization tool****SUPPLEMENTAL TABLE 5****Comparison of the “all NCAs” (ICD-10: Q00–Q89) risk ratio outcomes: studies with concomitant CAs excluded vs studies with concomitant CAs included**

| Risk groups    | Excluding cases with concomitant CAs | Including cases with concomitant CAs |
|----------------|--------------------------------------|--------------------------------------|
| <20 vs 20–30   | 1.21 [0.59–2.49; n=5]                | 1.08 [0.89–1.32; n=14]               |
| >35 vs 20–30   | 1.37 [0.76–2.45; n=6]                | 1.31 [1.07–1.61; n=13]               |
| >40 vs 20–30   | 1.25 [1.08–1.46; n=6]                | 1.44 [1.25–1.66; n=11]               |
| 30–35 vs 20–30 | 1.54 [0.55–4.32; n=6]                | 1.23 [0.85–1.78; n=13]               |
| 35–40 vs 20–30 | 1.73 [0.45–6.70; n=5]                | 1.47 [0.87–2.49; n=9]                |

CAs, chromosomal abnormalities.

SUPPLEMENTAL TABLE 6

## Summary of effect of year of publication on the maternal age dependence of risk of congenital anomalies

| ICD-10 NCA categories  | <20   |                | >35            |                | 30–35          |                | >40            |                | 35–40          |                |
|--|-------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|  | Trend | Subset         | Trend          | Subset         | Trend          | Subset         | Trend          | Subset         | Trend          | Subset         |
| Q00–Q89 all nonchromosomal anomalies                           | ✗     | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              |
| Q00–Q89 <sup>j</sup> all nonchromosomal anomalies <sup>j</sup> | ✗     | ✗              | ✓ <sup>a</sup> | ✗              | ✓ <sup>a</sup> | ✗              | ✓ <sup>b</sup> | ✗              | ✓ <sup>a</sup> | ✗              |
| Q00–Q07 malformations of the nervous system                    | ✗     | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              |
| Q00.0 anencephaly  | ✗     | ✓ <sup>c</sup> | ✗              | ✓ <sup>d</sup> | ✗              | ✗              | ✗              | —              | ✗              | —              |
| Q05 spina bifida   | ✗     | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | —              | ✗              | —              |
| Q20–Q26 malformations of the circulatory system                | ✗     | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              |
| Q35–Q37 cleft lip and cleft palate                             | ✗     | ✗              | ✗              | ✓ <sup>e</sup> | ✗              | ✗              | ✗              | —              | ✗              | —              |
| Q35 cleft palate   | ✗     | —              | ✗              | ✓ <sup>f</sup> | ✗              | ✗              | ✓ <sup>g</sup> | —              | ✗              | —              |
| Q79.2 exomphalos   | ✗     | ✓ <sup>h</sup> | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              | ✗              |
| Q79.3 gastroschisis  | ✗     | ✗              | ✗              | ✗              | ✗              | ✗ <sup>i</sup> | ✗              | ✓ <sup>h</sup> | ✗              | ✓ <sup>h</sup> |

The “trend” column shows if any trend could be detected visually in the study-level effect sizes of the full set of studies sorted by date of publication. The “subset” column shows if the subset of studies published since 2005 yielded a different pooled effect size compared to that of the full set of studies. ✗: no trend or difference detected. ✓: some trend or difference was detected. —: too few articles to analyze the subset.

<sup>a</sup> Slight nonsignificant negative trend; <sup>b</sup> Moderate nonsignificant negative trend; <sup>c</sup> Full set is just nonsignificant, subset is just significant; <sup>d</sup> Full set is nonsignificant risk effect, subset is significant protective effect; <sup>e</sup> Full set is nonsignificant, subset is significant; <sup>f</sup> The risk has increased; <sup>g</sup> Slight nonsignificant positive trend; <sup>h</sup> Full set is significant, subset is nonsignificant; <sup>i</sup> subset is less significant as the full set; <sup>j</sup> Only studies where concomitant chromosomal abnormality cases were excluded.